

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
31 January 2002 (31.01.2002)

PCT

(10) International Publication Number
WO 02/07747 A1

(51) International Patent Classification⁷: A61K 38/00,
C12N 9/12, C12Q 1/48

(21) International Application Number: PCT/US01/22347

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/219,244 18 July 2000 (18.07.2000) US

(71) Applicant (*for all designated States except US*): JOSLIN
DIABETES CENTER, INC. [US/US]; One Joslin Place,
Boston, MA 02115 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): KING, George, Liang
[US/US]; 101 Sentre Street, Dover, MA 02030 (US).

(74) Agents: MYERS, P., Louis et al.; Fish & Richardson P.C.,
225 Franklin Street, Boston, MA 02110-2804 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

BEST AVAILABLE COPY

WO 02/07747 A1

(54) Title: METHODS OF MODULATING FIBROSIS

(57) Abstract: The invention features method for modulating fibrosis and/or angiogenesis by inhibiting components of the VEGF signaling pathway. The methods are useful in the treatment of fibrotic and or angiogenesis related disorders.

METHODS OF MODULATING FIBROSIS

Related Applications

This application claims the benefit of U.S. Provisional application No. 60/219,244, filed on July 18, 2000, the contents of which are incorporated herein by reference in their entirety.

Federally Sponsored Research Or Development

The U.S. Government may have certain rights in this invention pursuant to Grant No. EY5110 awarded by the National Institutes of Health to George L. King.

Background

Angiogenesis and fibrosis are key components in development, growth, wound healing, and regeneration (Klagsbrun & D'Amore, (1991) *Annu. Rev. Physiol.* 53, 217-239). In addition, these processes commonly occur together in many disease states where neovascularization is believed to initiate the pathological cascade, including proliferative diabetic retinopathy (Aiello et al. (1998) *Diabetes Care* 21, 143-156), rheumatoid arthritis (Firestein (1999) *J. Clin. Invest.* 103, 3-4), and age-related macular degeneration (Lopez et al. (1996) *Invest. Ophthalmol. & Visual Sci.* 37, 855-868).

Vascular endothelial growth factor (VEGF) is expressed as a family of peptides of 121, 145, 165, 189, and 206 amino acid residues. Its expression is induced by hypoxia and is essential in the vasculogenesis process during development. Several receptors have been shown to mediate the action of VEGF, and most of them belong to the tyrosine kinase receptor family (Petrova et al. (1999) *Exp. Cell Res.* 253, 117-130). Upon the binding of VEGF to its receptors, multiple signaling cascades are activated, including the tyrosine phosphorylation of phospholipase C γ , elevation of intracellular calcium and diacylglycerol, activation of protein kinase C (PKC), and extracellular signal-regulated kinase (MAPK/ERK) for endothelial cell proliferation. In addition, VEGF also stimulates activation of phosphatidylinositol (PI) 3-kinase leading to Akt/PKB activation and possibly enhancing endothelial cell survival.

Connective tissue growth factor (CTGF) is a potent and ubiquitously expressed growth factor that has been shown to play a unique role in fibroblast proliferation, cell adhesion, and

the stimulation of extracellular matrix production (Frazier et al. (1996) *J. Invest. Dermatol.* 107, 404-411; Kireeva et al. (1997) *Exp. Cell Res.* 233, 63-77). The 38-kDa protein was originally identified in conditioned medium from human umbilical vein endothelial cells, and the expression was shown to be selectively stimulated by transforming growth factor- β (TGF- β) in cultured fibroblasts. Due to its mitogenic action on fibroblasts and its ability to induce the expression of the extracellular matrix molecules, collagen type I, fibronectin, and integrin $\alpha 5$, CTGF is supposed to play an important role in connective tissue cell proliferation and extracellular matrix deposition as one of the mediators of TGF- β . CTGF also seems to be an important player in the pathogenesis of various fibrotic disorders, since it was shown to be overexpressed in scleroderma, keloids, and other fibrotic skin disorders (Igarashi et al. (1996) *J. Invest. Dermatol.* 106, 729-733), as well as in stromal rich mammary tumors, and in advanced atherosclerotic lesions. Recently, the integrin $\alpha 5 \beta 3$ has been reported to serve as a receptor on endothelial cells for CTGF-mediated endothelial cell adhesion, migration, and angiogenesis (Babic et al. (1999) *Mol. Cell. Biol.* 19, 2958-2966).

Besides TGF- β , the expression of CTGF is reported to be regulated by dexamethasone in BALB/c 3T3 cells, high glucose in human mesangial cells, kinin in human embryonic fibroblasts, factor VIIa, and thrombin in WI-38 fibroblasts, tumor necrosis factor α in human skin fibroblast, and cAMP in bovine endothelial cells (Dammeier et al. (1998) *J. Biol. Chem.* 273, 18185-18190; Murphy et al. (1999) *J. Biol. Chem.* 274, 5830-5834; Ricupero et al. (2000) *J. Biol. Chem.* 275, 12475-12480; Pendurthi et al. (2000) *J. Biol. Chem.* 275, 14632-14641; Abraham et al. (2000) *J. Biol. Chem.* 275, 15220-15225; Boes et al. (1999) *Endocrinology* 140, 1575-1580).

Summary

The invention is based, in part, on the discovery that VEGF can regulate connective tissue growth factor (CTGF), e.g., through the PI3 Kinase-Akt pathway. CTGF is a potent diffusible growth factor which regulates extracellular matrix deposition and connective tissue cell proliferation. CTGF is a potent activator of fibrosis, angiogenesis, and extracellular matrix production. Modulation of the levels of CTGF via the VEGF pathway, e.g., by modulation of a VEGF activity, e.g., a VEGF signaling activity, e.g., a VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt 4, neuropilin-1 (NP-1), tie, or tie2 activity;

modulation of PI3-kinase; or modulation of Akt can thereby stimulate or alternatively reduce fibrosis and/or angiogenesis. Accordingly, one aspect of the invention features methods of modulating fibrosis. Another aspect features methods of modulating angiogenesis.

In one aspect, the invention features a method of decreasing fibrosis in a tissue, e.g., a skin, lung, retinal, renal, cardiac, or liver tissue of a subject, e.g., a human or non-human animal, by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity. In a preferred embodiment, the method includes identifying a subject in need of decreased fibrosis, e.g., a subject having a fibrotic disorder, e.g., a disorder described herein.

In a preferred embodiment, VEGF signaling is decreased by administering an agent that inhibits a component of the VEGF signal transduction pathway, e.g., an agent that decreases VEGF activity, decreases VEGF receptor (VEGFR) activity, e.g., KDR/flk1, Flt1, Flt4, NP-1, tie, or tie2 activity; decreases PI3-kinase activity; decreases an Akt activity; decreases an Erk activity.

In a preferred embodiment, KDR, Flt-4, Flt-1 or neuropilin activity is decreased.

In a preferred embodiment, the subject has a disorder related to unwanted or excessive fibrosis. In some embodiments, fibrosis is exhibited in, e.g., skin, liver, kidney, cardiac, or lung tissue. The disorder can be caused by scarring, e.g., keloid formation. Examples of other disorders related to unwanted or excessive fibrosis include, but are not limited to, scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis, e.g., diffuse interstitial pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; a disease of the kidney, e.g., glomerular sclerosis, renal tubulointerstitial fibrosis, or progressive renal disease; atherosclerotic plaques, e.g., restenosis; inflammatory bowel disease; Crohn's disease; arthritic joints, e.g., rheumatoid arthritis; cancer, e.g., invasive breast carcinoma, stromal rich mammary tumors, dermatofibromas, angiolipoma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture; macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal

fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments; or macular degeneration, e.g., age-related macular degeneration;

The method includes administering an agent which decreases CTGF activity or expression. In a preferred embodiment, the agent is an agent described herein that decreases a VEGF signaling activity.

In a preferred embodiment, CTGF activity or expression is decreased in an endothelial cell.

In a preferred embodiment, CTGF activity or expression is decreased in a pericyte.

An agent which decreases CTGF activity can be one or more of: an agent which decreases the level or activity of VEGF, e.g., an agent which inhibits VEGF interaction with a VEGF receptor (VEGFR), e.g., flt4, fltl, NP-1 tie, tie-2, and/or KDR/flk1; an agent which inhibits VEGF receptor activation; an agent which disrupts a VEGF-VEGFR complex; an agent which inhibits PI3 Kinase activity; an agent that inhibits VEGFR binding to p85, the catalytic subunit of PI3 kinase; an agent which inhibits AKT kinase activity.

In a preferred embodiment, VEGF is inhibited. VEGF can be inhibited by administering an agent which inhibits VEGF gene expression, protein production levels and/or activity. An agent which inhibits VEGF can be one or more of: a VEGF binding protein, e.g., a soluble VEGF binding protein, e.g., the ectodomain of a VEGF-receptor; an antibody that specifically binds to the VEGF protein, e.g., an antibody that disrupts VEGF's ability to bind to its natural cellular target, e.g., disrupts VEGF's ability to bind to a VEGF receptor, e.g., Fltl (VEGFR1), Flk/KDR (VEGFR2), NP-1, tie, tie-2, or Flt4 (VEGFR3); an antibody that disrupts the ability of a VEGF receptor to bind to VEGF; an antibody or small molecule which disrupts a complex formed by VEGF and its receptor; a mutated inactive VEGF or fragment which binds to a VEGF receptor but does not activate the receptor; a VEGF nucleic acid molecule which can bind to a cellular VEGF nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF ribozyme; an agent which decreases VEGF gene expression, e.g., a small molecule which binds the promoter of VEGF. In another preferred embodiment, VEGF is inhibited by decreasing the level of expression of an endogenous VEGF gene, e.g., by decreasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene can be decreased by: altering the regulatory sequences of the endogenous VEGF gene, e.g., by the

addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, the antibody which binds VEGF is a monoclonal antibody, e.g., a humanized chimeric or human monoclonal antibody.

In a preferred embodiment, VEGF interaction with its receptor is inhibited. An agent which inhibits a VEGF receptor, e.g., Flt1 (VEGFR1), Flk1/KDR (VEGFR2), neuropilin-1, tie, tie-2, or Flt4 (VEGFR3), can be one or more of: a VEGF receptor nucleic acid molecule which can bind to a cellular VEGF receptor nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or VEGF receptor ribozyme; an agent which decreases VEGF receptor gene expression, e.g., a small molecule which binds the promoter of a VEGF receptor. In another preferred embodiment, a VEGF receptor is inhibited by decreasing the level of expression of an endogenous VEGF receptor gene, e.g., by decreasing transcription of an VEGF receptor gene. In a preferred embodiment, transcription of a VEGF receptor gene can be decreased by: altering the regulatory sequences of an endogenous VEGF receptor gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA binding site for a transcriptional activator); as well as agents described above.

In a preferred embodiment, PI3 kinase is inhibited. An agent which inhibits PI3-kinase activity can be one or more of: a small molecule which inhibits PI3-kinase activity, e.g., LY294002; a protein or peptide that inhibits PI3 kinase activity, e.g., a PI3 kinase binding protein which binds to PI3-kinase but does not activate the enzyme, or a dominant negative form of p85; an antibody that specifically binds to the PI3-kinase protein, e.g., an antibody that disrupts PI3-kinase's catalytic activity or an antibody that disrupts the ability of cellular receptors to activate PI3-kinase; a PI3 kinase nucleic acid molecule which can bind to a cellular PI3 kinase nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or PI3-kinase ribozyme; an agent which decreases PI3-kinase gene expression, e.g., a small molecule which binds the promoter of PI3-kinase. In another preferred embodiment, PI3-kinase is inhibited by decreasing the level of expression of an endogenous PI3-kinase gene, e.g.,

by decreasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene can be decreased by: altering the regulatory sequences of the endogenous PI3-kinase gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator). In another preferred embodiment, PI3-kinase activity is inhibited by a specific small molecule inhibitor, e.g., wortmannin or LY294002.

In another preferred embodiment, AKT kinase is inhibited. An agent which inhibits AKT kinase activity can be one or more of: a specific small molecule which inhibits AKT activity; an AKT binding protein which binds to AKT but does not activate the enzyme; an antibody that specifically binds to the AKT protein, e.g., an antibody that disrupts AKT's catalytic activity or an antibody that disrupts the ability of the AKT PH domain to sense activating second messengers, e.g., phosphoinositides; a mutated inactive AKT or fragment which binds to a AKT receptor but does not activate the receptor; an AKT nucleic acid molecule which can bind to a cellular AKT nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or AKT ribozyme; an agent which decreases AKT gene expression, e.g., a small molecule which binds the promoter of AKT. In another preferred embodiment, AKT is inhibited by decreasing the level of expression of an endogenous AKT gene, e.g., by decreasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene can be decreased by: altering the regulatory sequences of the endogenous AKT gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

In one embodiment, increasing a PKC activity, e.g., a PKC α , PKC β 1, PKC β 2, or PKC γ activity, can inhibit PI3 kinase or Akt, thus decreasing CTGF expression or activity. The agent which increases the level of PKC activity can be one or more of the following: a small molecule which stimulates PKC activity, e.g., PMA; a PKC polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof; an agent which increases PKC nucleic acid expression; e.g., a small molecule which binds to the promoter region of PKC. In a preferred embodiment, PKC levels are

increased by administering, e.g., introducing, a nucleotide sequence encoding a PKC polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PKC coding region; a promoter sequence, e.g., a promoter sequence from a PKC gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PKC gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PKC gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PKC protein is increased by increasing the level of expression of an endogenous PKC gene, e.g., by increasing transcription of the PKC gene. In a preferred embodiment, transcription of the PKC gene is increased by: altering the regulatory sequence of the endogenous PKC gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PKC gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is inhibited. An agent which inhibits Erk kinase activity can be one or more of: a specific small molecule which inhibits Erk activity; a Erk binding protein which binds to Erk but does not activate the enzyme; an antibody that specifically binds to the Erk protein, e.g., an antibody that disrupts Erk's catalytic activity; a mutated inactive Erk or fragment which binds to a Erk receptor but does not activate the receptor; a Erk nucleic acid molecule which can bind to a cellular Erk nucleic acid sequence, e.g., mRNA, and inhibit expression of the protein, e.g., an antisense molecule or Erk ribozyme; an agent which decreases Erk gene expression, e.g., a small molecule which binds the promoter of Erk. In another preferred embodiment, Erk is inhibited by decreasing the level of expression of an endogenous Erk gene, e.g., by decreasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene can be decreased by: altering the regulatory sequences of the endogenous Erk gene, e.g., by the addition of a negative regulatory sequence (such as a DNA-binding site for a transcriptional repressor), or by the removal of a positive regulatory sequence (such as an enhancer or a DNA-binding site for a transcriptional activator).

Another aspect of the invention features methods of reducing angiogenesis by decreasing CTGF activity or expression. CTGF activity or expression is decreased by decreasing a VEGF signaling activity by any of the methods described herein. In preferred embodiments, angiogenesis is reduced to, e.g., treat a disorder related to excessive angiogenesis, e.g., tumor growth, tumor metastasis, arthritis, retinal neovascular disease, and retinal ischemia. The method includes administering an agent which decreases CTGF transcription or activity by inhibiting a component of the VEGF signaling pathway, e.g., by any of the agents mentioned above.

Another aspect of the invention features methods of increasing fibrosis.

In a preferred embodiment, the invention features a method of treating disorders related to insufficient fibrosis. The disorder can be the result of an injury. The disorder can be due to a genetic deficiency, a second physiological disorder or disease, or an environmental insult. In a preferred embodiment, the disorder is a wound. In another preferred embodiment the disorder is a damaged organ, e.g., an organ undergoing regeneration. The method includes administering an agent which increases the level of CTGF transcription.

An agent which increases the level of CTGF transcription can be one or more of: an agent which increases the level or activity of VEGF, e.g., a transition metal ion, e.g., manganese, cobalt, nickel, or combinations thereof; an agent which activates the VEGF receptor; an agent which increases PI3 Kinase activity; an agent which increases AKT kinase activity.

In a preferred embodiment, VEGF is increased. An agent which increases the level of VEGF activity can be one or more of the following; a small molecule, e.g., a transition metal ion; a peptide or protein, e.g., a monoclonal antibody, which stabilizes or assists the binding of VEGF to a VEGF receptor; a VEGF polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF polypeptide or functional fragment or analog thereof; an agent which increases VEGF nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF. In a preferred embodiment, VEGF levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF polypeptide or

functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF coding region; a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3'UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF protein is increased by increasing the level of expression of an endogenous VEGF gene, e.g., by increasing transcription of the VEGF gene. In a preferred embodiment, transcription of the VEGF gene is increased by: altering the regulatory sequence of the endogenous VEGF gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF gene to be transcribed more efficiently.

In a preferred embodiment, the VEGF receptor activity is increased. An agent which increases the level of VEGF receptor activity can be one or more of the following: an agent which activates a VEGF receptor, e.g., a monoclonal antibody which activates the VEGF receptor, e.g., a monoclonal antibody which activates a VEGF receptor in the absence of VEGF; a VEGF receptor ligand polypeptide (e.g., VEGF or placenta growth factor (PlGF)), or a functional fragment or analog thereof; a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof; an agent which increase VEGF receptor nucleic acid expression; e.g., a small molecule which binds to the promoter region of VEGF receptor. In a preferred embodiment, VEGF receptor levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a VEGF receptor polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a VEGF receptor coding region; a promoter sequence, e.g., a promoter sequence from a VEGF receptor gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5' untranslated region (UTR), e.g., a 5'UTR from a VEGF receptor

gene or from another gene, a 3'UTR, e.g., a 3'UTR from a VEGF receptor gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of VEGF receptor protein is increased by increasing the level of expression of an endogenous VEGF receptor gene, e.g., by increasing transcription of the VEGF receptor gene. In a preferred embodiment, transcription of the VEGF receptor gene is increased by: altering the regulatory sequence of the endogenous VEGF receptor gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the VEGF receptor gene to be transcribed more efficiently.

In a preferred embodiment, PI3-Kinase is increased. An agent which increases the level of PI3-kinase can be one or more of the following: a small molecule which activates PI3kinase; a PI3kinase polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a PI3kinase polypeptide or functional fragment or analog thereof; an agent which increase PI3-kinase nucleic acid expression, e.g., a small molecule which binds to the promoter region of PI3 kinase. In a preferred embodiment, PI3-kinase levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a PI3-kinase polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a PI3-kinase coding region; a promoter sequence, e.g., a promoter sequence from a PI3 kinase gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a PI3kinase gene or from another gene, a 3'UTR, e.g., a 3'UTR from a PI3-kinase gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of PI3kinase protein is increased by increasing the level of expression of an endogenous PI3-kinase gene, e.g., by increasing transcription of the PI3-kinase gene. In a preferred embodiment, transcription of the PI3-kinase gene is increased by: altering the regulatory sequence of the endogenous PI3 kinase gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator);

the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the PI3-kinase gene to be transcribed more efficiently.

In a preferred embodiment, AKT is increased. An agent which increases the level of AKT can be one or more of the following: a small molecule which activates AKT kinase activity, e.g., the phosphoinositide PIP₂; a polypeptide, e.g., insulin, which stimulates activation, e.g., phosphorylation, of AKT; a AKT polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof; an agent which increase AKT nucleic acid expression; e.g., a small molecule which binds to the promoter region of AKT. In a preferred embodiment, AKT levels are increased by administering, e.g., introducing, a nucleotide sequence encoding a AKT polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: a AKT coding region; a promoter sequence, e.g., a promoter sequence from a AKT gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from a AKT gene or from another gene, a 3'UTR, e.g., a 3'UTR from a AKT gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of AKT protein is increased by increasing the level of expression of an endogenous AKT gene, e.g., by increasing transcription of the AKT gene. In a preferred embodiment, transcription of the AKT gene is increased by: altering the regulatory sequence of the endogenous AKT gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the AKT gene to be transcribed more efficiently.

In another preferred embodiment, Erk kinase is increased. An agent which increases Erk kinase activity can be one or more of: a small molecule which activates Erk kinase activity; an Erk polypeptide or a functional fragment or analog thereof; a nucleotide sequence encoding

an Erk polypeptide or functional fragment or analog thereof; an agent which increases Erk nucleic acid expression; e.g., a small molecule which binds to the promoter region of Erk. In a preferred embodiment, Erk levels are increased by administering, e.g., introducing, a nucleotide sequence encoding an Erk polypeptide or functional fragment or analog thereof, into a particular cell, e.g., an endothelial cell, a fibroblast, or a pericyte, in the subject. The nucleotide sequence can be a genome sequence or a cDNA sequence. The nucleotide sequence can include: an Erk coding region; a promoter sequence, e.g., a promoter sequence from an Erk gene or from another gene; an enhancer sequence; untranslated regulatory sequences, e.g., a 5'untranslated region (UTR), e.g., a 5'UTR from an Erk gene or from another gene, a 3'UTR, e.g., a 3'UTR from an Erk gene or from another gene; a polyadenylation site; an insulator sequence. In another preferred embodiment, the level of Erk protein is increased by increasing the level of expression of an endogenous Erk gene, e.g., by increasing transcription of the Erk gene. In a preferred embodiment, transcription of the Erk gene is increased by: altering the regulatory sequence of the endogenous Erk gene, e.g., by the addition of a positive regulatory element (such as an enhancer or a DNA-binding site for a transcriptional activator); the deletion of a negative regulatory element (such as a DNA-binding site for a transcriptional repressor) and/or replacement of the endogenous regulatory sequence, or elements therein, with that of another gene, thereby allowing the coding region of the Erk gene to be transcribed more efficiently.

Another aspect of the invention features a method of screening for agents which increase or decrease fibrosis and/or angiogenesis to thereby treat disorders associated with increased or decreased fibrosis, e.g., the disorders mentioned above. The method includes: providing a cell, tissue, or subject, e.g., an experimental animal, e.g., an animal model for a fibrosis related disorder; contacting the cell, tissue or subject with a test agent; and determining whether the test agent inhibits a component of the VEGF signaling pathway.

In preferred embodiments, the screening can include screening for: an agent that inhibits VEGF activity; an agent that inhibits VEGFR signaling, e.g., an agent that inhibits the interaction between VEGF and a VEGFR; an agent that inhibits PI3 kinase activity; an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase; an agent that inhibits AKT activity; and/or an agent that inhibits ERK activity.

In some embodiments, the method can include one or more of the following steps:

applying VEGF to cells in culture, e.g., BREC or BREP; applying a candidate drug or a combinatorial library of drugs; assaying for levels of CTGF. CTGF levels can be assayed various methods commonly practiced in the art. In one embodiment, CTGF levels are assayed by Northern analysis for CTGF mRNA expression. In another embodiment CTGF levels are assayed by detect CTGF protein, e.g., with an antibody, e.g., using an ELISA assay or a Western blot assay. In another embodiment, CTGF transcription is monitored by assaying for a reporter protein, e.g., lacZ, chloramphenicol acetyltransferase (CAT), green fluorescent protein or variants thereof, and other fluorescent proteins and variants thereof, where the gene encoding the reporter protein is fused to the CTGF promoter and the ensemble is transfected into the cells. The methods can further include administering an agent identified by the screening methods described herein to an animal, e.g., an animal model for a fibrotic disorder.

Detailed Description

The inventors have discovered that VEGF can modulate the activity and/or expression of CTGF in a time- and concentration-dependent manner in cells and/or tissues with VEGF receptors, e.g., in endothelial cells, e.g., microvascular endothelial cells such as human retinal endothelial cells or bovine retinal endothelial cells (BREC), and in contractile cells, e.g., in capillary pericytes, e.g., in human or bovine retinal pericytes (BRPC). VEGF-induced modulation of CTGF can occur via the PI3 kinase pathway, e.g., via the KDR receptor-PI3 kinase-Erk pathway (e.g., in BREC), or the Flt1-PI3 kinase-Akt pathway (e.g., in BRPC). Modulation of CTGF via the VEGF pathway can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis-related disorders described herein.

VEGF receptor (VEGFR), e.g., Flt1 (VEGFR1), KDR/Flk1 (VEGFR2), Flt4 (VEGFR3), NP1, tie, or tie-2, can mediate increases in CTGF mRNA expression. The ability of Flt1 to induce increases in CTGF mRNA levels is demonstrated in the pericytes that have predominantly Flt1 receptors. In addition, placenta growth factor (PlGF), a Flt1 receptor-specific ligand, was able to induce CTGF mRNA levels in BRPC but not in BREC, indicating that VEGF can induce CTGF mRNA by activating through Flt1 in pericytes, e.g., BRPC. The KDR/Flk1 receptors in the endothelial cells can also induce CTGF gene expression since KDR/Flk1 receptors are the predominant VEGF receptors in endothelial cells.

The VEGF dose-response curves for CTGF in both BRPC and BREC are similar and

suggest that VEGF binds to high affinity receptors, consistent with the known K_d values of Flt1 and KDR/Flk1 at 10-100 pM. While not wanting to be bound by theory, VEGF-induced CTGF mRNA is most likely due to an induction of transcription rather than altering the half-life of CTGF mRNA since the addition of VEGF failed to change the degradation rates of CTGF mRNA. The time course of the action of VEGF on CTGF (which required 6-9 h) suggests this is potentially a chronic action of VEGF. In addition, the time needed to achieve maximum effect is also consistent with the calculated mRNA half-life of CTGF mRNA of 2-4 h.

From a biological perspective, the effects of VEGF on CTGF mRNA could potentially have important physiological impact for several reasons. First, the increase in CTGF mRNA results in increased protein levels. Second, the VEGF concentration that was minimally active (0.25 ng/ml) can easily bind and activate a significant percentage of the VEGFR-1, -2 receptors. Third, this low level of VEGF may exist even in non-pathological states, suggesting that low levels of VEGF may have physiological actions on maintaining extracellular matrix production via the induction of CTGF. At 2.5-25 ng/ml VEGF which are encountered in hypoxic and angiogenic states (Aiello et al. (1994) N. Engl. J. Med. 331, 1480-1487), the induction of CTGF expression by VEGF could potentially induce the fibrosis that frequently accompanies neovascularization. This possibility is supported further by the demonstration that the protein levels of CTGF expression were increased 10 h after the addition of VEGF that was consistent with the maximum increase in the mRNA levels at 6-9 h. In addition, the potency of VEGF on CTGF expression appeared to be similar to TGF-beta1, suggesting that both of them could induce fibrosis associated with neovascularization.

The activation of the endogenous tyrosine kinases of KDR/Flk1s can stimulate multiple signaling pathways, including Ras-Erk, PI3-kinase-Akt, and phospholipase CK-PKC cascades. The results in BREC described herein indicate that VEGF can increase the tyrosine phosphorylation of KDR/Flk1 and its interaction with p85 subunit of PI3-kinase. In addition, VEGF also activates the Erk1/2 pathway in BREC. In contrast, VEGF was unable to activate Erk1/2 but stimulated the activation of PI3-kinase and phosphorylation of Akt in BRPC. These results indicate that the signaling pathways for Flt1 in vascular cells are different from those for KDR/Flk1. The lack of effect on Erk1/2 activation also supports the hypothesis that Flt1, unlike KDR/Flk1, is not involved in mitogenic actions.

The results described herein provide strong evidence that VEGF is inducing CTGF gene

expression in both endothelial cells and pericytes via VEGFR1 or -R2 by the activation of PI3-kinase and Akt. This evidence includes the ability of wortmannin, a PI3-kinase inhibitor, to inhibit the effects of VEGFs in both cell types. Adenovirus containing dominant negative mutants of p85 subunit of PI3-kinase or Akt inhibited the action of VEGFs, whereas overexpression of dominant negative mutants of Ras and Erk1 by adenovirus vectors did not inhibit CTGF mRNA expression. Conversely, the overexpression of constitutive active Akt increased CTGF mRNA expression by 2.5-fold. The overexpression of either the wild type or dominant negative of PKC isoform did not alter the effects of VEGF on CTGF mRNA levels.

In summary, the results described herein show that VEGF can induce the expression of CTGF via VEGFR, e.g., Flt1, KDR/Flk1, Flt4, NP-1, tie, or tie-2, by the selectively activated PI3-kinase-Akt pathway but mostly independent of the Ras-Erk pathway. In addition, the spectrum of signaling pathways can be different among different VEGFRs, possibly reflecting their physiological roles. These results support the conclusion that VEGF, through its effects on CTGF expression, has physiological roles such as the maintenance of capillary strength and wound healing via the extracellular matrix production. In disease states, VEGF-induced CTGF may cause the proliferation of fibrocellular components in retinal neovascular diseases such as proliferative diabetic retinopathy and age-related macular degeneration.

Modulation of CTGF through the VEGF pathway, e.g., modulation of components of the VEGF pathway, e.g., Flt1, KDR, Flt4, neuropilin-1, PI3 kinase, Akt, or Erk, can be used to modulate fibrosis and/or angiogenesis, e.g., in the treatment of fibrosis related disorders. CTGF has been associated with a number of fibrosis-related disorders, e.g., scleroderma (e.g., morphea, generalized morphea, linear scleroderma); keloids; kidney fibrosis, e.g., glomerular sclerosis or renal tubulointerstitial fibrosis; pulmonary fibrosis; cardiac fibrosis; chemotherapy/radiation induced lung fibrosis; pancreatitis; renal disease; atherosclerotic plaques; inflammatory bowel disease; Crohn's disease; arthritic joints; cancer, e.g., invasive breast carcinoma, dermatofibromas, angioliipoma, and angioleiomyoma; hypertrophic scar; nodular fasciitis, eosinophilic fasciitis, dupuytren's contracture (*J. Invest. Dermatol.* 1996 106:729-733; *J Biol Chem.* 2001 276:10594-601; *Int J Biochem Cell Biol.* 1998 30:909-22; *J Eur Acad Dermatol Venereol.* 1998 11:1-8; *Int J Biochem Cell Biol.* 1998 Aug;30(8):909-22;

Ann Surg. 1999 Jul;230(1):63-71; J Cell Physiol. 1999 Oct;181(1):153-9; Curr Opin Nephrol Hypertens. 1999 Sep;8(5):543-8; J Am Soc Nephrol. 2001 Mar;12(3):472-84; J Rheumatol. 2000 Jan;27(1):149-54; J Mol Cell Cardiol. 2000 Oct;32(10):1805-19). Other fibrosis related diseases in which CTGF may be involved include macular degeneration, e.g., age-related macular degeneration; acute ocular neovascularization or diabetic retinopathy; general fibrosis syndrome, characterized by replacement of normal muscle tissue by fibrous tissue in varying degrees; retroperitoneal fibrosis; liver fibrosis; acute fibrosis, e.g., in response to various forms of trauma including accidental injuries, infections, surgery, burns, radiation or chemotherapy treatments.

Generation of Fragments

Fragments of components of the VEGF signaling pathway, e.g., VEGF, VEGFRs, PI3 kinase, AKT, can be used to increase VEGF signaling, thereby increasing CTGF activity, thereby increasing fibrosis or angiogenesis. For example, various fragments of VEGF are known and described, for example, in U.S. Patent No.: 5,935,820.

Fragments of a protein can be produced in several ways, e.g., recombinantly, by proteolytic digestion, or by chemical synthesis. Internal or terminal fragments of a polypeptide can be generated by removing one or more nucleotides from one end (for a terminal fragment) or both ends (for an internal fragment) of a nucleic acid which encodes the polypeptide. Expression of the mutagenized DNA produces polypeptide fragments. Digestion with "end-nibbling" endonucleases can thus generate DNA's which encode an array of fragments. DNA's which encode fragments of a protein can also be generated by random shearing, restriction digestion or a combination of the above-discussed methods.

Fragments can also be chemically synthesized using techniques known in the art such as conventional Merrifield solid phase f-Moc or t-Boc chemistry. For example, peptides of the present invention may be arbitrarily divided into fragments of desired length with no overlap of the fragments, or divided into overlapping fragments of a desired length.

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Random Methods

Amino acid sequence variants of a protein, e.g., a VEGF signaling pathway component described herein, can be prepared by random mutagenesis of DNA which encodes a protein or a

particular domain or region of a protein. Useful methods include PCR mutagenesis and saturation mutagenesis. A library of random amino acid sequence variants can also be generated by the synthesis of a set of degenerate oligonucleotide sequences. (Methods for screening proteins in a library of variants, e.g., screening for CTGF modulating activity or VEGF signaling agonist or antagonist activity, are elsewhere herein.)

PCR Mutagenesis

In PCR mutagenesis, reduced Taq polymerase fidelity is used to introduce random mutations into a cloned fragment of DNA (Leung et al., 1989, *Technique* 1:11-15). This is a very powerful and relatively rapid method of introducing random mutations. The DNA region to be mutagenized is amplified using the polymerase chain reaction (PCR) under conditions that reduce the fidelity of DNA synthesis by Taq DNA polymerase, e.g., by using a dGTP/dATP ratio of five and adding Mn^{2+} to the PCR reaction. The pool of amplified DNA fragments are inserted into appropriate cloning vectors to provide random mutant libraries.

Saturation Mutagenesis

Saturation mutagenesis allows for the rapid introduction of a large number of single base substitutions into cloned DNA fragments (Mayers et al., 1985, *Science* 229:242). This technique includes generation of mutations, e.g., by chemical treatment or irradiation of single-stranded DNA *in vitro*, and synthesis of a complimentary DNA strand. The mutation frequency can be modulated by modulating the severity of the treatment, and essentially all possible base substitutions can be obtained. Because this procedure does not involve a genetic selection for mutant fragments both neutral substitutions, as well as those that alter function, are obtained. The distribution of point mutations is not biased toward conserved sequence elements.

Degenerate Oligonucleotides

A library of homologs can also be generated from a set of degenerate oligonucleotide sequences. Chemical synthesis of a degenerate sequences can be carried out in an automatic DNA synthesizer, and the synthetic genes then ligated into an appropriate expression vector. The synthesis of degenerate oligonucleotides is known in the art (see for example, Narang, SA (1983) *Tetrahedron* 39:3; Itakura et al. (1981) *Recombinant DNA, Proc 3rd Cleveland Sympos.*

Macromolecules, ed. AG Walton, Amsterdam: Elsevier pp273-289; Itakura et al. (1984) *Annu. Rev. Biochem.* 53:323; Itakura et al. (1984) *Science* 198:1056; Ike et al. (1983) *Nucleic Acid Res.* 11:477. Such techniques have been employed in the directed evolution of other proteins (see, for example, Scott et al. (1990) *Science* 249:386-390; Roberts et al. (1992) *PNAS* 89:2429-2433; Devlin et al. (1990) *Science* 249: 404-406; Cwirla et al. (1990) *PNAS* 87: 6378-6382; as well as U.S. Patents Nos. 5,223,409, 5,198,346, and 5,096,815).

Generation of Analogs: Production of Altered DNA and Peptide Sequences by Directed Mutagenesis

Non-random or directed, mutagenesis techniques can be used to provide specific sequences or mutations in specific regions. These techniques can be used to create variants which include, e.g., deletions, insertions, or substitutions, of residues of the known amino acid sequence of a protein. The sites for mutation can be modified individually or in series, e.g., by (1) substituting first with conserved amino acids and then with more radical choices depending upon results achieved, (2) deleting the target residue, or (3) inserting residues of the same or a different class adjacent to the located site, or combinations of options 1-3.

Alanine Scanning Mutagenesis

Alanine scanning mutagenesis is a useful method for identification of certain residues or regions of the desired protein that are preferred locations or domains for mutagenesis, Cunningham and Wells (*Science* 244:1081-1085, 1989). In alanine scanning, a residue or group of target residues are identified (e.g., charged residues such as Arg, Asp, His, Lys, and Glu) and replaced by a neutral or negatively charged amino acid (most preferably alanine or polyalanine). Replacement of an amino acid can affect the interaction of the amino acids with the surrounding aqueous environment in or outside the cell. Those domains demonstrating functional sensitivity to the substitutions are then refined by introducing further or other variants at or for the sites of substitution. Thus, while the site for introducing an amino acid sequence variation is predetermined, the nature of the mutation per se need not be predetermined. For example, to optimize the performance of a mutation at a given site, alanine scanning or random mutagenesis may be conducted at the target codon or region and the expressed desired protein subunit variants are screened for the optimal combination of desired activity.

Oligonucleotide-Mediated Mutagenesis

Oligonucleotide-mediated mutagenesis is a useful method for preparing substitution, deletion, and insertion variants of DNA, see, e.g., Adelman et al., (*DNA* 2:183, 1983). Briefly, the desired DNA is altered by hybridizing an oligonucleotide encoding a mutation to a DNA template, where the template is the single-stranded form of a plasmid or bacteriophage containing the unaltered or native DNA sequence of the desired protein. After hybridization, a DNA polymerase is used to synthesize an entire second complementary strand of the template that will thus incorporate the oligonucleotide primer, and will code for the selected alteration in the desired protein DNA. Generally, oligonucleotides of at least 25 nucleotides in length are used. An optimal oligonucleotide will have 12 to 15 nucleotides that are completely complementary to the template on either side of the nucleotide(s) coding for the mutation. This ensures that the oligonucleotide will hybridize properly to the single-stranded DNA template molecule. The oligonucleotides are readily synthesized using techniques known in the art such as that described by Crea et al. (*Proc. Natl. Acad. Sci.* (1978) USA, 75: 5765).

Cassette Mutagenesis

Another method for preparing variants, cassette mutagenesis, is based on the technique described by Wells et al. (*Gene*, 34:315[1985]). The starting material is a plasmid (or other vector) which includes the protein subunit DNA to be mutated. The codon(s) in the protein subunit DNA to be mutated are identified. There must be a unique restriction endonuclease site on each side of the identified mutation site(s). If no such restriction sites exist, they may be generated using the above-described oligonucleotide-mediated mutagenesis method to introduce them at appropriate locations in the desired protein subunit DNA. After the restriction sites have been introduced into the plasmid, the plasmid is cut at these sites to linearize it. A double-stranded oligonucleotide encoding the sequence of the DNA between the restriction sites but containing the desired mutation(s) is synthesized using standard procedures. The two strands are synthesized separately and then hybridized together using standard techniques. This double-stranded oligonucleotide is referred to as the cassette. This cassette is designed to have 3' and 5' ends that are comparable with the ends of the linearized plasmid, such that it can be directly ligated to the plasmid. This plasmid now contains the mutated desired protein subunit DNA sequence.

Combinatorial Mutagenesis

Combinatorial mutagenesis can also be used to generate mutants. For example, the amino acid sequences for a group of homologs or other related proteins are aligned, preferably to promote the highest homology possible. All of the amino acids which appear at a given position of the aligned sequences can be selected to create a degenerate set of combinatorial sequences. The variegated library of variants is generated by combinatorial mutagenesis at the nucleic acid level, and is encoded by a variegated gene library. For example, a mixture of synthetic oligonucleotides can be enzymatically ligated into gene sequences such that the degenerate set of potential sequences are expressible as individual peptides, or alternatively, as a set of larger fusion proteins containing the set of degenerate sequences.

Primary High-Through-Put Methods for Screening Libraries of Peptide Fragments or Homologs

Various techniques are known in the art for screening generated mutant gene products. Techniques for screening large gene libraries often include cloning the gene library into replicable expression vectors, transforming appropriate cells with the resulting library of vectors, and expressing the genes under conditions in which detection of a desired activity, assembly into a trimeric molecules, binding to natural ligands, e.g., a receptor or substrates, facilitates relatively easy isolation of the vector encoding the gene whose product was detected. Each of the techniques described below is amenable to high through-put analysis for screening large numbers of sequences created, e.g., by random mutagenesis techniques.

Two Hybrid Systems

Two hybrid (interaction trap) assays can be used to identify a protein that interacts with a component of the VEGF signaling pathway, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 kinase (e.g., p85), AKT, ERK. These may include agonists, superagonists, and antagonists of the components. (The subject protein and a protein it interacts with are used as the bait protein and fish proteins.). These assays rely on detecting the reconstitution of a functional transcriptional activator mediated by protein-protein interactions with a bait protein. In particular, these assays make use of chimeric genes which express hybrid proteins. The first hybrid comprises a DNA-binding domain fused to the bait protein. e.g., a VEGF or VEGFR

molecule or a fragment thereof. The second hybrid protein contains a transcriptional activation domain fused to a "fish" protein, e.g. an expression library. If the fish and bait proteins are able to interact, they bring into close proximity the DNA-binding and transcriptional activator domains. This proximity is sufficient to cause transcription of a reporter gene which is operably linked to a transcriptional regulatory site which is recognized by the DNA binding domain, and expression of the marker gene can be detected and used to score for the interaction of the bait protein with another protein.

Display Libraries

In one approach to screening assays, the candidate peptides are displayed on the surface of a cell or viral particle, and the ability of particular cells or viral particles to bind an appropriate receptor protein via the displayed product is detected in a "panning assay". For example, the gene library can be cloned into the gene for a surface membrane protein of a bacterial cell, and the resulting fusion protein detected by panning (Ladner et al., WO 88/06630; Fuchs et al. (1991) *Bio/Technology* 9:1370-1371; and Goward et al. (1992) *TIBS* 18:136-140). In a similar fashion, a detectably labeled ligand can be used to score for potentially functional peptide homologs. Fluorescently labeled ligands, e.g., receptors, can be used to detect homolog which retain ligand-binding activity. The use of fluorescently labeled ligands, allows cells to be visually inspected and separated under a fluorescence microscope, or, where the morphology of the cell permits, to be separated by a fluorescence-activated cell sorter.

A gene library can be expressed as a fusion protein on the surface of a viral particle. For instance, in the filamentous phage system, foreign peptide sequences can be expressed on the surface of infectious phage, thereby conferring two significant benefits. First, since these phage can be applied to affinity matrices at concentrations well over 10^{13} phage per milliliter, a large number of phage can be screened at one time. Second, since each infectious phage displays a gene product on its surface, if a particular phage is recovered from an affinity matrix in low yield, the phage can be amplified by another round of infection. The group of almost identical *E. coli* filamentous phages M13, fd., and f1 are most often used in phage display libraries. Either of the phage gIII or gVIII coat proteins can be used to generate fusion proteins without disrupting the ultimate packaging of the viral particle. Foreign epitopes can be expressed at the NH₂-terminal end of pIII and phage bearing such epitopes recovered from a large excess of phage

lacking this epitope (Ladner et al. PCT publication WO 90/02909; Garrard et al., PCT publication WO 92/09690; Marks et al. (1992) *J. Biol. Chem.* 267:16007-16010; Griffiths et al. (1993) *EMBO J* 12:725-734; Clackson et al. (1991) *Nature* 352:624-628; and Barbas et al. (1992) *PNAS* 89:4457-4461).

A common approach uses the maltose receptor of *E. coli* (the outer membrane protein, LamB) as a peptide fusion partner (Charbit et al. (1986) *EMBO* 5, 3029-3037). Oligonucleotides have been inserted into plasmids encoding the LamB gene to produce peptides fused into one of the extracellular loops of the protein. These peptides are available for binding to ligands, e.g., to antibodies, and can elicit an immune response when the cells are administered to animals. Other cell surface proteins, e.g., OmpA (Schorr et al. (1991) *Vaccines* 91, pp. 387-392), PhoE (Agterberg, et al. (1990) *Gene* 88, 37-45), and PAL (Fuchs et al. (1991) *Bio/Tech* 9, 1369-1372), as well as large bacterial surface structures have served as vehicles for peptide display. Peptides can be fused to pilin, a protein which polymerizes to form the pilus-a conduit for interbacterial exchange of genetic information (Thiry et al. (1989) *Appl. Environ. Microbiol.* 55, 984-993). Because of its role in interacting with other cells, the pilus provides a useful support for the presentation of peptides to the extracellular environment. Another large surface structure used for peptide display is the bacterial motive organ, the flagellum. Fusion of peptides to the subunit protein flagellin offers a dense array of many peptides copies on the host cells (Kuwajima et al. (1988) *Bio/Tech.* 6, 1080-1083). Surface proteins of other bacterial species have also served as peptide fusion partners. Examples include the *Staphylococcus* protein A and the outer membrane protease IgA of *Neisseria* (Hansson et al. (1992) *J. Bacteriol.* 174, 4239-4245 and Klauser et al. (1990) *EMBO J.* 9, 1991-1999).

In the filamentous phage systems and the LamB system described above, the physical link between the peptide and its encoding DNA occurs by the containment of the DNA within a particle (cell or phage) that carries the peptide on its surface. Capturing the peptide captures the particle and the DNA within. An alternative scheme uses the DNA-binding protein LacI to form a link between peptide and DNA (Cull et al. (1992) *PNAS USA* 89:1865-1869). This system uses a plasmid containing the LacI gene with an oligonucleotide cloning site at its 3'-end. Under the controlled induction by arabinose, a LacI-peptide fusion protein is produced. This fusion retains the natural ability of LacI to bind to a short DNA sequence known as LacO operator (LacO). By installing two copies of LacO on the expression plasmid, the LacI-peptide fusion binds tightly to

the plasmid that encoded it. Because the plasmids in each cell contain only a single oligonucleotide sequence and each cell expresses only a single peptide sequence, the peptides become specifically and stably associated with the DNA sequence that directed its synthesis. The cells of the library are gently lysed and the peptide-DNA complexes are exposed to a matrix of immobilized receptor to recover the complexes containing active peptides. The associated plasmid DNA is then reintroduced into cells for amplification and DNA sequencing to determine the identity of the peptide ligands. As a demonstration of the practical utility of the method, a large random library of dodecapeptides was made and selected on a monoclonal antibody raised against the opioid peptide dynorphin B. A cohort of peptides was recovered, all related by a consensus sequence corresponding to a six-residue portion of dynorphin B. (Cull et al. (1992) *Proc. Natl. Acad. Sci. U.S.A.* 89-1869)

This scheme, sometimes referred to as peptides-on-plasmids, differs in two important ways from the phage display methods. First, the peptides are attached to the C-terminus of the fusion protein, resulting in the display of the library members as peptides having free carboxy termini. Both of the filamentous phage coat proteins, pIII and pVIII, are anchored to the phage through their C-termini, and the guest peptides are placed into the outward-extending N-terminal domains. In some designs, the phage-displayed peptides are presented right at the amino terminus of the fusion protein. (Cwirla, et al. (1990) *Proc. Natl. Acad. Sci. U.S.A.* 87, 6378-6382) A second difference is the set of biological biases affecting the population of peptides actually present in the libraries. The LacI fusion molecules are confined to the cytoplasm of the host cells. The phage coat fusions are exposed briefly to the cytoplasm during translation but are rapidly secreted through the inner membrane into the periplasmic compartment, remaining anchored in the membrane by their C-terminal hydrophobic domains, with the N-termini, containing the peptides, protruding into the periplasm while awaiting assembly into phage particles. The peptides in the LacI and phage libraries may differ significantly as a result of their exposure to different proteolytic activities. The phage coat proteins require transport across the inner membrane and signal peptidase processing as a prelude to incorporation into phage. Certain peptides exert a deleterious effect on these processes and are underrepresented in the libraries (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251). These particular biases are not a factor in the LacI display system.

The number of small peptides available in recombinant random libraries is enormous. Libraries of 10^7 - 10^9 independent clones are routinely prepared. Libraries as large as 10^{11} recombinants have been created, but this size approaches the practical limit for clone libraries. This limitation in library size occurs at the step of transforming the DNA containing randomized segments into the host bacterial cells. To circumvent this limitation, an *in vitro* system based on the display of nascent peptides in polysome complexes has recently been developed. This display library method has the potential of producing libraries 3-6 orders of magnitude larger than the currently available phage/phagemid or plasmid libraries. Furthermore, the construction of the libraries, expression of the peptides, and screening, is done in an entirely cell-free format.

In one application of this method (Gallop et al. (1994) *J. Med. Chem.* 37(9):1233-1251), a molecular DNA library encoding 10^{12} decapeptides was constructed and the library expressed in an *E. coli* S30 *in vitro* coupled transcription/translation system. Conditions were chosen to stall the ribosomes on the mRNA, causing the accumulation of a substantial proportion of the RNA in polysomes and yielding complexes containing nascent peptides still linked to their encoding RNA. The polysomes are sufficiently robust to be affinity purified on immobilized receptors in much the same way as the more conventional recombinant peptide display libraries are screened. RNA from the bound complexes is recovered, converted to cDNA, and amplified by PCR to produce a template for the next round of synthesis and screening. The polysome display method can be coupled to the phage display system. Following several rounds of screening, cDNA from the enriched pool of polysomes was cloned into a phagemid vector. This vector serves as both a peptide expression vector, displaying peptides fused to the coat proteins, and as a DNA sequencing vector for peptide identification. By expressing the polysome-derived peptides on phage, one can either continue the affinity selection procedure in this format or assay the peptides on individual clones for binding activity in a phage ELISA, or for binding specificity in a completion phage ELISA (Barret, et al. (1992) *Anal. Biochem* 204,357-364). To identify the sequences of the active peptides one sequences the DNA produced by the phagemid host.

Secondary Screens

The high through-put assays described above can be followed by secondary screens in order to identify further biological activities which will, e.g., allow one skilled in the art to differentiate agonists from antagonists. The type of a secondary screen used will depend on the

desired activity that needs to be tested. For example, an assay can be developed in which the ability to inhibit an interaction between a protein of interest (e.g., VEGF or PI3 kinase) and a ligand (e.g., VEGFR and AKT, respectively) can be used to identify antagonists from a group of peptide fragments isolated through one of the primary screens described above.

Therefore, methods for generating fragments and analogs and testing them for activity are known in the art. Once the core sequence of interest is identified, it is routine to perform for one skilled in the art to obtain analogs and fragments.

Peptide Mimetics

The invention also provides for reduction of the protein binding domains of the subject polypeptides, e.g., VEGF or VEGFR, to generate mimetics, e.g. peptide or non-peptide agents. See, for example, "Peptide inhibitors of human papillomavirus protein binding to retinoblastoma gene protein" European patent applications EP 0 412 762 and EP 0 031 080.

Non-hydrolyzable peptide analogs of critical residues can be generated using benzodiazepine (e.g., see Freidinger et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), azepine (e.g., see Huffman et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), substituted gamma lactam rings (Garvey et al. in *Peptides: Chemistry and Biology*, G.R. Marshall ed., ESCOM Publisher: Leiden, Netherlands, 1988), keto-methylene pseudopeptides (Ewenson et al. (1986) *J Med Chem* 29:295; and Ewenson et al. in *Peptides: Structure and Function* (Proceedings of the 9th American Peptide Symposium) Pierce Chemical Co. Rockland, IL, 1985), β -turn dipeptide cores (Nagai et al. (1985) *Tetrahedron Lett* 26:647; and Sato et al. (1986) *J Chem Soc Perkin Trans* 1:1231), and β -aminoalcohols (Gordon et al. (1985) *Biochem Biophys Res Commun* 126:419; and Dann et al. (1986) *Biochem Biophys Res Commun* 134:71).

Fusion Proteins

Polypeptides for modulating the level of a component of the VEGF signaling pathway can be fused to another protein or portion thereof. For example, a VEGF protein or antagonist or fragment thereof, can be operably linked to another polypeptide moiety to enhance solubility. Examples of a protein which can be fused with a protein or portions thereof include a plasma protein or fragment thereof, which can improve the circulating half life. For example, the fusion

protein can be a VEGF fragment-immunoglobulin (Ig) fusion protein in which the VEGF sequence is fused to a sequence derived from the immunoglobulin superfamily. Several soluble fusion protein constructs have been disclosed wherein the extracellular domain of a cell surface glycoprotein is fused with the constant F(c) region of an immunoglobulin. For example, Capon et al. (1989) *Nature* 337(9):525-531, provide guidance on generating a longer lasting CD4 analog by fusing CD4 to an immunoglobulin (IgG1). *See also*, Capon et al., U.S. Patent Numbers: 5,116,964 and 5,428,130 (CD4-IgG fusion constructs); Linsley et al., U.S. Patent Number 5,434,131 (CTLA4-IgG1 and B7-IgG1 fusion constructs); Linsley et al. (1991) *J. Exp. Med.* 174:561-569 (CTLA4-IgG1 fusion constructs); and Linsley et al. (1991) *J. Exp. Med.* 173:721-730 (CD28-IgG1 and B7-IgG1 fusion constructs). Such fusion proteins have proven useful for modulating receptor-ligand interactions and reducing inflammation *in vivo*. For example, fusion proteins in which an extracellular domain of cell surface tumor necrosis factor receptor (TNFR) proteins has been fused to an immunoglobulin constant (Fc) region have been used *in vivo*. *See, for example*, Moreland et al. (1997) *N. Engl. J. Med.* 337(3):141-147; and, van der Poll et al. (1997) *Blood* 89(10):3727-3734).

Antibodies

The invention also includes antibodies specifically reactive with a component of the VEGF signaling pathway described herein. Anti-protein/anti-peptide antisera or monoclonal antibodies can be made as described herein by using standard protocols (See, for example, *Antibodies: A Laboratory Manual* ed. by Harlow and Lane (Cold Spring Harbor Press: 1988)).

A component of the VEGF signaling pathway described herein, or a portion or fragment thereof, can be used as an immunogen to generate antibodies that bind the component using standard techniques for polyclonal and monoclonal antibody preparation. The full-length component protein can be used or, alternatively, antigenic peptide fragments of the component can be used as immunogens.

Typically, a peptide is used to prepare antibodies by immunizing a suitable subject, (e.g., rabbit, goat, mouse or other mammal) with the immunogen. An appropriate immunogenic preparation can contain, for example, a recombinant VEGF peptide, or a chemically synthesized VEGF peptide or antagonist. *See, e.g.*, U.S. Patent No. 5,460,959; and co-pending U.S. applications USSN 08/334,797; USSN 08/231,439; USSN 08/334,455; and USSN 08/928,881

which are hereby expressly incorporated by reference in their entirety. The nucleotide and amino acid sequences of components of the VEGF signaling pathway described herein are known. The preparation can further include an adjuvant, such as Freund's complete or incomplete adjuvant, or similar immunostimulatory agent. Immunization of a suitable subject with an immunogenic VEGF preparation induces a polyclonal anti-VEGF antibody response.

Antibodies to a component of the VEGF signaling pathway, or fragments thereof, can be used to inhibit the levels of such a component, thereby decreasing CTGF activity. Examples of antibody fragments include F(v), Fab, Fab' and F(ab')₂ fragments which can be generated by treating the antibody with an enzyme such as pepsin. The term "monoclonal antibody" or "monoclonal antibody composition", as used herein, refers to a population of antibody molecules that contain only one species of an antigen binding site capable of immunoreacting with a particular epitope. A monoclonal antibody composition thus typically displays a single binding affinity for a particular protein with which it immunoreacts.

Additionally, antibodies produced by genetic engineering methods, such as chimeric and humanized monoclonal antibodies, comprising both human and non-human portions, which can be made using standard recombinant DNA techniques, can be used. Such chimeric and humanized monoclonal antibodies can be produced by genetic engineering using standard DNA techniques known in the art, for example using methods described in Robinson et al. International Application No. PCT/US86/02269; Akira, et al. European Patent Application 184,187; Taniguchi, M., European Patent Application 171,496; Morrison et al. European Patent Application 173,494; Neuberger et al. PCT International Publication No. WO 86/01533; Cabilly et al. U.S. Patent No. 4,816,567; Cabilly et al. European Patent Application 125,023; Better et al., *Science* 240:1041-1043, 1988; Liu et al., *PNAS* 84:3439-3443, 1987; Liu et al., *J. Immunol.* 139:3521-3526, 1987; Sun et al. *PNAS* 84:214-218, 1987; Nishimura et al., *Canc. Res.* 47:999-1005, 1987; Wood et al., *Nature* 314:446-449, 1985; and Shaw et al., *J. Natl. Cancer Inst.* 80:1553-1559, 1988; Morrison, S. L., *Science* 229:1202-1207, 1985; Oi et al., *BioTechniques* 4:214, 1986; Winter U.S. Patent 5,225,539; Jones et al., *Nature* 321:552-525, 1986; Verhoeyan et al., *Science* 239:1534, 1988; and Beidler et al., *J. Immunol.* 141:4053-4060, 1988.

In addition, a human monoclonal antibody directed against a component of the VEGF signaling pathway described herein can be made using standard techniques. For example, human monoclonal antibodies can be generated in transgenic mice or in immune deficient mice

engrafted with antibody-producing human cells. Methods of generating such mice are describe, for example, in Wood et al. PCT publication WO 91/00906, Kucherlapati et al. PCT publication WO 91/10741; Lonberg et al. PCT publication WO 92/03918; Kay et al. PCT publication WO 92/03917; Kay et al. PCT publication WO 93/12227; Kay et al. PCT publication 94/25585; Rajewsky et al. Pct publication WO 94/04667; Ditullio et al. PCT publication WO 95/17085; Lonberg, N. et al. (1994) *Nature* 368:856-859; Green, L.L. et al. (1994) *Nature Genet.* 7:13-21; Morrison, S.L. et al. (1994) *Proc. Natl. Acad. Sci. USA* 81:6851-6855; Bruggeman et al. (1993) *Year Immunol* 7:33-40; Choi et al. (1993) *Nature Genet.* 4:117-123; Tuailon et al. (1993) *PNAS* 90:3720-3724; Bruggeman et al. (1991) *Eur J Immunol* 21:1323-1326; Duchosal et al. PCT publication WO 93/05796; U.S. Patent Number 5,411,749; McCune et al. (1988) *Science* 241:1632-1639, Kamel-Reid et al. (1988) *Science* 242:1706; Spanopoulou (1994) *Genes & Development* 8:1030-1042; Shinkai et al. (1992) *Cell* 68:855-868). A human antibody-transgenic mouse or an immune deficient mouse engrafted with human antibody-producing cells or tissue can be immunized with a component of the VEGF signaling pathway described herein or an antigenic peptide thereof and splenocytes from these immunized mice can then be used to create hybridomas. Methods of hybridoma production are well known.

Human monoclonal antibodies against components of the VEGF signaling pathway described herein can also be prepared by constructing a combinatorial immunoglobulin library, such as a Fab phage display library or a scFv phage display library, using immunoglobulin light chain and heavy chain cDNAs prepared from mRNA derived from lymphocytes of a subject. *See, e.g.,* McCafferty et al. PCT publication WO 92/01047; Marks et al. (1991) *J. Mol. Biol.* 222:581-597; and Griffiths et al. (1993) *EMBO J* 12:725-734. In addition, a combinatorial library of antibody variable regions can be generated by mutating a known human antibody. For example, a variable region of a human antibody known to bind VEGF, can be mutated, by for example using randomly altered mutagenized oligonucleotides, to generate a library of mutated variable regions which can then be screened to bind to VEGF. Methods of inducing random mutagenesis within the CDR regions of immunoglobulin heavy and/or light chains, methods of crossing randomized heavy and light chains to form pairings and screening methods can be found in, for example, Barbas et al. PCT publication WO 96/07754; Barbas et al. (1992) *Proc. Nat'l Acad. Sci. USA* 89:4457-4461.

The immunoglobulin library can be expressed by a population of display packages, preferably derived from filamentous phage, to form an antibody display library. Examples of methods and reagents particularly amenable for use in generating antibody display library can be found in, for example, Ladner et al. U.S. Patent No. 5,223,409; Kang et al. PCT publication WO 92/18619; Dower et al. PCT publication WO 91/17271; Winter et al. PCT publication WO 92/20791; Markland et al. PCT publication WO 92/15679; Breitling et al. PCT publication WO 93/01288; McCafferty et al. PCT publication WO 92/01047; Garrard et al. PCT publication WO 92/09690; Ladner et al. PCT publication WO 90/02809; Fuchs et al. (1991) *Bio/Technology* 9:1370-1372; Hay et al. (1992) *Hum Antibod Hybridomas* 3:81-85; Huse et al. (1989) *Science* 246:1275-1281; Griffiths et al. (1993) *supra*; Hawkins et al. (1992) *J Mol Biol* 226:889-896; Clackson et al. (1991) *Nature* 352:624-628; Gram et al. (1992) *PNAS* 89:3576-3580; Garrad et al. (1991) *Bio/Technology* 9:1373-1377; Hoogenboom et al. (1991) *Nuc Acid Res* 19:4133-4137; and Barbas et al. (1991) *PNAS* 88:7978-7982. Once displayed on the surface of a display package (e.g., filamentous phage), the antibody library is screened to identify and isolate packages that express an antibody that binds a component of the VEGF signaling pathway described herein. In a preferred embodiment, the primary screening of the library involves panning with an immobilized component of the VEGF signaling pathway described herein and display packages expressing antibodies that bind immobilized a component of the VEGF signaling pathway described herein are selected.

Antisense Nucleic Acid Sequences

Nucleic acid molecules which are antisense to a nucleotide encoding a component of the VEGF signaling pathway described herein, e.g., VEGF, VEGFR (e.g., flt1, flt4, KDR, neuropilin), PI3 Kinase, AKT, can be used as an agent which inhibits expression of the component. An "antisense" nucleic acid includes a nucleotide sequence which is complementary to a "sense" nucleic acid encoding the component, e.g., complementary to the coding strand of a double-stranded cDNA molecule or complementary to an mRNA sequence. Accordingly, an antisense nucleic acid can form hydrogen bonds with a sense nucleic acid. The antisense nucleic acid can be complementary to an entire coding strand, or to only a portion thereof. For example, an antisense nucleic acid molecule which antisense to the "coding region" of the coding strand of a nucleotide sequence encoding the component can be used.

The coding strand sequences encoding components of the VEGF signaling pathway described herein are known. Given the coding strand sequences encoding these components, antisense nucleic acids can be designed according to the rules of Watson and Crick base pairing. The antisense nucleic acid molecule can be complementary to the entire coding region of mRNA, but more preferably is an oligonucleotide which is antisense to only a portion of the coding or noncoding region of mRNA. For example, the antisense oligonucleotide can be complementary to the region surrounding the translation start site of the mRNA. An antisense oligonucleotide can be, for example, about 5, 10, 15, 20, 25, 30, 35, 40, 45 or 50 nucleotides in length. An antisense nucleic acid can be constructed using chemical synthesis and enzymatic ligation reactions using procedures known in the art. For example, an antisense nucleic acid (e.g., an antisense oligonucleotide) can be chemically synthesized using naturally occurring nucleotides or variously modified nucleotides designed to increase the biological stability of the molecules or to increase the physical stability of the duplex formed between the antisense and sense nucleic acids, e.g., phosphorothioate derivatives and acridine substituted nucleotides can be used. Examples of modified nucleotides which can be used to generate the antisense nucleic acid include 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xanthine, 4-acetylcytosine, 5-(carboxyhydroxymethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5'-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine. Alternatively, the antisense nucleic acid can be produced biologically using an expression vector into which a nucleic acid has been subcloned in an antisense orientation (i.e., RNA transcribed from the inserted nucleic acid will be of an antisense orientation to a target nucleic acid of interest).

Administration

An agent which modulates the level of expression of a component of the VEGF signaling pathway described herein can be administered to a subject by standard methods. For example, the agent can be administered by any of a number of different routes including intravenous, intradermal, subcutaneous, oral (e.g., inhalation), transdermal (topical), and transmucosal. In one embodiment, the VEGF signaling pathway modulating agent can be administered topically.

The agent which modulates protein levels, e.g., nucleic acid molecules, polypeptides, fragments or analogs, modulators, and antibodies (also referred to herein as "active compounds") can be incorporated into pharmaceutical compositions suitable for administration to a subject, e.g., a human. Such compositions typically include the nucleic acid molecule, polypeptide, modulator, or antibody and a pharmaceutically acceptable carrier. As used herein the language "pharmaceutically acceptable carrier" is intended to include any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like, compatible with pharmaceutical administration. The use of such media and agents for pharmaceutically active substances are known. Except insofar as any conventional media or agent is incompatible with the active compound, such media can be used in the compositions of the invention. Supplementary active compounds can also be incorporated into the compositions.

A pharmaceutical composition can be formulated to be compatible with its intended route of administration. Solutions or suspensions used for parenteral, intradermal, or subcutaneous application can include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. pH can be adjusted with acids or bases, such as hydrochloric acid or sodium hydroxide. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.

Pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersion. For intravenous administration, suitable carriers include physiological saline, bacteriostatic water, Cremophor EL™ (BASF, Parsippany, NJ) or phosphate buffered saline (PBS). In all cases, the composition must be sterile and should be

fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, ascorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars, polyalcohols such as manitol, sorbitol, sodium chloride in the composition. Prolonged absorption of the injectable compositions can be brought about by including in the composition an agent which delays absorption, for example, aluminum monostearate and gelatin.

Sterile injectable solutions can be prepared by incorporating the active compound (e.g., a VEGF polypeptide or anti-VEGF antibody) in the required amount in an appropriate solvent with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Generally, dispersions are prepared by incorporating the active compound into a sterile vehicle which contains a basic dispersion medium and the required other ingredients from those enumerated above. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying which yields a powder of the active ingredient plus any additional desired ingredient from a previously sterile-filtered solution thereof.

Oral compositions generally include an inert diluent or an edible carrier. They can be enclosed in gelatin capsules or compressed into tablets. For the purpose of oral therapeutic administration, the active compound can be incorporated with excipients and used in the form of tablets, troches, or capsules. Oral compositions can also be prepared using a fluid carrier for use as a mouthwash, wherein the compound in the fluid carrier is applied orally and swished and expectorated or swallowed. Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition. The tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a

disintegrating agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate or Sterotes; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.

Systemic administration can also be by transmucosal or transdermal means. For transmucosal or transdermal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known, and include, for example, for transmucosal administration, detergents, bile salts, and fusidic acid derivatives. Transmucosal administration can be accomplished through the use of nasal sprays or suppositories. For transdermal administration, the active compounds are formulated into ointments, salves, gels, or creams as generally known in the art.

In one embodiment, the active compounds are prepared with carriers that will protect the compound against rapid elimination from the body, such as a controlled release formulation, including implants and microencapsulated delivery systems. Biodegradable, biocompatible polymers can be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and polylactic acid. Methods for preparation of such formulations will be apparent to those skilled in the art. The materials can also be obtained commercially from Alza Corporation and Nova Pharmaceuticals, Inc. Liposomal suspensions (including liposomes targeted to infected cells with monoclonal antibodies to viral antigens) can also be used as pharmaceutically acceptable carriers. These can be prepared according to methods known to those skilled in the art, for example, as described in U.S. Patent No. 4,522,811.

The nucleic acid molecules described herein can be inserted into vectors and used as gene therapy vectors. Gene therapy vectors can be delivered to a subject by, for example, intravenous injection, local administration (see U.S. Patent 5,328,470) or by stereotactic injection (see e.g., Chen et al., *PNAS* 91:3054-3057, 1994). The pharmaceutical preparation of the gene therapy vector can include the gene therapy vector in an acceptable diluent, or can include a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery vector can be produced intact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can include one or more cells which produce the gene delivery system.

The pharmaceutical compositions can be included in a container, pack, or dispenser together with instructions for administration.

The agent which modulates the activity of a component of the VEGF signaling pathway described herein can be administered by locally administration, e.g., topical administration. The agent can be applied once or it can be administered continuously, e.g., the agent is administered with sufficient frequency such that the affect on the VEGF protein level is maintained for a selected period, e.g., 5, 10, 20, 30, 50, 90, 180, 365 days or more. The administration of an agent which modulates, e.g., increases or inhibits, the level of a component of the VEGF signaling pathway described herein, e.g., a VEGF polypeptide or an anti-VEGF antibody, can also be repeated.

Transition Metals

Transition metal ions have been shown to enhance expression of the VEGF gene thereby increasing VEGF protein levels. *See* U.S. Patent No.: 5,480,975. Thus, in one aspect, a transition metal ion can be used to increase CTGF, thereby increasing fibrosis or angiogenesis, by increasing expression of VEGF.

The transition metals are the group consisting of the fourth, fifth and sixth levels of the periodic table and which fill the d orbital. They include such elements as Ni, Co, Mn, Zn, V, Cr, Fe, Cu, Mo, etc. The preferred candidate metal ions for use are manganese, cobalt and nickel.

Selection of other appropriate metal ions involves determining whether, and at what level, the ion will induce VEGF expression. Particularly for systemic applications, selection also involves a review of toxicity. Suitable techniques for those determinations are provided below in U.S. Patent No.: 5,480,795. Preferred ions are those with a substantial range between VEGF induction and toxicity.

The transition metal can be administered internally (systemic or local administration) in the form of a salt or free ion in a biologically compatible tablet or capsule, gel, or liquid, or it can be administered externally in the form of a biologically compatible powder, salve, liquid, or transdermal patch. Any physiologically acceptable anion such as chloride, sulfate, etc., can be included in the composition.

Appropriate release rates and dosages can be determined in order to affect the targeted tissue without substantial systemic effect. For example, these parameters can be determined as described in U.S. Patent No.: 5,480,795.

Gene Therapy

The gene constructs of the invention can also be used as a part of a gene therapy protocol to deliver nucleic acids encoding either an agonistic or antagonistic form of a component of the VEGF signaling pathway described herein. The invention features expression vectors for in vivo transfection and expression of a component of the VEGF signaling pathway described herein in particular cell types so as to reconstitute the function of, or alternatively, antagonize the function of the component in a cell in which that polypeptide is misexpressed. Expression constructs of such components may be administered in any biologically effective carrier, e.g. any formulation or composition capable of effectively delivering the component gene to cells in vivo. Approaches include insertion of the subject gene in viral vectors including recombinant retroviruses, adenovirus, adeno-associated virus, and herpes simplex virus-1, or recombinant bacterial or eukaryotic plasmids. Viral vectors transfect cells directly; plasmid DNA can be delivered with the help of, for example, cationic liposomes (lipofectin) or derivatized (e.g. antibody conjugated), polylysine conjugates, gramicidin S, artificial viral envelopes or other such intracellular carriers, as well as direct injection of the gene construct or CaPO₄ precipitation carried out in vivo.

A preferred approach for in vivo introduction of nucleic acid into a cell is by use of a viral vector containing nucleic acid, e.g. a cDNA, encoding a component of the VEGF signaling pathway described herein. Infection of cells with a viral vector has the advantage that a large proportion of the targeted cells can receive the nucleic acid. Additionally, molecules encoded within the viral vector, e.g., by a cDNA contained in the viral vector, are expressed efficiently in cells which have taken up viral vector nucleic acid.

Retrovirus vectors and adeno-associated virus vectors can be used as a recombinant gene delivery system for the transfer of exogenous genes in vivo, particularly into humans. These vectors provide efficient delivery of genes into cells, and the transferred nucleic acids are stably integrated into the chromosomal DNA of the host. The development of specialized cell lines (termed "packaging cells") which produce only replication-defective retroviruses has increased

the utility of retroviruses for gene therapy, and defective retroviruses are characterized for use in gene transfer for gene therapy purposes (for a review see Miller, A.D. (1990) *Blood* 76:271). A replication defective retrovirus can be packaged into virions which can be used to infect a target cell through the use of a helper virus by standard techniques. Protocols for producing recombinant retroviruses and for infecting cells in vitro or in vivo with such viruses can be found in *Current Protocols in Molecular Biology*, Ausubel, F.M. et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals. Examples of suitable retroviruses include pLJ, pZIP, pWE and pEM which are known to those skilled in the art. Examples of suitable packaging virus lines for preparing both ecotropic and amphotropic retroviral systems include *Crip, *Cre, *2 and *Am. Retroviruses have been used to introduce a variety of genes into many different cell types, including epithelial cells, in vitro and/or in vivo (see for example Eglitis, et al. (1985) *Science* 230:1395-1398; Danos and Mulligan (1988) *Proc. Natl. Acad. Sci. USA* 85:6460-6464; Wilson et al. (1988) *Proc. Natl. Acad. Sci. USA* 85:3014-3018; Armentano et al. (1990) *Proc. Natl. Acad. Sci. USA* 87:6141-6145; Huber et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8039-8043; Ferry et al. (1991) *Proc. Natl. Acad. Sci. USA* 88:8377-8381; Chowdhury et al. (1991) *Science* 254:1802-1805; van Beusechem et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:7640-7644; Kay et al. (1992) *Human Gene Therapy* 3:641-647; Dai et al. (1992) *Proc. Natl. Acad. Sci. USA* 89:10892-10895; Hwu et al. (1993) *J. Immunol.* 150:4104-4115; U.S. Patent No. 4,868,116; U.S. Patent No. 4,980,286; PCT Application WO 89/07136; PCT Application WO 89/02468; PCT Application WO 89/05345; and PCT Application WO 92/07573).

Another viral gene delivery system useful in the present invention utilizes adenovirus-derived vectors. The genome of an adenovirus can be manipulated such that it encodes and expresses a gene product of interest but is inactivated in terms of its ability to replicate in a normal lytic viral life cycle. See, for example, Berkner et al. (1988) *BioTechniques* 6:616; Rosenfeld et al. (1991) *Science* 252:431-434; and Rosenfeld et al. (1992) *Cell* 68:143-155. Suitable adenoviral vectors derived from the adenovirus strain Ad type 5 dl324 or other strains of adenovirus (e.g., Ad2, Ad3, Ad7 etc.) are known to those skilled in the art. Recombinant adenoviruses can be advantageous in certain circumstances in that they are not capable of infecting nondividing cells and can be used to infect a wide variety of cell types, including epithelial cells (Rosenfeld et al. (1992) cited supra). Furthermore, the virus particle is relatively

stable and amenable to purification and concentration, and as above, can be modified so as to affect the spectrum of infectivity. Additionally, introduced adenoviral DNA (and foreign DNA contained therein) is not integrated into the genome of a host cell but remains episomal, thereby avoiding potential problems that can occur as a result of insertional mutagenesis *in situ* where introduced DNA becomes integrated into the host genome (e.g., retroviral DNA). Moreover, the carrying capacity of the adenoviral genome for foreign DNA is large (up to 8 kilobases) relative to other gene delivery vectors (Berkner et al. cited *supra*; Haj-Ahmand and Graham (1986) *J. Virol.* 57:267).

Yet another viral vector system useful for delivery of the subject gene is the adeno-associated virus (AAV). Adeno-associated virus is a naturally occurring defective virus that requires another virus, such as an adenovirus or a herpes virus, as a helper virus for efficient replication and a productive life cycle. (For a review see Muzyczka et al. (1992) *Curr. Topics in Micro. and Immunol.* 158:97-129). It is also one of the few viruses that may integrate its DNA into non-dividing cells, and exhibits a high frequency of stable integration (see for example Flotte et al. (1992) *Am. J. Respir. Cell. Mol. Biol.* 7:349-356; Samulski et al. (1989) *J. Virol.* 63:3822-3828; and McLaughlin et al. (1989) *J. Virol.* 62:1963-1973). Vectors containing as little as 300 base pairs of AAV can be packaged and can integrate. Space for exogenous DNA is limited to about 4.5 kb. An AAV vector such as that described in Tratschin et al. (1985) *Mol. Cell. Biol.* 5:3251-3260 can be used to introduce DNA into cells. A variety of nucleic acids have been introduced into different cell types using AAV vectors (see for example Hermonat et al. (1984) *Proc. Natl. Acad. Sci. USA* 81:6466-6470; Tratschin et al. (1985) *Mol. Cell. Biol.* 4:2072-2081; Wondisford et al. (1988) *Mol. Endocrinol.* 2:32-39; Tratschin et al. (1984) *J. Virol.* 51:611-619; and Flotte et al. (1993) *J. Biol. Chem.* 268:3781-3790).

In addition to viral transfer methods, such as those illustrated above, non-viral methods can also be employed to cause expression of a component of the VEGF signaling pathway described herein in the tissue of an animal. Most nonviral methods of gene transfer rely on normal mechanisms used by mammalian cells for the uptake and intracellular transport of macromolecules. In preferred embodiments, non-viral gene delivery systems of the present invention rely on endocytic pathways for the uptake of the subject gene by the targeted cell. Exemplary gene delivery systems of this type include liposomal derived systems, poly-lysine conjugates, and artificial viral envelopes. Other embodiments include plasmid injection systems

such as are described in Meuli et al. (2001) *J Invest Dermatol.* 116(1):131-135; Cohen et al. (2000) *Gene Ther* 7(22):1896-905; or Tam et al. (2000) *Gene Ther* 7(21):1867-74.

In a representative embodiment, a gene encoding a component of the VEGF signaling pathway described herein can be entrapped in liposomes bearing positive charges on their surface (e.g., lipofectins) and (optionally) which are tagged with antibodies against cell surface antigens of the target tissue (Mizuno et al. (1992) *No Shinkei Geka* 20:547-551; PCT publication WO91/06309; Japanese patent application 1047381; and European patent publication EP-A-43075).

In clinical settings, the gene delivery systems for the therapeutic gene can be introduced into a patient by any of a number of methods, each of which is familiar in the art. For instance, a pharmaceutical preparation of the gene delivery system can be introduced systemically, e.g. by intravenous injection, and specific transduction of the protein in the target cells occurs predominantly from specificity of transfection provided by the gene delivery vehicle, cell-type or tissue-type expression due to the transcriptional regulatory sequences controlling expression of the receptor gene, or a combination thereof. In other embodiments, initial delivery of the recombinant gene is more limited with introduction into the animal being quite localized. For example, the gene delivery vehicle can be introduced by catheter (see U.S. Patent 5,328,470) or by stereotactic injection (e.g. Chen et al. (1994) *PNAS* 91: 3054-3057).

The pharmaceutical preparation of the gene therapy construct can consist essentially of the gene delivery system in an acceptable diluent, or can comprise a slow release matrix in which the gene delivery vehicle is imbedded. Alternatively, where the complete gene delivery system can be produced in tact from recombinant cells, e.g. retroviral vectors, the pharmaceutical preparation can comprise one or more cells which produce the gene delivery system.

Cell Therapy

A component of the VEGF signaling pathway described herein can also be increased in a subject by introducing into a cell, e.g., an endothelial cell, fibroblast or a keratinocyte, a nucleotide sequence that modulates the production of the component, e.g., a nucleotide sequence encoding a component polypeptide or functional fragment or analog thereof, a promoter sequence, e.g., a promoter sequence from a VEGF gene or from another gene; an

enhancer sequence, e.g., 5' untranslated region (UTR), e.g., a 5' UTR from a VEGF gene or from another gene, a 3' UTR, e.g., a 3' UTR from a VEGF gene or from another gene; a polyadenylation site; an insulator sequence; or another sequence that modulates the expression of VEGF. The cell can then be introduced into the subject.

Primary and secondary cells to be genetically engineered can be obtained from a variety of tissues and include cell types which can be maintained propagated in culture. For example, primary and secondary cells include fibroblasts, keratinocytes, epithelial cells (e.g., mammary epithelial cells, intestinal epithelial cells), endothelial cells, glial cells, neural cells, formed elements of the blood (e.g., lymphocytes, bone marrow cells), muscle cells (myoblasts) and precursors of these somatic cell types. Primary cells are preferably obtained from the individual to whom the genetically engineered primary or secondary cells are administered. However, primary cells may be obtained for a donor (other than the recipient).

The term "primary cell" includes cells present in a suspension of cells isolated from a vertebrate tissue source (prior to their being plated i.e., attached to a tissue culture substrate such as a dish or flask), cells present in an explant derived from tissue, both of the previous types of cells plated for the first time, and cell suspensions derived from these plated cells. The term "secondary cell" or "cell strain" refers to cells at all subsequent steps in culturing. Secondary cells are cell strains which consist of secondary cells which have been passaged one or more times.

Primary or secondary cells of vertebrate, particularly mammalian, origin can be transfected with an exogenous nucleic acid sequence which includes a nucleic acid sequence encoding a signal peptide, and/or a heterologous nucleic acid sequence, e.g., encoding a component of the VEGF signaling pathway described herein or an agonist or antagonist thereof, and produce the encoded product stably and reproducibly in vitro and in vivo, over extended periods of time. A heterologous amino acid can also be a regulatory sequence, e.g., a promoter, which causes expression, e.g., inducible expression or upregulation, of an endogenous sequence. An exogenous nucleic acid sequence can be introduced into a primary or secondary cell by homologous recombination as described, for example, in U.S. Patent No.: 5,641,670, the contents of which are incorporated herein by reference. The transfected primary or secondary cells may also include DNA encoding a selectable marker which confers a selectable phenotype upon them, facilitating their identification and isolation.

Vertebrate tissue can be obtained by standard methods such a punch biopsy or other surgical methods of obtaining a tissue source of the primary cell type of interest. For example, punch biopsy is used to obtain skin as a source of fibroblasts or keratinocytes. A mixture of primary cells is obtained from the tissue, using known methods, such as enzymatic digestion or explanting. If enzymatic digestion is used, enzymes such as collagenase, hyaluronidase, dispase, pronase, trypsin, elastase and chymotrypsin can be used.

The resulting primary cell mixture can be transfected directly or it can be cultured first, removed from the culture plate and resuspended before transfection is carried out. Primary cells or secondary cells are combined with exogenous nucleic acid sequence to, e.g., stably integrate into their genomes, and treated in order to accomplish transfection. As used herein, the term "transfection" includes a variety of techniques for introducing an exogenous nucleic acid into a cell including calcium phosphate or calcium chloride precipitation, microinjection, DEAE-dextrin-mediated transfection, lipofection or electrophoration, all of which are routine in the art.

Transfected primary or secondary cells undergo sufficient number doubling to produce either a clonal cell strain or a heterogeneous cell strain of sufficient size to provide the therapeutic protein to an individual in effective amounts. The number of required cells in a transfected clonal heterogeneous cell strain is variable and depends on a variety of factors, including but not limited to, the use of the transfected cells, the functional level of the exogenous DNA in the transfected cells, the site of implantation of the transfected cells (for example, the number of cells that can be used is limited by the anatomical site of implantation), and the age, surface area, and clinical condition of the patient.

The transfected cells, e.g., cells produced as described herein, can be introduced into an individual to whom the product is to be delivered. Various routes of administration and various sites (e.g., renal sub capsular, subcutaneous, central nervous system (including intrathecal), intravascular, intrahepatic, intrasplanchnic, intraperitoneal (including intraomental), intramuscularly implantation) can be used. One implanted in individual, the transfected cells produce the product encoded by the heterologous DNA or are affected by the heterologous DNA itself. For example, an individual who suffers from fibrosis is a candidate for implantation of cells producing an antagonist of a component of the VEGF signaling pathway described herein.

An immunosuppressive agent e.g., drug, or antibody, can be administered to a subject at a dosage sufficient to achieve the desired therapeutic effect (e.g., inhibition of rejection of the

cells). Dosage ranges for immunosuppressive drugs are known in the art. See, e.g., Freed et al. (1992) N. Engl. J. Med. 327:1549; Spencer et al. (1992) N. Engl. J. Med. 327:1541; Widner et al. (1992) N. Engl. J. Med. 327:1556). Dosage values may vary according to factors such as the disease state, age, sex, and weight of the individual.

Examples

Example 1: VEGF modulates CTGF mRNA Expression

The effects of VEGF on the expression of CTGF mRNA were studied by Northern blot analysis in BREC and BRPC. 25 ng/ml VEGF increased CTGF mRNA (~2.4 kb) levels in a time-dependent manner, reaching a maximum after 6 h in BREC (3.1 ± 0.70 -fold, $p < 0.001$) and after 9 h in BRPC (2.0 ± 0.22 -fold, $p < 0.01$).

The dose response to VEGF-induced CTGF mRNA expression was studied after 6 h of VEGF stimulation. The expression of CTGF mRNA was up-regulated in a dose-dependent manner, with significant increases observed at concentrations as low as 0.25 ng/ml in both BREC and BRPC. Maximal increases were observed at VEGF concentrations of 25 ng/ml in both BREC and BRPC.

Since BREC and BRPC may express both KDR and Flt1, we examined the effects of PlGF, a Flt1-specific ligand, on the induction of CTGF gene expression in vascular cells. CTGF mRNA levels were not affected after stimulation of 25 ng/ml of PlGF in BREC. In contrast, PlGF increased CTGF mRNA after 3 h of stimulation, which peaked after 9 h in BRPC (1.9 ± 0.30 -fold, $p < 0.01$), suggesting that VEGF-induced CTGF gene expression was mediated primarily by KDR in BREC and Flt1 in BRPC.

Example 2: VEGF Induction of CTGF Protein Production

To determine if the effects of VEGF on CTGF mRNA were correlated with its protein level, CTGF protein expression was assessed by Western blot analysis using anti-human CTGF antibody. The detected size of CTGF protein was ~38 kDa in both BREC and BRPC. VEGF (25 ng/ml) increased the level of CTGF protein after 10 h in both BREC and BRPC. Comparative studies were performed on the effects of VEGF (25 ng/ml) and TGF- β 1 (10 ng/ml) on the expression of CTGF mRNA and protein. VEGF and TGF- β 1 increased CTGF protein expression by a similar amount (2.5 ± 0.4 - and 2.8 ± 0.8 -fold, respectively, in BREC). CTGF

mRNA levels were also increased a similar extent (3.0 ± 0.3 - and 3.3 ± 0.5 -fold, respectively).

Example 3: Effects of VEGF on the Half-life of CTGF mRNA

The effects of VEGF on the stability of CTGF mRNA were examined. Northern blot analyses were performed with addition of actinomycin D ($5 \mu\text{g/ml}$) after 6 h of VEGF (25 ng/ml) stimulation. In BREC and BRPC3, the half-life of CTGF mRNA was 1.7 and 3.6 h, respectively. There was no significant difference between VEGF-treated and -untreated cells.

Example 4: Effects of Cycloheximide on CTGF mRNA Regulation

In order to examine the possibility that VEGF regulates CTGF mRNA expression through new protein synthesis of cytokines or transcription factors, cells were treated for 6 h with VEGF (25 ng/ml) and a protein synthesis inhibitor, cycloheximide ($10 \mu\text{g/ml}$). Cycloheximide did not prevent the increase of CTGF mRNA. Addition of both VEGF and cycloheximide increased CTGF mRNA 2.4 ± 0.41 -fold in BREC and 2.5 ± 0.40 -fold in BRPC after 6 h as compared with cycloheximide alone ($p < 0.01$). These data suggest that the stimulation of CTGF mRNA expression by VEGF was not induced by increased synthesis of a regulatory protein.

Example 5: Involvement of Erk and PI3-Kinase-Akt in VEGF Signaling

Since Erk and PI3-kinase-Akt pathways have been reported to play central roles in VEGF signaling and biological actions, it was investigated whether or not VEGF can activate Erk and PI3-kinase-Akt pathways equally in BREC and BRPC. Immunoblot analysis of immunoprecipitates of KDR from BREC stimulated with VEGF or PlGF using an antibody to phosphotyrosine and PI3-kinase p85 subunit demonstrated that VEGF, but not PlGF, promoted the tyrosine phosphorylation of KDR and interactions of KDR and p85 subunit of PI3-kinase. In contrast, Immunoblot analysis of immunoprecipitates of Flt1 from BRPC stimulated with VEGF or PlGF demonstrated that both VEGF and PlGF increased the tyrosine phosphorylation of Flt1 and interactions of Flt1 and p85 subunit of PI3-kinase. These data suggest that VEGF can activate the receptor tyrosine phosphorylation and interaction with PI3-kinase p85 subunit in both KDR and Flt1.

To investigate the activation of Akt and Erk, we next performed immunoblot analysis with anti-phosphorylated Akt or anti-phosphorylated Erk antibodies using total cell lysates from BREC or BRPC stimulated with VEGF. VEGF induced phosphorylation of both Akt and Erk in BREC by 3.1- and 5.8-fold, but only induced phosphorylation of Akt in BRPC by 2.6-fold. No effect on Erk phosphorylation was observed in BRPC. These data suggest that VEGF activated both Erk and PI3-kinase-Akt pathways in BREC, but stimulated only PI3-kinase-Akt pathway in BRPC.

Since the activation of PI3-kinase by VEGF has not been reported in BRPC, we studied the effects of VEGF on PI3-kinase activity in BRPC. The addition of VEGF (25 ng/ml) increased PI3-kinase activity in a time-dependent manner by 2.1 ± 0.27 -fold ($p < 0.01$) after 5 min and by 1.6 ± 0.17 -fold ($p < 0.05$) after 10 min in BRPC.

Example 6: Effects of PKC, Erk, and PI3-Kinase Inhibition on VEGF-induced CTGF Expression

To investigate the signaling pathways involved in VEGF-induced CTGF expression, the effects of inhibition of PKC, Erk, and PI3-kinase were determined. Cells were treated with 25 ng/ml VEGF for 6 h after pretreatment with the kinase inhibitor GF 109203X, a classical and novel PKC-specific inhibitor (1 μ M); PD98059, a MAPK/Erk kinase inhibitor (20 μ M); or wortmannin, a PI3-kinase inhibitor (100 nM). Neither GF 109203X nor PD98059 had significant effects on VEGF-induced CTGF mRNA expression, but wortmannin inhibited the effects of VEGF by $88 \pm 6.5\%$ ($p < 0.01$) in BREC and $78 \pm 22\%$ ($p < 0.01$) in BRPC. To confirm further the involvement of PI3-kinase in VEGF-induced CTGF expression, recombinant adenoviruses were used encoding dominant negative K-ras (DN Ras), dominant negative extracellular signal-regulated kinase (DNERk), or $\Delta p85$ of PI3-kinase. BREC were transfected with each adenoviral vector, followed by stimulation with 25 ng/ml VEGF for 6 h. Neither DN Ras nor DNERk had significant effects on VEGF-induced increase in CTGF mRNA, but $\Delta p85$ of PI3-kinase completely inhibited VEGF-induced CTGF expression ($p < 0.001$).

Example 7: Role of PKC ζ and Akt/PKB in VEGF-induced CTGF Expression

Since it has been reported that atypical PKC and Akt/PKB have significant roles as signaling molecules downstream of PI3-kinase, the involvement of PKC ζ and Akt in this process were examined. BREC were infected with each adenoviral vector, followed by

stimulation with 25 ng/ml VEGF for 6 h. Neither wild type PKC ζ nor dominant negative PKC ζ (DNPKC ζ) had significant effects on VEGF-induced increase in CTGF mRNA. In contrast, infection with constitutive active Akt (CAAkt) increased CTGF mRNA expression 2.1 ± 0.21 -fold ($p < 0.01$) without VEGF and 2.5 ± 0.40 -fold with VEGF. Overexpression with adenoviral vector containing dominant negative Akt (DNAkt) inhibited VEGF-induced CTGF expression by $85 \pm 13\%$ ($p < 0.01$).

Example 8: Methods

A) **Materials**-- Endothelial cell basal medium was purchased from Clonetics (San Diego, CA). Endothelial cell growth factor was purchased from Roche Molecular Biochemicals. Dulbecco's modified Eagle's medium and fetal bovine serum were obtained from Life Technologies, Inc. VEGF, placenta growth factor (PlGF), TGF- β 1, and anti-CTGF antibody were ordered from R & D Systems (Minneapolis, MN). Anti-KDR (Flk1) and anti-Flt1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Protein A-Sepharose was purchased from Amersham Pharmacia Biotech. Anti-phospho-Erk, anti-Erk, anti-phospho-Akt, and anti-Akt were purchased from New England Biolabs (Beverly, MA). Anti-p85 and anti-phosphotyrosine were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY). Phosphatidylinositol (PI) was purchased from Avanti (Alabaster, AL), and PD98059, wortmannin, and GF 109203X were obtained from Calbiochem. All other materials were ordered from Fisher and Sigma.

B) **Cell Culture**-- Primary cultures of bovine retinal endothelial cells (BREC) and pericytes (BRPC) were isolated by homogenization and a series of filtration steps as described previously. BREC were subsequently cultured with endothelial cell basal medium supplemented with 10% plasma-derived horse serum, 50 mg/liter heparin, and 50 μ g/ml endothelial cell growth factor. BRPC were cultured in Dulbecco's modified Eagle's medium with 5.5 mM glucose and 20% fetal bovine serum. Cells were cultured in 5% CO₂ at 37 °C, and media were changed every 3 days. Cells were characterized for their homogeneity by immunoreactivity with anti-factor VIII antibody for BREC and with monoclonal antibody 3G5 for BRPC. Cells remained morphologically unchanged under these conditions, as confirmed by light microscopy. Only cells from passages 2 through 7 were used for the experiments.

C) *Recombinant Adenoviruses*— cDNA of constitutive active Akt (CAAkt, Gag protein fused to N-terminal of wild type Akt) was constructed as in Burgering et al. (1995) *Nature* 376, 599-602. cDNA of dominant negative Akt (DNAkt, substituted Thr-308 to Ala and Ser-473 to Ala) was constructed as described in Kitamura et al. (1998) *Mol. Cell. Biol.* 18, 3708-3717. cDNA of dominant negative K-Ras (DNK-Ras, substituted Ser-17 to Asn) was kindly provided by Dr. Takai (Osaka University). cDNA of dominant negative extracellular signal-regulated kinase (DNERK, substituted Lys-52 to Arg in ATP-binding site) was constructed as described in Her et al. (1993) *Biochem. J.* 296, 25-3. cDNA of $\Delta p85$ was kindly provided by Dr. Kasuga (Kobe University). cDNA of PKC ζ was kindly provided by Dr. Douglas Ways (Lilly). cDNA of dominant negative PKC ζ (DNPKC ζ , substituted Lys-273 to Trp in ATP-binding site) was constructed as in Uberall et al. (1999) *J. Cell Biol.* 144, 413-425.

The recombinant adenoviruses were constructed by homologous recombination between the parental virus genome and the expression cosmid cassette or shuttle vector. The adenoviruses were applied at a concentration of 1×10^8 plaque-forming units/ml, and adenoviruses with the same parental genome carrying the *lacZ* gene or enhanced green fluorescein protein gene (CLONTECH, Palo Alto, CA) were used as controls. Expression of each recombinant protein was confirmed by Western blot analysis and increased about 10-fold compared with cells infected with the control adenovirus.

D) *Immunoprecipitation*— Cells were washed three times with cold phosphate-buffered saline and solubilized in 200 μ l of lysis buffer (1% Triton X-100, 50 mmol/liter HEPES, 10 mmol/liter EDTA, 10 mmol/liter sodium pyrophosphate, 100 mmol/liter sodium fluoride, 1 mmol/liter sodium orthovanadate, 1 μ g/ml aprotinin, 1 μ g/ml leupeptin, and 2 mmol/liter phenylmethylsulfonyl fluoride). After centrifugation at 12,000 rpm for 10 min, 1.0 mg of protein was subjected to immunoprecipitation. To clear the protein extract, protein A-Sepharose (20 μ l of a 50% suspension) was added to the cell lysates, after which they were incubated for 1 h, followed by centrifugation and collection of the supernatant. A specific rabbit anti-KDR or Flt1 antibody was added and rocked at 4 °C for 2 h; 20 μ l of protein A-Sepharose was then added, and the sample was rocked for another 2 h at 4 °C. For denaturation, protein A-Sepharose antigen-antibody conjugates were separated by centrifugation, washed five times, and boiled for

3 min in Laemmli sample buffer.

E) Western Blot Analysis-- Immunoprecipitated proteins or 30 μ g of total cell lysates were subjected to SDS-gel electrophoresis and electrotransferred to nitrocellulose membrane (Bio-Rad). The membrane was soaked in blocking buffer (phosphate-buffered saline containing 0.1% Tween 20 and 5% bovine serum albumin) for 1 h at room temperature and incubated with primary antibody overnight at 4 °C followed by incubation with horseradish peroxidase-conjugated secondary antibody (Amersham Pharmacia Biotech). Visualization was performed using the enhanced chemiluminescence detection system (ECL, Amersham Pharmacia Biotech) per the manufacturer's instructions.

F) PI3-Kinase Assay-- PI3-kinase activities were measured by the *in vitro* phosphorylation of PI as in Xia et al. (1996) J. Clin. Invest. 98, 2018-2026. Cells were lysed in ice-cold lysis buffer containing 50 mM HEPES, pH 7.5, 137 mM NaCl, 1 mM $MgCl_2$, 1 mM $CaCl_2$, 2 mM Na_3VO_4 , 10 mM NaF, 2 mM EDTA, 1% Nonidet P-40, 10% glycerol, 1 mM phenylmethylsulfonyl fluoride, 2 μ g/ml aprotinin, 5 μ g/ml leupeptin, and 1 μ g/ml pepstatin. Insoluble material was removed by centrifugation at $15,000 \times g$ for 10 min at 4 °C. PI3-kinase was immunoprecipitated from aliquots of the supernatant with antiphosphotyrosine antibodies. After successive washings, the pellets were resuspended in 50 μ l of 10 mM Tris, pH 7.5, 100 mM NaCl, and 1 mM EDTA. 10 μ l of 100 mM $MgCl_2$ and 10 μ l of PI (2 μ g/ μ l) sonicated in 10 mM Tris, pH 7.5, with 1 mM EGTA was added to each pellet. The PI3-kinase reaction was initiated by the addition of 5 μ l of 0.5 mM ATP containing 30 μ Ci of [γ - ^{32}P]ATP. After 10 min at room temperature with constant shaking, the reaction was stopped by the addition of 20 μ l of 8 N HCl and 160 μ l of chloroform/methanol (1:1). The samples were centrifuged, and the organic phase was removed and applied to silica gel TLC plates developing in $CHCl_3/CH_3OH/H_2O/NH_4OH$ (60:47:11:2). The radioactivity in spots was quantified by PhosphorImager (Molecular Dynamics, Sunnyvale, CA).

G) Amplification of Human CTGF cDNA Using Reverse Transcriptase-Polymerase Chain Reaction (PCR)-- cDNA templates for PCR were synthesized by reverse transcriptase (First Strand cDNA Synthesis Kit, Amersham Pharmacia Biotech) from human fibroblast

according to the method recommended by the manufacturer. A standard PCR was performed (PCR optimizer kit, Invitrogen, Carlsbad, CA) using 5'-AGGGCCTCTTCTGTGACTTCG-3' (sense primer) and 5'-TCATGCCATGTCTCCGTACATC-3' (antisense primer). The PCR products were then subcloned into a vector (pCRII, Invitrogen) and sequenced in their entirety, and comparison with the published human sequences revealed complete sequence identity. This cDNA probe was used for hybridization.

H) Northern Blot Analysis-- Total RNA was isolated using acid-guanidinium thiocyanate, and Northern blot analysis was performed. Total RNA (20 µg) was electrophoresed through 1% formaldehyde-agarose gels and then transferred to a nylon membrane. ³²P-Labeled cDNA probes were generated by use of labeling kits (Megaprime DNA labeling systems, Amersham Pharmacia Biotech). After ultraviolet cross-linking using a UV cross-linker (Stratagene, La Jolla, CA), blots were pre-hybridized, hybridized, and washed in 0.5× SSC, 5% SDS at 65 °C with 4 changes over 1 h. All signals were analyzed using a PhosphorImager, and lane loading differences were normalized.

I) Analysis of CTGF mRNA Half-life-- CTGF mRNA half-life experiments were carried out using BREC and BRPC. The cells were exposed to vehicle or VEGF (25 ng/ml) for the indicated periods prior to mRNA stability measurements. Transcription was inhibited by the addition of actinomycin D (5 µg/ml). For inhibition of protein synthesis, cells were treated with cycloheximide (10 µg/ml) for the times indicated.

J) Statistical Analysis-- Determinations were performed in triplicate, and all experiments were repeated at least three times. Results are expressed as the mean ± S.D., unless otherwise indicated. Statistical analysis employed Student's *t* test or analysis of variance to compare quantitative data populations with normal distributions and equal variance. Data were analyzed using the Mann-Whitney rank sum test or the Kruskal-Wallis test for populations with non-normal distributions or unequal variance. A *p* value of <0.05 was considered statistically significant.

All patents and references cited herein are hereby incorporated by reference in their

WO 02/07747

PCT/US01/22347

entirety.

We claim:

1. A method of decreasing fibrosis in a tissue of a subject, comprising:
identifying a subject in need of decreased fibrosis; and
administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
2. The method of claim 1, wherein the agent decreases the level or activity of VEGF or a VEGF receptor (VEGFR).
3. The method of claim 2, wherein the VEGFR is KDR, Flt1, Flt4 or neuropilin.
4. The method of claim 2, wherein the agent is selected from the group of: a VEGF binding or VEGF receptor (VEGFR) binding protein that inhibits VEGF binding to VEGFR; an antibody to VEGF or VEGFR that inhibits VEGF or VEGFR activity; a mutated VEGF or VEGFR or fragment thereof that inhibits VEGF signaling; a VEGF or VEGFR nucleic acid molecule that inhibits expression of VEGF or VEGFR; and a small molecule that inhibits transcription or activity of VEGF or VEGFR.
5. The method of claim 1, wherein the agent decreases the level or activity of AKT.
6. The method of claim 5, wherein the agent is selected from the group of: an AKT binding protein that inhibits AKT activity; an antibody to AKT that inhibits AKT activity; a mutated AKT or fragment thereof that inhibits AKT activity; an AKT nucleic acid molecule that inhibits expression of AKT; and a small molecule that inhibits transcription or activity of AKT.
7. The method of claim 1, wherein the agent decreases the level or activity of PI3 kinase.
8. The method of claim 7, wherein the agent is selected from the group of: a PI3 kinase binding protein that inhibits PI3 kinase activity; an antibody to PI3 kinase that inhibits PI3 kinase

activity; a mutated PI3 kinase or fragment thereof that inhibits PI3 kinase activity; a PI3 kinase nucleic acid molecule that inhibits expression of PI3 kinase; and a small molecule that inhibits transcription or activity of PI3 kinase.

9. The method of claim 7, wherein the agent is LY294002.
10. The method of claim 7, wherein the agent is wortmannin.
11. The method of claim 1, wherein the subject has a fibrosis related disorder.
12. The method of claim 1, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, or retinal tissue.
13. A method of decreasing angiogenesis in a tissue of a subject, comprising:
 - identifying a subject in need of decreased angiogenesis; and
 - administering to the subject an agent that inhibits a component of the VEGF signal transduction pathway, wherein the agent decreases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
14. The method of claim 13, wherein the tissue is skin tissue, lung tissue, cardiac tissue, kidney tissue, liver tissue, retinal tissue, or cancerous or tumor tissue.
15. The method of claim 13, wherein the agent is selected from the group of:
 - a) an agent that inhibits VEGF activity;
 - b) an agent that inhibits VEGFR signaling;
 - c) an agent that inhibits PI3 kinase activity;
 - d) an agent that inhibits a VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that inhibits AKT activity; and
 - f) an agent that inhibits ERK activity.

16. The method of claim 15, wherein the VEGFR is KDR or Flt1.
17. A method of increasing fibrosis in a subject, comprising:
 - identifying a subject in need of increased fibrosis; and
 - administering to the subject an agent that induces a component of the VEGF signal transduction pathway, wherein the agent increases a connective tissue growth factor (CTGF) activity in the tissue of the subject.
18. The method of claim 17, wherein the agent is selected from the group of:
 - a) an agent that decreases a PKC activity;
 - b) an agent that increases VEGF activity;
 - c) an agent that increases VEGFR signaling;
 - d) an agent that increases VEGFR interaction with p85 subunit of PI3-kinase;
 - e) an agent that increases PI3 kinase activity; and
 - f) an agent that increases AKT activity.
19. The method of claim 17, wherein the agent is VEGF or placental growth factor (PlGF)
20. The method of claim 17, wherein the agent is a transition metal ion.
21. The method of claim 18, wherein the VEGFR is KDR or Flt1.
22. A method of screening for a compound that decreases fibrosis or angiogenesis, comprising:
 - providing a cell, tissue, or subject;
 - contacting the cell, tissue, or subject with a test compound; and
 - determining whether the test compound inhibits a component of the VEGF signaling pathway.
23. The method of claim 22, further comprising contacting the cell, tissue, or subject with VEGF.

24. The method of claim 22, further comprising assaying the cell, tissue or subject for a CTGF activity.
25. The method of claim 22, wherein the cell is an endothelial cell
26. The method of claim 22, wherein the cell is a bovine retinal endothelial cell (BREC) or bovine retinal pericyte (BRPC).

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
27 December 2001 (27.12.2001)

PCT

(10) International Publication Number
WO 01/97850 A2

(51) International Patent Classification⁷: **A61K 45/06**

(21) International Application Number: **PCT/EP01/06976**

(22) International Filing Date: **20 June 2001 (20.06.2001)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:
00250194.8 23 June 2000 (23.06.2000) EP
00250214.4 28 June 2000 (28.06.2000) EP

(71) Applicant: **SCHERING AKTIENGESELLSCHAFT**
[DE/DE]; Müllerstrasse 178, 13353 Berlin (DE).

(71) Applicants and

(72) Inventors: **SIEMEISTER, Gerhard** [DE/DE]; Reimer-
swalder Steig 26, 13503 Berlin (DE). **HABEREY, Mar-
tin** [DE/DE]; Steinstr. 1, 12169 Berlin (DE). **THIER-
AUCH, Karl-Heinz** [DE/DE]; Hochwildpfad 45, 14169
Berlin (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— *without international search report and to be republished
upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*



WO 01/97850 A2

(54) Title: **COMBINATIONS AND COMPOSITIONS WHICH INTERFERE WITH VEGF/VEGF AND ANGIOPOIETIN/TIE
RECEPTOR FUNCTION AND THEIR USE (II)**

(57) Abstract: The present invention describes the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

**Combinations and compositions which interfere with VEGF/ VEGF and
angiopoietin/ Tie receptor function and their use (II)**

- 5 The present invention provides the combination of substances interfering with the biological activity of Vascular Endothelial Growth Factor (VEGF)/VEGF receptor systems (compound I) and substances interfering with the biological function of Angiopoietin/Tie receptor systems (compound II) for inhibition of vascularization and for cancer treatment.

10

Protein ligands and receptor tyrosine kinases that specifically regulate endothelial cell function are substantially involved in physiological as well as in disease-related angiogenesis. These ligand/receptor systems include the Vascular Endothelial Growth Factor (VEGF) and the Angiopoietin (Ang) families, and their
15 receptors, the VEGF receptor family and the tyrosine kinase with immunoglobulin-like and epidermal growth factor homology domains (Tie) family. The members of the two families of receptor tyrosine kinases are expressed primarily on endothelial cells. The VEGF receptor family includes Flt1 (VEGF-R1), Flk1/KDR (VEGF-R2), and Flt4 (VEGF-R3). These receptors are recognized by members of
20 the VEGF-related growth factors in that the ligands of Flt1 are VEGF and placenta growth factor (PIGF), whereas Flk1/KDR binds VEGF, VEGF-C and VEGF-D, and the ligands of Flt4 are VEGF-C and VEGF-D (Nicosia, Am. J. Pathol. 153, 11-16, 1998). The second family of endothelial cell specific receptor tyrosine kinases is represented by Tie1 and Tie2 (also known as Tek). Whereas Tie1 remains an
25 orphan receptor, three secreted glycoprotein ligands of Tie2, Ang1, Ang2, and Ang3/Ang4 have been discovered (Davis et al., Cell 87, 1161-1169, 1996; Maisonpierre et al., Science 277, 55-60, 1997; Valenzuela et al., Proc. Natl. Acad. Sci. USA 96, 1904-1909, 1999; patents: US 5,521,073; US 5,650,490; US 5,814,464).

30

The pivotal role of VEGF and of its receptors during vascular development was exemplified in studies on targeted gene inactivation. Even the heterozygous disruption of the VEGF gene resulted in fatal deficiencies in vascularization (Carmeliet et al., Nature 380, 435-439, 1996; Ferrara et al., Nature 380, 439-442,

1996). Mice carrying homozygous disruptions in either Flt1 or Flk1/KDR gene die in mid-gestation of acute vascular defects. However, the phenotypes are distinct in that Flk1/KDR knock-out mice lack both endothelial cells and a developing hematopoietic system (Shalaby et al. *Nature* 376, 62-66, 1995), whereas Flt1
5 deficient mice have normal hematopoietic progenitors and endothelial cells, which fail to assemble into functional vessels (Fong et al., 376, 66-70, 1995). Disruption of the Flt4 gene, whose extensive embryonic expression becomes restricted to lymphatic vessels in adults, revealed an essential role of Flt4 for the remodeling and maturation of the primary vascular networks into larger blood vessels during
10 early development of the cardiovascular system (Dumont et al., *Science* 282, 946-949, 1998). Consistent with the lymphatic expression of Flt4 in adults overexpression of VEGF-C in the skin of transgenic mice resulted in lymphatic, but not vascular, endothelial proliferation and vessel enlargement (Jeltsch et al., *Science* 276, 1423-1425, 1997). Moreover, VEGF-C was reported to induce
15 neovascularization in mouse cornea and chicken embryo chorioallantoic membrane models of angiogenesis (Cao et al., *Proc. Natl. Acad. Sci. USA* 95, 14389-14394, 1998).

The second class of endothelial cell specific receptor tyrosine kinases has also
20 been found to be critically involved in the formation and integrity of vasculature. Mice deficient in Tie1 die of edema and hemorrhage resulting from poor structural integrity of endothelial cells of the microvasculature (Sato et al., *Nature* 376, 70-74, 1995; Rodewald & Sato, *Oncogene* 12, 397-404, 1996). The Tie2 knock-out phenotype is characterized by immature vessels lacking branching networks and
25 lacking periendothelial support cells (Sato et al., *Nature* 376, 70-74, 1995; Dumont et al., *Genes Dev.* 8, 1897-1909, 1994). Targeted inactivation of the Tie2 ligand Ang1, as well as overexpression of Ang2, an inhibitory ligand, resulted in phenotypes similar to the Tie2 knock out (Maisonpierre et al., *Science* 277, 55-60, 1997; Suri et al., *cell* 87, 1171-1180). Conversely, increased vascularization was
30 observed upon transgenic overexpression of Ang1 (Suri et al., *Science* 282, 468-471, 1998; Thurston et al., *Science* 286, 2511-2514, 1999).

The results from angiogenic growth factor expression studies in corpus luteum development (Maisonpierre et al., *Science* 277, 55-60, 1997; Goede et al. *Lab.*

Invest. 78, 1385-1394, 1998), studies on blood vessel maturation in the retina (Alon et al., Nature Med. 1, 1024-1028, 1995; Benjamin et al, Development 125, 1591-1598, 1998), and gene targeting and transgenic experiments on Tie2, Ang1, and Ang2, suggest a fundamental role of the Angiopoietin/Tie receptor system in
5 mediating interactions between endothelial cells and surrounding pericytes or smooth muscle cells. Ang1, which is expressed by the periendothelial cells and seems to be expressed constitutively in the adult, is thought to stabilize existing mature vessels. Ang2, the natural antagonist of Ang1 which is expressed by endothelial cells at sites of vessel sprouting, seems to mediate loosening of
10 endothelial-periendoneothelial cell contacts to allow vascular remodeling and sprouting in cooperation with angiogenesis initiators such as VEGF, or vessel regression in the absence of VEGF (Hanahan, Science 277, 48-50, 1997).

In pathological settings associated with aberrant neovascularization elevated
15 expression of angiogenic growth factors and of their receptors has been observed. Most solid tumors express high levels of VEGF and the VEGF receptors appear predominantly in endothelial cells of vessels surrounding or penetrating the malignant tissue (Plate et al., Cancer Res. 53, 5822-5827, 1993). Interference with the VEGF/VEGF receptor system by means of VEGF-neutralizing antibodies
20 (Kim et al., Nature 362, 841-844, 1993), retroviral expression of dominant negative VEGF receptor variants (Millauer et al., Nature 367, 576-579, 1994), recombinant VEGF-neutralizing receptor variants (Goldman et al., Proc. Natl. Acad. Sci. USA 95, 8795-8800, 1998), or small molecule inhibitors of VEGF receptor tyrosine kinase (Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60,
25 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000), or targeting cytotoxic agents via the VEGF/VEGF receptor system (Arora et al., Cancer Res. 59, 183-188, 1999; EP 0696456A2) resulted in reduced tumor growth and tumor vascularization. However, although many tumors were inhibited by interference with the VEGF/VEGF receptor system, others were unaffected (Millauer et al.,
30 Cancer Res. 56, 1615-1620, 1996). Human tumors as well as experimental tumor xenografts contain a large number of immature blood vessels that have not yet recruited periendothelial cells. The fraction of immature vessels is in the range of 40% in slow growing prostate cancer and 90% in fast growing glioblastoma. A selective obliteration of immature tumor vessels was observed upon withdrawal of

VEGF by means of downregulation of VEGF transgene expression in a C6 glioblastoma xenograft model. This result is in accordance with a function of VEGF as endothelial cell survival factor. Similarly, in human prostate cancer shutting off VEGF expression as a consequence of androgen-ablation therapy led to selective apoptotic death of endothelial cells in vessels lacking periendothelial cell coverage. In contrast, the fraction of vessels which resisted VEGF withdrawal showed periendothelial cell coverage (Benjamin et al., J. Clin. Invest. 103, 159-165, 1999).

10 The observation of elevated expression of Tie receptors in the endothelium of metastatic melanomas (Kaipainen et al., Cancer Res. 54, 6571-6577, 1994), in breast carcinomas (Salvén et al., Br. J. Cancer 74, 69-72, 1996), and in tumor xenografts grown in the presence of dominant-negative VEGF receptors (Millauer et al., Cancer Res. 56, 1615-1620, 1996), as well as elevated expression of Flt4
15 receptors in the endothelium of lymphatic vessels surrounding lymphomas and breast carcinomas (Jussila et al., Cancer Res. 58, 1599-1604, 1998), and of VEGF-C in various human tumor samples (Salvén et al., Am. J. Pathol. 153, 103-108, 1998), suggested these endothelium-specific growth factors and receptors as candidate alternative pathways driving tumor neovascularization. The high
20 upregulation of Ang2 expression already in early tumors has been interpreted in terms of a host defense mechanism against initial cooption of existing blood vessels by the developing tumor. In the absence of VEGF, the coopted vessels undergo regression leading to necrosis within the center of the tumor. Contrarily, hypoxic upregulation of VEGF expression in cooperation with elevated Ang2
25 expression rescues and supports tumor vascularization and tumor growth at the tumor margin (Holash et al., Science 284, 1994-1998, 1999; Holash et al., Oncogene 18, 5356-5362, 1999).

Interference with Tie2 receptor function by means of Angiopoietin-neutralizing
30 Tie2 variants consisting of the extracellular ligand-binding domain has been shown to result in inhibition of growth and vascularization of experimental tumors (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al. Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Comparing the effects of interference with the endothelium-specific receptor

tyrosine kinase pathways by means of paracrine expression of the respective extracellular receptor domains on the same cellular background demonstrated inhibition of tumor growth upon blockade of the VEGF receptor system and of the Tie2 receptor system, respectively (Siemeister et al., Cancer Res. 59, 3185-3191, 5 1999).

It is known that the inhibition of the VEGF/VEGR receptor system by various methods resulted only in slowing down growth of most experimental tumors (Millauer et al., Nature 367, 576-579, 1994; Kim et al., Nature 362, 841-844, 1993; Millauer et al., Cancer Res. 56, 1615-1620, 1996; Goldman et al., Proc. Natl. 10 Acad. Sci. USA 95, 8795-8800, 1998; Fong et al., Cancer Res. 59, 99-106, 1999; Wedge et al., Cancer Res. 60, 970-975, 2000; Wood et al. Cancer Res. 60, 2178-2189, 2000; Siemeister et al., Cancer Res. 59, 3185-3191, 1999). Even by escalation of therapeutic doses a plateau level of therapeutic efficacy was achieved (Kim et al., Nature 362, 841-844, 1993; Wood et al. Cancer Res. 60, 15 2178-2189, 2000). Similar results were observed upon interference with the Angiopoietin/Tie2 receptor system (Lin et al., J. Clin. Invest. 103, 159-165, 1999; Lin et al., Proc. Natl. Acad. Sci. USA 95, 8829-8834, 1998; Siemeister et al., Cancer Res. 59, 3185-3191, 1999).

20 However, there is a high demand for methods that enhance the therapeutic efficacy of anti-angiogenous compounds.

Searching for methods that enhance the therapeutic efficacy of anti-angiogenic compounds, superior anti-tumor effects were observed unexpectedly upon 25 combination of inhibition of VEGF/VEGF receptor systems and interference with biological function of Angiopoietin/Tie receptor systems. The mode of action underlying the superior effects observed may be that interference biological function of Angiopoietin/Tie receptor systems destabilizes endothelial cell-peri-endothelial cell interaction of existing mature tumor vessels and thereby 30 sensitizes the endothelium to compounds directed against VEGF/VEGF receptor systems.

Based on this unexpected finding the present invention provides the combination of functional interference with VEGF/VEGF receptor systems and with

Angiopoietin/Tie receptor systems for inhibition of vascularization and of tumor growth.

The pharmaceutical composition consists of two components: compound I inhibits the biological activity of one or several of the VEGF/VEGF receptor systems or
5 consists of cytotoxic agents which are targeted to the endothelium via recognition of VEGF/VEGF receptor systems. Compound II interferes with the biological function of one or several of Angiopoietin/Tie receptor systems or consists of cytotoxic agents which are targeted to the endothelium via recognition of Angiopoietin/Tie receptor systems. Alternatively, compound I inhibits the biological
10 activity of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems and compound II consists of cytotoxic agents which are targeted to the endothelium via recognition of one or several of the VEGF/VEGF receptor systems or of the Angiopoietin/Tie receptor systems. Targeting or modulation of the biological activities of VEGF/VEGF receptor
15 systems and of Angiopoietin/Tie receptor systems can be performed by

- (a) compounds which inhibit receptor tyrosine kinase activity,
- (b) compounds which inhibit ligand binding to receptors,
- (c) compounds which inhibit activation of intracellular signal pathways of the
20 receptors,
- (d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- (e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents
25 or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- (f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

30

A compound comprised by compositions of the present invention can be a small molecular weight substance, an oligonucleotide, an oligopeptide, a recombinant protein, an antibody, or conjugates or fusionproteins thereof. An example of an inhibitor is a small molecular weight molecule which inactivates a receptor tyrosine

kinase by binding to and occupying the catalytic site such that the biological activity of the receptor is decreased. Kinase inhibitors are known in the art (Sugen: SU5416, SU6668; Fong et al. (1999), *Cancer Res.* 59, 99-106; Vajkoczy et al., *Proc. Am. Associ. Cancer Res. San Francisco* (2000), Abstract ID 3612; Zeneca: ZD4190, ZD6474; Wedge et al. (2000), *Cancer Res.* 60, 970-975; Parke-Davis PD0173073, PD0173074; Johnson et al., *Proc. Am. Associ. Cancer Res., San Francisco* (2000), Abstract ID 3614; Dimitroff et al. (1999), *Invest. New Drugs* 17, 121-135). An example of an antagonist is a recombinant protein or an antibody which binds to a ligand such that activation of the receptor by the ligand is prevented. Another example of an antagonist is an antibody which binds to the receptor such that activation of the receptor is prevented. An example of an expression modulator is an antisense RNA or ribozyme which controls expression of a ligand or a receptor. An example of a targeted cytotoxic agent is a fusion protein of a ligand with a bacterial or plant toxin such as *Pseudomonas* exotoxin A, Diphtheria toxin, or Ricin A. An example of a targeted coagulation-inducing agent is a conjugate of a single chain antibody and tissue factor. Ligand-binding inhibitors such as neutralizing antibodies which are known in the art are described by Genentech (rhUMAbVEGF) and by Presta et al. (1997), *Cancer Res.* 57, 4593-4599. Ligand-binding receptor domains are described by Kendall & Thomas (1993), *Proc. Natl. Acad. Sci., U.S.A.* 90, 10705-10709; by Goldman et al. (1998) *Proc. Natl. Acad. Sci., U.S.A.* 95, 8795-8800 and by Lin et al. (1997), *J. Clin. Invest.* 100, 2072-2078. Further, dominant negative receptors have been described by Millauer et al. (1994), *Nature* 367, 567-579.


Receptor blocking antibodies have been described by Imclone (c-p1C11, US 5,874,542). Further known are antagonistic ligand mutants (Siemeister et al. (1998), *Proc. Natl. Acad. Sci., U.S.A.* 95, 4625-4629). High affinity ligand- or receptor binding oligo nucleotides have been described by NeXstar (NX-244) and Drolet et al. (1996), *Nat. Biotech* 14, 1021-1025. Further, small molecules and peptides have been described.

Expression regulators have been described as anti-sense oligo nucleotides and as ribozymes (RPI, Angiozyme™, see RPI Homepage).

Examples for delivery-/Targeting-Systems have been described as ligand/
 antibody-toxin-fusion-proteins or conjugates (Arora et al. (1999), Cancer Res. 59,
 183-188 and Olson et al. (1997), Int. J. Cancer 73, 865-870), as endothel cell
 targeting of liposomes (Spragg et al. (1997), Prog. Natl. Acad. Sci, U.S.A94, 8795-
 5 8800, and as endothel cell targeting plus coagulation-induction (Ran et al., (1998),
 Cancer Res. 58, 4646-4653).

10 Small molecules which inhibit the receptor tyrosine kinase activity are for example
 molecules of general formula I

15



20

in which


r has the meaning of 0 to 2,

n has the meaning of 0 to 2;

25

R₃ und R₄ a) each independently from each other have the meaning
 of lower alkyl,

b) together form a bridge of general partial formula II,




5

m

wherein the binding is via the two terminal C- atoms, and has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

10



15

wherein one or two of the ring members T_1, T_2, T_3, T_4 has the meaning of nitrogen, and each others have the meaning of CH, and the bining is via the atoms T_1 and T_4 ;

G

20

has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

A, B, D, E and T

25

independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

Q has the meaning of lower alkyl, lower alkyloxy or halogene,
R₁ and R₂ independently from each other have the meaning of H or
lower alkyl,
X has the meaning of imino, oxa or thia;
5 Y has the meaning of hydrogen, unsubstituted or substituted
aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and
Z has the meaning of amino, mono- or disubstituted amino,
halogen, alkyl, substituted alkyl, hydroxy, etherified or
esterified hydroxy, nitro, cyano, carboxy, esterified
10 carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted
carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio,
phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl,
phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl,
phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if
15 more than one rest Z is present ($m \geq 2$), the substituents Z are
equal or different from each other, and wherein the bonds
marked with an arrow are single or double bonds; or an N-
oxide of said compound, wherein one or more N-atoms carry
an oxygen atom, or a salt thereof.

20

A preferred salt is the salt of an organic acid, especially a succinate.


These compounds can preferentially be used as compound I or II in the inventive
pharmaceutical composition.

25

Compounds which stop a tyrosin phosphorylation, or the persistent angiogenesis,
respectively, which results in a prevention of tumor growth and tumor spread, are
for example

anthranil acid derivatives of general formula IV

30



in which

A


has the meaning of group =NR²,

W


has the meaning of oxygen, sulfur, two hydrogen atoms or the group =NR⁸,

Z

has the meaning of the group =NR¹⁰ or =N-, -N(R¹⁰)- (CH₂)_q, branched or unbranched C₁₋₆-Alkyl or is the group



or A, Z and R¹ together form the group



m, n and o

q

R_a, R_b, R_c, R_d, R_e, R_f

has the meaning of 0 – 3,

has the meaning of 1 – 6,

independently from each other have the meaning of hydrogen, C₁₋₄ alkyl or the group =NR¹⁰, and/or R_a and/or R_b together with R_c and/or R_d or R_c together with R_e and/or R_f form a bound, or up to two of the groups R_a-R_f form a bridge with each up to 3 C-atoms with R¹ or R²,

has the meaning of group =NR⁹ or =N-,

has the meaning of group -(CH₂)_p,

has the meaning of integer 1-4,

has the meaning of unsubstituted or optionally substituted with one or more of halogene, C₁₋₆-alkyl, or C₁₋₆-alkyl or C₁₋₆-alkoxy, which is

optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or

heteroaryl,

has the meaning of hydrogen or C₁₋₆-alkyl, or


form a bridge with up to 3 ring atoms with R_a-R_f together with Z or R₁,

has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally substituted with one or more of für halogen, C₁₋₆-alkyl, C₁₋₆-alkoxy or hydroxy,

independently from each other have the meaning of hydrogen, halogen or C₁₋₆-alkoxy, C₁₋₆-alkyl or

R⁴, R⁵, R⁶ and R⁷


C₁₋₆-carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogen, or R⁵ and R⁶ together form the group



- 5 R⁸, R⁹ and R¹⁰ independently from each other have the meaning of hydrogen or C₁₋₆-alkyl, as well as their isomers and salts.


10 These compounds can also preferentially be used as compound I or II in the inventive pharmaceutical composition.

More preferentially compounds of general formula V




- 15 V,
in which
R¹ has the meaning of group


20




14



in which R⁵ is chloro, bromo or the group -OCH₃,



in which R⁷ is -CH₃ or chloro,




in which R^8 is $-CH_3$, fluoro, chloro or $-CF_3$

in which R^4 is fluoro, chloro, bromo, $-CF_3$, $-N=C$, $-CH_3$, $-OCF_3$ or $-CH_2OH$

in which R^6 is $-CH_3$ or chloro

R^2

has the meaning of pyridyl or the group



and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts can be used as compound I or II in the inventive pharmaceutical composition.

These compounds have the same properties as already mentioned above under

compound IV and can be used for the treatment of angiogeneous diseases.

Compositions comprise compounds of general formulars I, IV and V, alone or in combination.

The above mentioned compounds are also claimed matter within the inventive combinations.

A further example for ligand binding inhibitors are peptides and DNA sequences coding for such peptides, which are used for the treatment of angiogeneous diseases. Such peptides and DNA sequences are disclosed in Seq. ID No. 1 to 59 of the sequence protocoll. It has been shown that Seq. ID Nos. 34 and 34a are of main interest.

Claimed matter of the instant invention are therefor pharmaceutical compositions

- 5 a) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 10 b) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems,
- 15 c) comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium,
- 20 d) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 25 e) comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems,
- 30 f) comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems,
- g) comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems and

h) comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.

5

For a sequential therapeutical application the inventive pharmaceutical compositions can be applied simultaneously or separately .

The inventive compositions comprise as compound I or as compound II at least one of

10

- a) compounds which inhibit receptor tyrosine kinase activity,
- b) compounds which inhibit ligand binding to receptors,
- c) compounds which inhibit activation of intracellular signal pathways of the receptors,
- 15 d) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of
- 20 VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

These compositions are also claimed matter of the present invention.

25

Also claimed matter of the present invention are pharmaceutical compositions which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.

Of most value are pharmaceutical compositions, which comprise as compound I and/ or II Seq. ID Nos. 34a und pharmaceutical compositions according to claims

30 which comprise as compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

Further preferred matter of the present invention are pharmaceutical compositions, which comprise as compound I and/ or II at least one small molecule of general formula I, general formula IV and/ or general formula V.

- 5 The most preferred compound which can be used as compound I or II in the inventive composition is (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate.

Therefore, claimed matter of the present invention are also pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II, and most preferred pharmaceutical compositions, which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate; pharmaceutical compositions, which comprise as compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35; pharmaceutical compositions, which comprise as compound I L19 scFv-tTF conjugate and as compound II sTie2.

The small molecule compounds, proteins and DNA's expressing proteins, as mentioned above can be used as medicament alone, or in form of formulations for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaucoma, kidney diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis and damage of nerve tissues.

The treatment of the damaged nerve tissues with the inventive combination hinders the rapid formation of scars at the damaged position. Thus, there is no

scar formation before the axons communicate with each other. Therefore a reconstruction of the nerve bindings is much more easier.

Further, the inventive combinations can be used for suppression of the ascites
5 formation in patients. It is also possible to suppress VEGF oedemas.
For the use of the inventive combinations as medicament the compounds will be formulated as pharmaceutical composition. Said formulation comprises beside the active compound or compounds acceptable pharmaceutically, organically or inorganically inert carriers, such as water, gelatine, gum arabic, lactose, starch,
10 magnesium stearate, talcum, plant oils, polyalkylene glycols, etc. Said pharmaceutical preparations can be applied in solid form, such as tablets, pills, suppositories, capsules, or can be applied in fluid form, such as solutions, suspensions or emulsions.

If necessary, the compositions additionally contain additives, such as
15 preservatives, stabilizer, detergents or emulgators, salts for alteration of the osmotic pressure and/ or buffer.

These uses are also claimed matter of the instant invention, as well as the formulations of the active compounds

20 For parenteral application especially injectable solutions or suspensions are suitable, especially hydrous solutions of the active compound in polyhydroxyethoxylated castor-oil are suitable.

As carrier also additives can be used, such as salts of the gallic acid or animal or plant phospholipids, as well as mixtures thereof, and liposomes or ingredients
25 thereof.

For oral application especially suitable are tablets, pills or capsules with talcum and/ or hydrocarbon carriers or binders, such as lactose, maize or potato starch. The oral application can also be in form of a liquid, such as juice, which optionally contains a sweetener.

30 The dosis of the active compound differs depending on the application of the compound, age and weight of the patient, as well as the form and the progress of the disease.

The daily dosage of the active compound is 0,5-1000 mg, especially 50-200 mg.

The dosis can be applied as single dose or as two or more daily dosis.

These formulations and application forms are also part of the instant invention.

Combined functional interference with VEGF/VEGF receptor systems and with
5 Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to interference with one
ligand/receptor system overlaps with the biological response to interference with a
second ligand/receptor system. Alternatively, combined functional interference
with VEGF/VEGF receptor systems or with Angiopoietin/Tie receptor systems and
10 targeting of cytotoxic agents via VEGF/VEGF receptor systems or via
Angiopoietin/Tie receptor systems can be performed simultaneously, or in
sequential order such that the biological response to functional interference with a
ligand/receptor system overlaps in time with targeting of cytotoxic agents.

15 The invention is also directed to a substance which functional interferes with both
VEGF/VEGF receptor systems and Angiopoietin/Tie receptor systems, or which
are targeted via both VEGF/VEGF receptor systems and Angiopoietin/Tie receptor
systems.

20 VEGF/VEGF receptor systems include the ligands VEGF-A, VEGF-B, VEGF-C,
VEGF-D, PlGF, and the receptor tyrosine kinases VEGF-R1 (Flt1), VEGF-R2
(KDR/Flk1), VEGF-R3 (Flt4), and their co-receptors (i.e. neuropilin-1).
Angiopoietin/Tie receptor systems include Ang1, Ang2, Ang3/Ang4, and
angiopoietin related polypeptides which bind to Tie1 or to Tie2, and the receptor
25 tyrosine kinases Tie1 and Tie2.

Pharmaceutical compositions of the present invention can be used for medicinal
purposes. Such diseases are, for example, cancer, cancer metastasis,
angiogenesis including retinopathy and psoriasis. Pharmaceutical compositions of
30 the present invention can be applied orally, parenterally, or via gene therapeutic
methods.

Therefor the present invention also concerns the use of pharmaceutical
compositions for the production of a medicament for the treatment of tumors,

cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant nephrosclerosis, thrombotic microangiopathic syndrome, transplantation rejections
5 and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

The following examples demonstrate the feasibility of the disclosed invention, without restricting the invention to the disclosed examples.

5 Example 1

Superior effect on inhibition of tumor growth via combination of inhibition of the VEGF A/VEGF receptor system together with functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention was demonstrated in an A375v human melanoma xenograft model.

10

Human melanoma cell line A375v was stably transfected to overexpress the extracellular ligand-neutralizing domain of human Tie2 receptor tyrosine kinase (sTie2; compound II) (Siemeister et al., Cancer Res. 59, 3185-3191, 1999). For control, A375v cells were stably transfected with the empty expression vector (A375v/pCEP). Swiss *nu/nu* mice were s.c. injected with 1×10^6 transfected
15 A375v/sTie2 or A375v/pCEP tumor cells, respectively. Animals receiving compound I were treated for up to 38 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60,
20 2178-2189, 2000). Various modes of treatment are described in Table 1. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 1

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

5 Tumors derived from A375v/pCEP control cells reached a size of approx. 250 mm² (mean area) within 24 days (Figure 1) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) or separate interference with Angiopoietin/Tie2 receptor system by means of
10 expression of sTie2 (compound II, treatment group 3) delayed growth of tumors to a size of approx. 250 mm² to 31 days, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of interference with the VEGF/VEGF receptor system by means of the kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen
15 succinate (compound I + compound II, treatment group 4) delayed growth of the tumors to a size of approx. 250 mm² to 38 days.

This result clearly demonstrates the superior effect of a combination of interference with the VEGF-A/VEGF receptor system and the Angiopoietin/Tie2 receptor system over separate modes of intervention.

Example 2

Combination of functional interference with the Angiopoietin/Tie2 receptor system and neutralization of VEGF-A is superior to separate modes of intervention in
5 inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated twice weekly over a period of time of 4 weeks with intraperitoneal doses of
10 200 µg of the VEGF-A-neutralizing monoclonal antibody (mAb) 4301-42-35 (Schlaeppli et al., J. Cancer Res. Clin. Oncol. 125, 336-342, 1999). Various modes of treatment are described in Table 2. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its
15 perpendicular.

Table 2

treatment group	mode of treatment	
	mAb 4301-42-35 (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000
20 mm³ within 28 days (Figure 2) without treatment (group 1). Tumors treated with the VEGF-A-neutralizing mAb 4301-42-35 (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with

Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and neutralizing of VEGF-A by means of the mAb 4301-42-35 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of neutralization of VEGF-A and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 3

Combination of functional interference with the Angiopoietin/Tie2 receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is superior to separate modes of intervention in inhibition of tumor growth.

5

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) was expressed in *E. coli* and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods described by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound I were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 3. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

10

15

Table 3

treatment group	mode of treatment	
	scFv-tTF conjugate (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 3) without treatment (group 1). Tumors treated with the coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound I, treatment group 2) grew to a volume of approx. 500 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm², respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 300 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown. Similar effects can be expected upon targeting of cytotoxic agents to VEGF/VEGF receptor systems.

Example 4

Combination of functional interference with the VEGF/VEGF receptor system and targeting of a coagulation-inducing protein via the VEGF/VEGF receptor system is
5 superior to separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of a single chain antibody (scFv) specifically recognizing the human VEGF-A/VEGF receptor I complex (WO 99/19361) which was expressed in E. coli and conjugated to coagulation-inducing recombinant human truncated tissue factor (tTF) by methods
15 descibed by Ran et al. (Cancer Res. 58, 4646-4653, 1998). When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated on day 0 and on day 4 with intravenous doses of 20 µg of the scFv-tTF conjugate. Various modes of treatment are described in Table 4. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor
20 growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 4

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	scFv-tTF conjugate (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

- 5 Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 4) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the
- 10 coagulation-inducing tTF targeted to the VEGF-A/VEGF receptor I complex via the scFv-tTF conjugate (compound II, treatment group 3) grew to a volume of approx. 500 mm³ within 28 days. Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex
- 15 (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 400 mm³ within 28 days.

The superior effect of a combination of targeting of the coagulation-inducing tTF to the VEGF-A/VEGF receptor I complex and functional interference with the

20 VEGF/VEGF receptor system over separate modes of intervention is clearly

shown. Similar effects can be expected upon targeting of cytotoxic agents to Angiopoietin/Tie receptor systems.

Example 5

Combination of functional interference with the Angiopoietin/Tie2 receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
 5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/sTie2 cells and from A375v/pCEP cells were induced in nude mice as described in example 1. A fusion protein (L19 scFv-tTF) consisting of L19 single chain antibody specifically recognizing the oncofoetal ED-
 10 B domain of fibronectin and the extracellular domain of tissue factor was expressed in *E. coli* as described by Nilsson et al. (Nat. Med., in press). Further, L19 scFv-tTF data have been represented by D. Neri and F. Nilsson (Meeting "Advances in the application of monoclonal antibodies in clinical oncology", Samos, Greece, 31. May-2. June 2000). When tumors reached a size of approx.
 15 200 mm³ animals receiving compound I were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of treatment are described in Table 5. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

20

Table 5

treatment group	mode of treatment	
	L19 scFv-tTF (compound I)	sTie2 (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/sTie2	-	+
Group 4: A375v/sTie2	+	+

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 5) without treatment (group 1). Tumors treated with the coagulation-inducing L19 scFv-tTF (compound I, treatment group 2) grew to a volume of approx. 450 mm³ within 28 days. Interference with Angiopoietin/Tie2 receptor system by means of expression of sTie2 (compound II, treatment group 3) reduced growth of tumors within 28 day to a volume of approx. 600 mm³, respectively. Combination of interference with the Angiopoietin/Tie2 system by means of expression of sTie2 and of targeting the endothelium with L19 scFv-tTF (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 250 mm³ within 28 days.

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the Angiopoietin/Tie2 receptor system over separate modes of intervention is clearly shown.

Example 6

Combination of functional interference with the VEGF/VEGF receptor system and endothelium-specific targeting of a coagulation-inducing protein is superior to
5 separate modes of intervention in inhibition of tumor growth.

Tumors derived from A375v/pCEP cells were induced in nude mice as described in example 1. Animals receiving compound I were treated for up to 28 days with daily oral doses of 50 mg/kg of the VEGF receptor tyrosine kinase inhibitor (4-
10 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (Wood et al., Cancer Res. 60, 2178-2189, 2000). Compound II consists of L19 scFv-tTF fusion protein as described in example 5. When tumors reached a size of approx. 200 mm³ animals receiving compound II were treated with a single intravenous dose of 20 µg of L19 scFv-tTF in 200 µl saline. Various modes of
15 treatment are described in Table 6. Animals were sacrificed for ethical reasons when tumors of group 1 exceeded a volume of approx. 1000 mm³. Tumor growth was determined by caliper measurement of the largest diameter and its perpendicular.

Table 6

treatment group	mode of treatment	
	(4-Chlorophenyl)[4-(4-pyridylmethyl)-phthal-azin-1-yl]ammonium hydrogen succinate (compound I)	L19 scFv-tTF (compound II)
Group 1: A375v/pCEP	-	-
Group 2: A375v/pCEP	+	-
Group 3: A375v/pCEP	-	+
Group 4: A375v/pCEP	+	+

5

Tumors derived from A375v/pCEP control cells reached a size of approx. 1000 mm³ within 28 days (Figure 6) without treatment (group 1). Separate treatment with the VEGF receptor inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate (compound I, treatment group 2) resulted in a reduction of the tumor volumes to approx. 550 mm³. Tumors treated with the coagulation-inducing L19 scFv-tTF targeted to the endothelium (compound II, treatment group 3) grew to a volume of approx. 450 mm³ within 28 days.

10

Combination of inhibition of VEGF receptor tyrosine kinase by means of (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate and of targeting the VEGF receptor complex (compound I + compound II, treatment group 4) resulted in a inhibition of tumor growth to a volume of approx. 200 mm³ within 28 days.

15

The superior effect of a combination of targeting of L19 scFv-tTF to the endothelium and functional interference with the VEGF/VEGF receptor system over separate modes of intervention is clearly shown.

5

10

Description of the figures

Fig. 1 shows the superior effect of combination of interference with VEGF/VEGF receptor system by means of an specific tyrosine kinase inhibitor and with the
5 Angiopoietin/Tie2 receptor system by means of a soluble receptor domain on inhibition of tumor growth (treatment modes of groups 1-4 are given in Table 1).

The abbreviations have the following meaning:

	mock, con.	=	treatment group 1
	mock+VEGF-A	=	treatment group 2
10	sTIE2-cl13	=	treatment group 3
	sTIE2-cl13+VEGF-A	=	treatment group 4

Fig. 2 shows the superior effect on tumor growth inhibition of combination of
15 VEGF-neutralization and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 2).

20 Fig. 3 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 3).

25

Fig. 4 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing tTF to the VEGF/VEGF receptor I complex via a scFv-tTF conjugate and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-
30 Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 4).

Fig. 5 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with Angiopoietin/Tie2 receptor system over separate modes of intervention (treatment modes of groups 1-4 are given in Table 5).

Fig. 6 shows the superior effect on tumor growth inhibition of combination of targeting of the coagulation-inducing L19 scFv-tTF fusion protein to the endothelium and functional interference with VEGF/VEGF receptor system by means of the VEGF receptor tyrosine kinase inhibitor (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate over separate modes of intervention (treatment modes of groups 1-4 are given in Table 6).

CLAIMS

1. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF
5 receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
2. Pharmaceutical compositions comprising one or several agents as compound I
10 which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems.
- 15 3. Pharmaceutical compositions comprising one or several agents as compound I which modulates the biological function of one or several of the VEGF/VEGF receptor systems or of one or several of the Angiopoietin/ Tie receptor systems and comprising one or several agents as compound II which are targeted to the endothelium.
- 20 4. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie
25 receptor systems.
5. Pharmaceutical compositions comprising one or several agents as compound I which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems, and comprising one or several agents as compound II which
30 are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
6. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the VEGF/VEGF

receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the VEGF/VEGF receptor systems.

- 5 7. Pharmaceutical compositions comprising one or several agents as compound I which modulate the biological function of one or several of the Angiopoietin/Tie receptor systems, and comprising one or several agents as compound II which are targeted to the endothelium via one or several of the Angiopoietin/Tie receptor systems.
- 10 8. Pharmaceutical compositions comprising one or several agents which interfere with both the function of one or several of the VEGF/VEGF receptor systems and the function of one or several of the Angiopoietin/Tie receptor systems.
- 15 9. Pharmaceutical compositions according to claims 1-8 which are intended for simultaneous or separate sequential therapeutical application.
10. Pharmaceutical compositions according to claims 1-8 which comprise as compound I at least one of
- 20 a) compounds which inhibit receptor tyrosine kinase activity,
b) compounds which inhibit ligand binding to receptors,
c) compounds which inhibit activation of intracellular signal pathways of the receptors,
d) compounds which inhibit or activate expression of a ligand or of a
25 receptor of the VEGF or Tie receptor system,
e) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor
30 systems,
f) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

11. Pharmaceutical compositions according to claims 1-8 which comprise as compound II at least one of

- g) compounds which inhibit receptor tyrosine kinase activity,
- h) compounds which inhibit ligand binding to receptors,
- 5 i) compounds which inhibit activation of intracellular signal pathways of the receptors,
- j) compounds which inhibit or activate expression of a ligand or of a receptor of the VEGF or Tie receptor system,
- 10 k) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which target cytotoxic agents or coagulation-inducing agents to the endothelium via recognition of VEGF/VEGF receptor or Angiopoietin/Tie receptor systems,
- 15 l) delivery systems, such as antibodies, ligands, high-affinity binding oligonucleotides or oligopeptides, or liposomes, which are targeted to the endothelium and induce necrosis or apoptosis.

12. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II at least one of Seq. ID Nos. 1-59.


20

13. Pharmaceutical compositions according to claims 1-11 which comprise as compound I and/ or II Seq. ID Nos. 34a

14. Pharmaceutical compositions according to claims 1-11 which comprise as
25 compound I and/ or II at least one of sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTFconjugate.

15. Pharmaceutical compositions according to claims 1-11 which comprise as
30 compound I and/ or II at least one small molecule of general formula I

41



in which

5

r

has the meaning of 0 to 2,

n


has the meaning of 0 to 2;

R₃ und R₄

a) each independently from each other have the meaning of lower alkyl,

10

b) together form a bridge of general partial formula II,



15


wherein the binding is via the two terminal C- atoms,
and

m

has the meaning of 0 to 4; or

c) together form a bridge of partial formula III

20



has wherein one or two of the ring members T_1, T_2, T_3, T_4 the meaning of nitrogen, and each others have the meaning of CH, and the binig is via the atoms T_1 and T_4 ;

5 G has the meaning of $C_1 - C_6$ - alkyl, $C_2 - C_6$ - alkylene or $C_2 - C_6$ - alkenylene; or $C_2 - C_6$ - alkylene or $C_3 - C_6$ - alkenylene, which are substituted with acyloxy or hydroxy; $-CH_2-O-$, $-CH_2-S-$, $-CH_2-NH-$, $-CH_2-O-CH_2-$, $-CH_2-S-CH_2-$, $-CH_2-NH-CH_2$, oxa ($-O-$), thia ($-S-$) or imino ($-NH-$),

10 A, B, D, E and T independently from each other have the meaning of N or CH, with the provisio that not more than three of these Substituents have the meaning of N,

15 Q has the meaning of lower alkyl, lower alkyloxy or halogene,

R_1 and R_2 independently from each other have the meaning of H or lower alkyl,

20 X has the meaning of imino, oxa or thia;


Y has the meaning of hydrogen, unsubstituted or substituted aryl, heteroaryl, or unsubstituted or substituted cycloalkyl; and

Z has the meaning of amino, mono- or disubstituted amino, halogen, alkyl, substituted alkyl, hydroxy, etherificated or esterificated hydroxy, nitro, cyano, 25 carboxy, esterificated carboxy, alkanoyl, carbamoyl, N-mono- or N, N- disubstituted carbamoyl, amidino, guanidino, mercapto, sulfo, phenylthio, phenyl-lower-alkyl-thio, alkyl-phenyl-thio, phenylsulfinyl, phenyl-lower-alkyl-sulfinyl, alkylphenylsulfinyl, phenylsulfonyl, 30 phenyl-lower-alkan-sulfonyl, or alkylphenylsulfonyl, whereas, if more than one rest Z is present ($m \geq 2$), the substituents Z are equal or different from each other, and wherein the bonds marked with an arrow are single

or double bonds; or an N-oxide of said compound,
 wherein one or more N-atoms carry an oxygen atom,
 or a salt thereof,

and/or a compound of general formula IV


5



in which

- 10 A has the meaning of group $=NR^2$,
 W has the meaning of oxygen, sulfur, two hydrogen atoms
 or the group $=NR^8$,
 Z has the meaning of the group $=NR^{10}$ or $=N-$, $-N(R^{10})-$
 $(CH_2)_q-$, branched or unbranched C_{1-6} -Alkyl or is the
 group


15



or A, Z and R^1 together form the group

20

44




5	m, n and o	has the meaning of 0 – 3,
	q	has the meaning of 1 – 6,
	R _a , R _b , R _c , R _d , R _e , R _f	independently from each other have the meaning of hydrogen, C ₁₋₄ alkyl or the group =NR ¹⁰ , and/or R _a and/or R _b together with R _c and/or R _d or R _c together with R _e and/or R _f form a bound, or up to two of the groups R _a -R _f form a bridge with each up to 3 C-atoms with R ¹ or R ² ,
10	X	has the meaning of group =NR ⁹ or =N-,
	Y	has the meaning of group -(CH ₂) _p ,
	p	has the meaning of integer 1-4,
15	R ¹	has the meaning of unsubstituted or optionally substituted with one or more of halogene, C ₁₋₆ -alkyl, or C ₁₋₆ -alkyl or C ₁₋₆ -alkoxy, which is optionally substituted by one or more of halogen, or is unsubstituted or substituted aryl or
20	R ²	heteroaryl,
	R ³	has the meaning of hydrogen or C ₁₋₆ -alkyl, or form a bridge with up to 3 ring atoms with R _a -R _f together with Z or R ₁ ,
25		has the meaning of monocyclic or bicyclic aryl or heteroaryl which is unsubstituted or optionally

R^4, R^5, R^6 and R^7

substituted with one or more of für halogen, C_{1-6} -alkyl, C_{1-6} -alkoxy or hydroxy,


independently from each other have the meaning of hydrogen, halogene or C_{1-6} -alkoxy, C_{1-6} -alkyl or C_{1-6} -carboxyalkyl, which are unsubstituted or optionally substituted with one or more of halogene, or R^5 and R^6 together form the group



R^8, R^9 and R^{10}

independently from each other have the meaning of hydrogen or C_{1-6} -alkyl, as well as their isomers and salts,

and/ or a compound of general formula V





V,

in which


R^1 has the meaning of group

46




in which R^5 is chloro, bromo or the group $-OCH_3$,

5



in which R^7 is $-CH_3$ or chloro,



in which R^8 is -CH₃, fluoro, chloro or -CF₃


in which R^4 is fluoro, chloro, bromo, -CF₃, -N=C, -CH₃, -OCF₃ or -CH₂OH

in which R^6 is -CH₃ or chloro

5

R^2

has the meaning of pyridyl or the group



10

and

R^3

has the meaning of hydrogen or fluoro, as well as their isomers and salts.

16. Pharmaceutical compositions according to claim 15 which comprise as compound I and/ or II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate

17. Pharmaceutical compositions according to claims 1-16 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate, sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, and as compound II (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium hydrogen succinate sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate, with the proviso that compound I is not identically to compound II.

25

18. Pharmaceutical compositions according to claims 1-17 which comprise as compound I (4-Chlorophenyl)[4-(4-pyridylmethyl)-phthalazin-1-yl]ammonium

hydrogen succinate and as compound II sTie2, mAB 4301-42-35, scFv-tTF and/ or L19 scFv-tTF conjugate.

19. Pharmaceutical compositions according to claims 1-17 which comprise as
5 compound I mAB 4301-42-35 and as compound II sTie2, and/ or scFv-tTF conjugate.

20. Pharmaceutical compositions according to claims 1-17 which comprise as
10 compound I scFv-tTF conjugate and as compound II sTie2 and/ or mAB 4301-42-35.

21. Pharmaceutical compositions according to claims 1-17 which comprise as
compound I L19 scFv-tTF conjugate and as compound II sTie2.

15 22. Use of pharmaceutical compositions according to claims 1-21, for the production of a medicament for the treatment of tumors, cancers, psoriasis, arthritis, such as rheumatoide arthritis, hemangioma, angiofibroma, eye diseases, such as diabetic retinopathy, neovascular glaukoma, kidney diseases, such as glomerulonephritis, diabetic nephropathie, malignant
20 nephrosclerosis, thrombic microangiopathic syndrome, transplantation rejections and glomerulopathy, fibrotic diseases, such as cirrhotic liver, mesangial cell proliferative diseases, arteriosclerosis, damage of nerve tissues, suppression of the ascites formation in patients and suppression of VEGF oedemas.

25




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6

Sequence Identifier

5

<110> Schering Aktiengesellschaft

10

<120> Combinations and compositions which interfere with VEGF/ VEGF and angiopoietin/ Tie receptor function and their use II

<130> 51867AEPMLXX00-P

15

<140>

<141>

<160> 59

20

<210> 1

<211> 1835

<212> DNA

<213> Human

25

<400> 1

30

35

40

45

50

55

```
ttttacagtt ttccttttct tcagagttta ttttgaattt tcatttttgg ataaccaagc 60
agctctttta gaagaatgca cagaagagtc attctggcac ttttggatag tacataagat 120
tttctttttt tttttttaa tttttttaat agtcacattc agctcgcttg ctcaaaccag 180
actcccacat tgggtgagca agatgagccc ataggattcc agagttaata cgtaaccgta 240
tatacaaaac gccaaaaaac cataatggtg ccacagggat ggagcagggg agggcatctc 300
taacgtgtcc tctagtctat cttcgctaaa cagaacccac gttacacatg ataactagag 360
agcacactgt gttgaaacga ggatgctgac cccaaatggc acttggcagc atgcagttta 420
aagcaaaaaga gacatccttt aataactgta taaaatccag gcagttccat taaagggggt 480
aagaaaacca acaacaacaa aaagcgaggg actgtctggt gtcactgtca aaaaggcact 540
tgtagttaat gggaccagga ttggaggact cttagctgat acagatttca gtacgatttc 600
attaaggc ttggatgta agagaggaca ctcagcgggt cctgaaggga gacgctgaga 660
tggaaccgtg agaagcggaa cagatgaaca caaaggaatc aaatctttac aaccaaattg 720
catttaagcg acaacaaaaa aaggcaaac ccaaaacgca acctaacca agcaaatct 780
aagcaaaatc agacaacgaa gcagcgatgc atagctttcc tttgagagaa cgcatacctt 840
gagacgctac gtgccaacct aagtctctaa cgacagcttc acagtaggat tattgtgata 900
aaaatgactc aagcgatgca aaaagtttca tctgttccca gaatccgagg gagaactgag 960
gtgatcgta gagcatagcg acatcacgtg cggtttctta atgtccctgg tggcggatac 1020
gccgagtcct cggaaggaca tctggacacc actttcagcc acctccttgc aggggcgaca 1080
tccgccaaag tcatccttta ttccgagtaa taactttaat tcctttctaa catttacacg 1140
gcaaacagga atgcagtaaa cgtccacgtc cgtcccacgg ctgggctgcc gttccgtttc 1200
ctccacgaac gggtaacgcgc ttccatgaga aaggatattt ggcaatttta tattccacag 1260
tcaggtgggt ctgcgatagc tcatttaatg ttaaacgcca tcaggggcct ctccctccgt 1320
ttctgccagg ggcttttctt gtcttctcct tggcgagctc gtgggcagat cttctctggt 1380
gggggctggc tgctggctcc gagggggcat ccgcagtcct tctggtcgtc tcctcctgca 1440
ggctgggcag ctggccacca cttctccgac tcgaccctc caacaagcat cgcagggcac 1500
tgtcctcggg ggtacagacc gtggtccac attcgctacc actctgttcc acgtcatcca 1560
ggtacacgag ctgcgtgtag gccgtgctgt ctggggctcg aggctctttc tgctgggtgct 1620
cttgacggg cggttagttc tgctgcagag acaaagcatc tccccttccc ttccgggctg 1680
attttggttc attcatatct acgccagagt ccaaactggc atcattactt ccgttccttc 1740
cagctctttg gagaatcaat gtatgaatgt ctaacctgac cgttggacct gccatccaag 1800
gagacgaacc acgcccgggg gtgcggaage ggct
```

60

<210> 2

<211> 581

<212> DNA

<213> Human

<400> 2

5 gttctagatt gttttattca gtaattagct ctttaagaccc ctggggcctg tgctacccag 60
acactaacia cagtctctat ccagttgctg gttctgggtg acgtgatctc cccatcatga 120
tcaacttact tcctgtggcc cattagggaa gtggtgacct cgggagctat ttgcctgttg 180
agtgcacaca cctggaaaca tactgctctc attttttcat ccacatcagt gagaaatgag 240
tggcccgtta gcaagatata actatgcaat catgcaacia agctgcctaa taacatttca 300
10 tttattacag gactaaaagt tcattattgt ttgtaaagga tgaattcata acctctgcag 360
agttatagtt catacacagt tgatttccat ttataaaggc agaaagtcct tgttttctct 420
aatgtcaag ctttgactga aaactcccgt ttttccagtc actggagtgt gtgcgtatga 480
aagaaaatct ttagcaatta gatgggagag aagggaata gtacttgaaa ttagggccct 540
cacctcccca tgacatcctc catgagcctc ctgatgtagt g

15 <210> 3
<211> 516
<212> DNA
<213> Human

<400> 3

25 tagagatggt ggttgatgac ccccgggatc tggagcagat gaatgaagag tctctggaag 60
tcagcccaga catgtgcatc tacatcacag aggacatgct catgtcgcgg aacctgaatg 120
gacactctgg gttgattgtg aaagaaattg ggtcttccac ctcgagctct tcagaaacag 180
ttgttaagct tcgtggccag agtactgatt ctcttccaca gactatatgt cggaaaccaa 240
agacctccac tgatcgacac agcttgagcc tcgatgacat cagactttac cagaaagact 300
tcctgcgcat tgcaggctctg tgcaggaca ctgctcagag ttacaccttt ggatgtggcc 360
atgaactgga tgaggaaggc ctctattgca acagttgctt ggcccagcag tgcataca 420
30 tccaagatgc ttttccagtc aaaagaacca gcaataactt ttctctggat ctactcatg 480
atgaagtccc agagtattgt gtgtaaagtc cgtctg

<210> 4
<211> 1099
<212> DNA
35 <213> Human

<400> 4

40 cccacaacac agggggcctg aaacacgcca gcctctcctc tgtggtcagc ttggcccagt 60
cctgctcact ggatcacagc ccattgtagg tggggcatgg tggggatcag ggcccctggc 120
ccacggggag gtagaagaag acctggtccg tgtaagggtc tgagaagggt ccctgggtcg 180
ggggtgcgtc ttggccttgc cgtgccctca tccccgggt gaggcagcga cacagcaggt 240
gcaccaactc cagcagggtta agcaccaggg agatgagtcc aaccaccaac atgaagatga 300
45 tgaagatggt cttctccgtg gggcgagaga caaagcagtc cagaggttag gggcagggtg 360
ctcgctggca cacaacacag ggctccatgg tccagccgta caggcgccac tggccataga 420
ggaagcctgc ctctagcaca ctcttgca gaacactggc gacatagggt cccatcagt 480
ctccgcggat gcgcaggcga ccattctctg ccaccgagat cttggccatc tgacgtctta 540
cggccgcccag cgcccgctcc acctgtgggt ccttggccgg cagtggccgc agctccccct 600
ccttctgccg cagccgctct tctcgccgag acaggtaaat gacatggccc aggttagacca 660
50 ggggtgggtg gctgacgaag aggaactgca gcacccagta gcggatgtgg gagatgggga 720
aggcctggtc atagcagacg ttggtgcagc ctggctgggc cgtgttacac tcgaaatctg 780
actgctcgtc accccacact gactcgccgg ccaggcccag gatgaggatg cggaagatga 840
agagcaccgt cagccagatc ttacccacca cggtcgagtg ctctggacc tgggtccagca 900
acttctccac gaagccccag tcacccatgg ctcccgggcc tccgtcggca aggagacaga 960
55 gcacgtcagt gtgtcagcat ggcatacttc tegtctgccc agcaacaagc ctgcagggag 1020
gtctgccacg cccgttctac cgcctgcctg ccgggcggcc caggtggagg tggggacgat 1080
ggccggagtg acgcccgcg

<210> 5
60 <211> 1015
<212> DNA
<213> Human

<400> 5

65 gaggataggg agcctgggggt caggagtgtg ggagacacag cgagactctg tctccaaaaa 60

5 aaaaagtgct ttttgaaaat gttgaggttg aaatgatggg aaccaacatt ctttggattt 120
 agtgggggagc ataatagcaa acaccccctt gggttcgcaca tgtacaggaa tgggacccag 180
 ttgggggcaca gccatggact tccccgccct ggaatgtgtg gtgeaaagtg gggccagggc 240
 ccagacccaa gaggagaggg tgggtccgcag acaccccggg atgtcagcat cccccgacct 300
 gcctttctggc ggcacctccc ggggtgctgtg ttgagtcagc aggcattgggg tgagagcctg 360
 gtatatgtcg ggaacagggt gcagggggcca agcggttcctc cttcagcctt gacttggggc 420
 atgcaccccc tctcccccaa acacaaacaa gcacttctcc agtatgggtg caggacagggt 480
 gtcctttcag tctctgtgtt atgacctcaa gtcctacttg ggccttcag cccagcctgt 540
 gttgtaacct ctgctgcttc aagaccacac ctggaagatt cttcttccct ttgaaggaga 600
 10 atcatcattg ttgctttatc acttctaaga cattttgtac ggcacggaca agttaaacag 660
 aatgtgcttc cctccctggg gtctcacacg ctccacagag aatgccacag gggccgtgca 720
 ctgggcaggc ttctctgtag aaccccaggg gcttcggccc agaccacagc gtcttgccct 780
 gagcctagag cagggagtcc cgaacttctg cattcacaga ccacctccac aattgttata 840
 accaaaggcc tctgttctg ttatttctact taaatcaaca tgctattttg ttttctactca 900
 15 cttctgactt tagcctcgtg ctgagccgtg tatccatgca gtcattgttca cgtgctagtt 960
 acgtttttct tcttacacat gaaaataaat gcataagtgt tagaagaaaa aaaaa

 <210> 6
 <211> 2313
 20 <212> DNA
 <213> Human

 <400> 6

 25 ccagagcagg cctggtggtg agcagggacg gtgcaccgga cggcgggacg gagcaaattg 60
 gtctggccat ggagcacgga gggtcctacg ctcgggcggg gggcagctct cggggctgct 120
 ggtattacct gcgctacttc ttctcttcg tctccctcat ccaattcctc atcatcctgg 180
 ggctcgtgct ctctcatggtc tatggcaacg tgcacgtgag cacagagtc aacctgcagg 240
 ccaccgagcg ccgagccgag ggcctataca gtcagctcct agggctcacg gcctcccagt 300
 30 ccaacttgac caaggagctc aacttcacca cccgcgccaa ggatgccatc atgcagatgt 360
 ggctgaatgc tcgcccgcag ctggaccgca tcaatgccag cttccgccag tgccagggtg 420
 accgggtcat ctacacgaac aatcagaggt acatggctgc catcatcttg agtgagaagc 480
 aatgcagaga tcaattcaag gacatgaaca agagctgcga tgccttgctc ttcattgctga 540
 atcagaaggt gaagacgctg gaggtggaga tagccaagga gaagaccatt tgcactaagg 600
 35 ataaggaaag cgtgctgctg aacaaacgcg tggcggagga acagctgggt gaatgcgtga 660
 aaacccggga gctgcagcac caagagcgcc actggccaag gagcaactgc aaaagggtgca 720
 agccctctgc ctgcccctgg acaaggacaa gtttgagatg gaccttcgta acctgtggag 780
 ggactccatt atcccacgca gcctggacaa cctgggttac aacctctacc atcccctggg 840
 40 ctcggaattg gcctccatcc gcagagcctg cgaccacatg cccagcctca tgagctccaa 900
 ggtggaggag ctggcccggg gcctccgggc ggatategaa cgcgtggccc gcgagaactc 960
 agacctcaa cgccagaagc tgggaagcca gcagggcctg cgggccagtc aggaggcgaa 1020
 acagaagggt gagaaggagg cttagggccc ggaggccaag ctccaagctg aatgctcccg 1080
 gcagacccag cttagcgttg aggagaaggc ggtgctgcgg aaggaacgag acaacctggc 1140
 caaggagctg gaagagaaga agagggaggc ggagcagctc aggatggagc tggccatcag 1200
 45 aaactcagcc ctggacacct gcatcaagac caagtcgcag ccgatgatgc cagtgtcaag 1260
 gcccattggg cctgtcccca acccccagcc catcgaccca gctagcctgg aggagttcaa 1320
 gaggaagatc ctggagtccc agaggccccc tgcaggcatc cctgtagccc catccagtgg 1380
 ctgaggaggc tccaggcctg aggaccaagg gatggcccga ctcgggcggt tgaggaggat 1440
 gcagggatat gctcacagcg cccgacacaa cccctcccgc ccgcccccaa ccaccaggg 1500
 50 ccaccatcag acaactccct gcatgcaaac ccctagtacc ctctcacacc cgcacccgcg 1560
 cctcacgac cctcaccag agcacacggc cgcgagatg acgtcacgca agcaacggcg 1620
 ctgacgtcac atatcacctg ggtgatggcg tcacgtggcc atgtagacgt cacgaagaga 1680
 tatagcgatg gcgtcgtgca gatgcagcac gtcgcacaca gacatgggga acttggcatg 1740
 acgtcacacc gagatgcagc aacgacgtca cgggccaatgt cgacgtcaca catattaatg 1800
 55 tcacacagac gcggcgatgg catcacacag acgggtgatg tgtcacacac agacacagtg 1860
 acaacacaca ccatgacaac gacacctata gatatggcac caacatcaca tgcacgcatg 1920
 ccctttcaca cacactttct acccaattct cacctagtgt cacgttcccc cgaccctggc 1980
 acacgggcca aggtacccac aggatcccat cccctcccgc acagccctgg gcccagcac 2040
 ctcccctcct ccagcttctt ggctcccag ccacttctc acccccagtg cctggacccg 2100
 60 gaggtgagaa caggaagcca ttcacctccg ctccctgagc gtgagtgttt ccaggacccc 2160
 ctcgggggccc tgagccgggg gtgagggtca cctgtgtcgc ggaggggagc cactccttct 2220
 cccccaactc ccagccctgc ctgtggcccc ttgaaatgtt ggtggcactt aataaatatt 2280
 agtaaattcct taaaaaaaaa aaaaaaaaaa aaa

 65 <210> 7
 <211> 389

<212> DNA
<213> Human

<400> 7

5

gccaaaaaga tggcttcaaa agtaagaatg aaacatttga tccattcagc tttaggctat 60
gccactggat tcatgtctag aaaagatagg ataatttctg taaagaaatg aagaccttgc 120
tattctaaaa tcagatcctt acagatccag atttcaggaa acaatacat aggggactaa 180
ctttccttgt tcagattagt ttttctcctt tgcacccagc tatataatat gaggaagtat 240
10 tgacttttta aaagtgtttt agttttccat ttctttgata tgaaaagtaa ttttccggga 300
gaaccctgag ctattaataa tctatgtggc tagtgcgat atattggtct gaatttggtc 360
tccttttgtg gtgtccagtg ggtaacatc

<210> 8
15 <211> 157
<212> DNA
<213> Human

<400> 8

20

tgctttaaac agctgtgtca aaaactgaca tcagagagta aattgaattt ggttttgtag 60
gaagcaggaa gcaagccac tcaaactgta aatttggcat gagggatcca gtaactttct 120
cctcaatctg tgaactatat gtgagtttga tattttg

25 <210> 9
<211> 561
<212> DNA
<213> Human

30 <400> 9

aatagtcaaa acataaacia aagctaatta actggcactg ttgtcacctg agactaagtg 60
gatgttgttg gctgacatac aggtcagcc agcagagaaa gaattctgaa ttccccttgc 120
tgaactgaac tattctgtta catatggttg acaaactctg gtgttatttc ttttctacct 180
35 accatattta aatttatgag tatcaaccga ggacatagtc aaaccttcga tgatgaacat 240
tcctgatttt ttgcctgatt aatctctgtt gagctctact tgtggtcatt caagatttta 300
tgatgttgaa aggaaaagtg aatatgacct ttaaaaattg tattttgggt gatgatagtc 360
tcaccactat aaaactgtca attattgcct aatgttaaag atatccatca ttgtgattaa 420
ttaaacttat aatgagtatt cttaatggag aattcttaat ggatggatta tcccctgac 480
40 ttttctttaa aatttctctg cacacacagg acttctcatt ttccaataaa tgggtgtact 540
ctgcccacat ttctaggaaa a

<210> 10
45 <211> 1508
<212> DNA
<213> Human

<400> 10

50 cacaaacacg agagactcca cggctctgct gagcaccgcc agcctcctag gctccagcac 60
tcgcaggtec attcttctgc acgagcctct ctgtccagat ccataagcac ggtcagctca 120
gggtcgcgga gcagtacgag gacaagtacc agcagcagct cctctgaaca gagactgcta 180
ggatcatcct tctcctccgg gcctgttget gatggcataa tccgggtgca acccaaactct 240
gagctcaagc caggtgagct taagccactg agcaaggaag atttgggcct gcacgcctac 300
55 aggtgtgagg actgtggcaa gtgcaaagt aaggagtga cctacccaag gcctctgcca 360
tcagactgga tctgcgacaa gcagtgcctt tgctcggccc agaactgat tgactatggg 420
acttgtgtat gctgtgtgaa aggtctcttc tatcactgtt ctaatgatga tgaggacaac 480
tgtgctgaca acccatgttc ttgcagccag tctcactgtt gtacacgatg gtcagccatg 540
gggtgcatgt ccctcttttt gccttgttta tgggtgttacc ttccagccaa gggttgcctt 600
60 aaattgtgcc aggggtgtta tgaccgggtt aacaggcctg gttgccgctg taaaaactca 660
aacacagttt gctgcaaagt tcccactgtc cccctagga actttgaaaa accaactag 720
catcattaat caggaatatt acagtaatga ggattttttc tttctttttt taatacacat 780
atgcaaccaa ctaaacagtt ataactcttg cactgttaat agaaagtgtg gatagtcttt 840
gctgtttgct gtgaaatgct ttttgtccat gtgccgtttt aactgatatg cttgttagaa 900
65 ctgagctaag ggagctcaaa gtatgagata cagaacttgg tgacccatgt attgcataag 960
ctaaagcaac acagacactc ctaggcaaag tttttgtttg tgaatagtag ttgcaaaact 1020

5
10
15
20
25
30
35
40
45
50
55
60
65

tgtaaattag cagatgactt ttttccattg ttttctccag agagaatgtg ctatatTTTT 1080
gtatatataa taatatttgc aactgtgaaa aacaagtggg gccatactac atggcacaga 1140
cacaaaatat tatactaata tggtgtacat tcggaagaat gtgaatcaat cagtatgttt 1200
ttagattgta ttttgcctta cagaaagcct ttattgtaag actctgattt ccctttggac 1260
ttcatgtata ttgtacagtt acagtaaaat tcaaccttta ttttctaatt ttttcaacat 1320
attgttttagt gtaaagaata tttatttgaa gttttattat tttataaaaa agaattttta 1380
ttttaagagg catcttataa attttgcctt ttttatgagg atgtgatagt tgctgcaaat 1440
gaggggttac agatgcatat gtccaatata aaatagaaaa tatattaacg tttgaaatta 1500
aaaaaaaa

<210> 11
<211> 389
<212> DNA
<213> Human

<400> 11

gggcaggtga tcagggcaca catttcccggt ccattgagac agtagcattc ccggcaccca 60
tcgtgccage tctcctcatt tttatgatga tgaccatcca cggtgagaca agtgcccgac 120
aggatgggtg gccagctga agcacaggcc gctctgactg tgcagataag acagccgtga 180
ctgtcctgct ggaaacccaa ggggcagatc ttactgcatg agagctctgg acatttctta 240
cagcgacaga tgtcacagcc gtgcttattc ttcagcaatc caagtggaca atacttgtca 300
cagattatgg gtctgcactt cttgggcctt gggcggcact cacagatctc acagttttgg 360
acctcggccg cgaccacgct gggtagcga

<210> 12
<211> 981
<212> DNA
<213> Human

<400> 12

tttttttttt ttggattgca aaaatttatt aaaattggag acactgtttt aatcttcttg 60
tgccatgaga ctccatcagg cagtctataa agaccactgg gaggtgagg atcacttgag 120
cccagaagtt tgaggctgta gtaagcttca aaggccactg cactctagct tgggtgaggc 180
aagacccttt caagcagtaa gctgcatgct tgcttggtgt ggtcattaaa aaccctagtt 240
taggataaca acatattaat cagggcaaaa tacaatgtg tgatgcttgt tagtagagta 300
acctcagaat caaaatggaa cggttttaca gtgatatcat tatatttcat ttggcagaat 360
cattacatca ttggttacac tgaaaatcat cacatgtacc aaaagctgac tcacctagtt 420
taggataaca ggtctgcctg tttgaagatg aaaaataata ccattttaa atttgcccta 480
ctcaatttcc ttctcagtc ctttttaact tttaaacagc taatcactcc catctacaga 540
ttaagggtga tatgccacca aaaccttttg ccaccttaa aatttccttc aaagttaa 600
ctaagtgcctg catttcttca atcatgaatt ctgagtcctt tgcttcttta aaacttgctc 660
cacacagtgt agtcaagccg actctccata cccaagcaag tcatccatgg ataaaaacgt 720
taccaggagc agaaccatta agctgggtcca ggcaagttgg actccaccat ttcaacttcc 780
agctttctgt ctaatgcctg tgtgccaatg gcttgagtta ggcttgctct ttaggacttc 840
agtagctatt ctcatccttc cttggggaca caactgtcca taagggtgcta tccagagcca 900
cactgcatct gcaccagca ccatacctca caggagtcga ctcccacgag ccgcctgtat 960
ataagagttc ttttgatgac g

<210> 13
<211> 401
<212> DNA
<213> Human

<400> 13

ataactacag cttcagcaga caactaaaga gactgcatta aggtgatttc tctggctata 60
aagagagccc ggccgcagag catgtgactg ctgggacctc tgggataggc aacactgccc 120
tctctcccc agagcgaccc cccgggcagg tcggggccca agaatgacc cagcaactgc 180
tccctacca gcacactctc ttactgcca cctgcaatta tgctgtgaag atgactgggt 240
gtggatcatc cgattcagag aaatcaagat ctatgacctt ttaggcaaa gagagaaact 300
tgaggaattg ctgaggacta ctgaaccttg ttttgctttt ttaaaaaata ctaaatcctc 360
acttcagcat atttagttgt cattaaaatt aagctgatat t

<210> 14

<211> 1002
<212> DNA
<213> Human

5 <400> 14

gacaatataa aaagtggaaa caagcataaa ttgcagacat aaaataatct tctggtagaa 60
acagttgtgg agaacagggt gagtagagca acaacaacaa aagcctatgc agtcaccttc 120
10 tttgaaaatg ttaaatacaa gtccctattct ctttgtccag ctgggttttag ctagaggtag 180
ccaattactt ctcttaagggt ccatggcatt cgccaggatt ctataaaagc caagttaact 240
gaagtaaata tctggggccc atcgaccccc cactaagtac tttgtcacca tgttgtatct 300
taaaagtcac ttttctactgt ttgactcaga atttgggact tcagagtcaa acttcattgc 360
ttactccaaa cccagtttaa ttccccactt ttttaagtag gcttagcttt gagtgatttt 420
15 tggctataac cgaaatgtaa atccaccttc aaacaacaaa gtttgacaag actgaaatgt 480
tactgaaaac aatggtgccca tatgctccaa agacatttcc ccaagataac tgccaaagag 540
tttttgagga ggacaatgat catttattat gtaggagcct tgatatctct gcaaaataga 600
attaatacag ctcaaagga gtagtaacca agcttttctg cccaggaagt aacaaacatc 660
actacgaaca tgagagtaca agaggaaact ttcataatgc attttttcat tcatacattc 720
attcaataaa cattagccaa gctaagtgtc caagccactg tgccaggtag taacaatata 780
20 acaacaataa aagacacagt ccttcctctc aagggtgtca gtctagtagg gaagatgatt 840
attcattaaa atttttggtg catcagaatc atgaggagct tgtcaaaaat gtaaattcct 900
gcctatgttc tcagatatcc tgggttaggtc aggagtggga acccaaatc aattctttta 960
acaaacacta aagggtgattc taacacaggc ggtgtgagga cc

25 <210> 15
<211> 280
<212> DNA
<213> Human

30 <400> 15

cgagggtgggc caccctgtgc tgggtctgaga tttttaaatg aggattacat tatectattt 60
ataatattcc tatttctaate tattgtattc ttacaattaa atgtatcaaa taattcttaa 120
aaacattatt agaaacaaac tgccctaatac cttataagac taaaaaaatc accaagatga 180
35 aactgtatta tgactctcaa tatttaaaaca tttaaaaaaa tgtagtggtt tgtaagcac 240
caatcttaac tatttcacct gcccggggcgg ccgctcgagg

40 <210> 16
<211> 2041
<212> DNA
<213> Human

<400> 16

45 cccccgcag aactcccccc tggaatagga tttttaaaac ccttgacaat tagaaatcct 60
atagaggtta gcatttttta ggtaaaaata tgggtgcccc tacagggatc atgcaacttc 120
cttaaaacca attcagcaca tatgtataaa gaaccctttt taaaaacatt tgtacttgaa 180
atacagacac agtgatgctg aagacactaa acaaaaactg aaaagtacta taccttgata 240
aattttgtta ttgccttctt tagagacttt ataactctta gttgattttc aaggacttga 300
50 atttaataat ggggtaatta cacaagacgt aaaggatttt ttaaaaacaa gtattttttt 360
ttaccttag catcaattct ttataaaga atgctaaata aattacattt tttgttcagt 420
aaaactgaag atagaccatt taaatgcttc taccaaattt aacgcagctt aattagggac 480
caggtagata ttttcttctg aacatttttg gtcaagcatg tctaaccata aaagcaaatg 540
gaattttaag aggtagattt tttttccatg atgcattttg ttaataaatg tgtcaagaaa 600
55 ataaaaacaa gcactgagtg tgttctcttg aagtataagg gtctaataaa aaataaaaaga 660
tagatatattg ttatagtctg acatttttaac agtcatagta ttagacgttt cgtgaccagt 720
gcattttgga ctctctcagg atcaaaatac gagtctgccca actgtattaa atcctcctcc 780
accccccca ccagttgggtc cacagcttcc tgggtgggtc ttgtcatcaa atccattggg 840
ccgaaatgaa catgaagcag atgcagcttg gagggcccg gctcgagcat tcaactcttg 900
60 ttectgtaaa tatagtttat tgtcttttgt tatagcatcc ataagttctt tctgtagagg 960
tgggtctcca tttatccaga gtccactggg tgggttatta ccacttaaac cattagtact 1020
atgctgtttt ttatacaaaa gcacataagc tgtgtccttt ggaaacctgc tcgtaatttt 1080
ctggactgac tgaaatgaag taaatgtcac tctactgtca ttaataaaaa acccattctt 1140
ttgacatttc cttattttcc aaatcctgtt caaaaactgc actgggacta tctctcccta 1200
65 gtaaatgact ctgggaggat gctaatacca gagcctcaga ctgggtggtag atctgatatg 1260
aagagtctgt acttgtgata tttctggcat aagaatagta atgcccactt tcagaggata 1320

taccagagtg aaccacaacg gaacttaata gatagggcac caattttgtg caggaagctt 1380
 catcagtccc tgaaggcttt aatttttttag caagggtctc actaagatca gtgaagtcaa 1440
 catctacaga ccaactttct gacaatgaag agaaagaagt aattcttcta actggcaact 1500
 ccaaaaccag tggccagtga tacattgtct aaaattttcc ttctcacatg atacttctga 1560
 5 tcatatgaaa atctcaggag agtaagaata aggtattcag gttcctccgt gatttgcata 1620
 gttttctcag ctttttgcag agaggcacag ttttcacaat aatattgggt atcaccagta 1680
 agaatctctg gagcccaaaa aataatttag taagtcagtt actgaagggt tggtttcacc 1740
 tcccggtttc tgaggtacat ctttattaac aagaatcttg ttagattcgt tagggacaga 1800
 agtgttttca gaacagtaaa actcattagg aggactgcct atgggttttt cattcacaag 1860
 10 tgagtacacag atgaaggcag ctgttggttg attataaact actggctctt ctgaaggacc 1920
 gggtagacag gcttgcatta gaccaccatc ttgtatactg ggtgatgatg ctggatcttg 1980
 gacagacatg ttttccaaag aagaggaagc acaaaacgca agcgaaagat ctgtaaaggc 2040
 t

15 <210> 17
 <211> 235
 <212> DNA
 <213> Human

20 <400> 17

cgccccgggc aggtgtcagg ggttccaaac cagcctgggg aaacacagcg tagaccctc 60
 acctctacaa ataaaaaatt aaaaaattag ccagggtgtg cagcgaacaa ctgtagtctc 120
 agatactcag gagactgagc tggaaaggat cacttgagcc caagaagttc aaggttacag 180
 25 tgggccacga tcatgtcatt acactccagc ttgggtgaca aaatgagact gtcta

<210> 18
 <211> 2732
 <212> DNA
 30 <213> Human

<400> 18

gtgtggagtt tcagctgcta ttgactataa gagctatgga acagaaaaag cttgctggct 60
 35 tcatgttgat aactacttta tatggagctt cattggacct gttaccttca ttattctgct 120
 aaatattatc ttcttggtga tcacattgtg caaaatgggt aagcattcaa acactttgaa 180
 accagattct agcagggttg aaaacattaa gtcttgggtg cttggcgctt tcgctcttct 240
 gtgtcttctt ggcctcacct ggtccttttg gttgcttttt attaatgagg agactattgt 300
 gatggcatat ctcttcacta tttttaatgc tttccaggga gtgttcattt tcatcttca 360
 40 ctgtgctctc caaaagaaag tacgaaaaga atatggcaag tgcttcagac actcatactg 420
 ctgtggaggc ctcccaactg agagtcccca cagttcagtg aaggcatcaa ccaccagaac 480
 cagtgtctgc ttttctctg gcacacagag tcgtataaga agaattgtga atgatactgt 540
 gagaaaacaa tcagaatctt cttttatctc aggtgacatc aatagcactt caacacttaa 600
 tcaagggtgc ataatctta atatattatt acaggactga catcacatgg tctgagagcc 660
 45 catcttcaag atttatatca ttttagaggac attcactgaa caatgccagg gatacaagtg 720
 ccatggatac tctaccgcta aatggtaatt ttaacaacag ctactcgctg cacaagggtg 780
 actataatga cagcgtgcaa gttgtggact gtggactaag tctgaatgat actgcttttg 840
 agaaaatgat catttcagaa ttagtgacaa acaacttacg gggcagcagc aagactcaca 900
 acctcgagct cagctacca gtcaaacctg tgattggagg tagcagcagt gaagatgatg 960
 50 ctattgtggc agatgcttca tctttaatgc acagcgacaa cccagggtg gagctccatc 1020
 acaaagaact cgaggcacca cttattcctc agcggactca ctcccttctg taccaacccc 1080
 agaagaaagt gaagtccgag ggaactgaca gctatgtctc ccaactgaca gcagaggctg 1140
 aagatcacct acagtccccc aacagagact ctctttatac aagcatgccc aatcttagag 1200
 actctcccta tccggagagc agcctgaca tggaagaaga cctctctccc tccaggagga 1260
 55 gtgagaatga ggacatttac tataaaagca tgccaaatct tggagctggc catcagcttc 1320
 agatgtgcta ccagatcagc aggggcaata gtgatggtta tataatcccc attaaacaaag 1380
 aagggtgtat tccagaagga gatgttagag aaggacaaat gcagctgggt acaagtcttt 1440
 aatcatacag ctaaggaatt ccaagggccca catgagagta ttaataaata aagacaccat 1500
 tggcctgacg cagctccctc aaactctgct tgaagagatg actcttgacc tgtggttctc 1560
 60 tgggtgtaaaa aagatgactg aaccttgacg ttctgtgaat ttttataaaa catacaaaaa 1620
 ctttgtatat acacagagta tactaaagtg aattatttgt tacaagaaa agagatgcca 1680
 gccagggtatt ttaagattct gctgctgttt agagaaattg tgaaacaagc aaaacaaaac 1740
 tttccagcca ttttactgca gcagtctgtg aactaaattt gtaaataatg ctgcaccatt 1800
 tttgtaggcc tgcattgtat tatatacaag acgtaggctt taaaatcctg tgggacaaat 1860
 65 ttactgtacc ttactattcc tgacaagact tggaaaagca ggagagatat tctgcatcag 1920
 tttgcagttc actgcaaatc ttttacatta aggcaaagat tgaaaacatg cttaccact 1980

agcaatcaag ccacaggcct tatttcatat gtttcctcaa ctgtacaatg aactattctc 2040
 atgaaaaatg gctaaagaaa ttatatattt ttctattgct agggtaaaat aaatacattt 2100
 gtgtccaact gaaatataat tgtcattaaa ataattttta agagtgaaga aaatattgtg 2160
 5 aaaagctctt ggttgccacat gttatgaaat gttttttctt acactttgtc atggtaagtt 2220
 ctactcattt tcacttcttt tccactgtat acagtgttct gctttgacaa agttagtctt 2280
 tattacttac atttaaattt cttattgcca aaagaacgtg ttttatgggg agaacaacac 2340
 tctttgaagc cagttatgtc atgccttgca caaaagtgat gaaatctaga aaagattgtg 2400
 tgtcacccct gtttattctt gaacagaggg caaagagggc actgggcact tctcacaaac 2460
 tttctagtga acaaaagggt cctatttctt tttaaaaaaa taaaataaaa cataaatatt 2520
 10 actcttccat attccttctg cctatatitga gtaatttaatt ttttttatga taaagttcta 2580
 atgaaatgta aattgtttca gcaaaattct gctttttttt catccctttg tgtaaacctg 2640
 ttaataatga gcccatcact aatatccagt gtaaagttta acacggtttg acagtaaata 2700
 aatgtgaatt ttttcaagtt aaaaaaaaaa aa

15 <210> 19
 <211> 276
 <212> DNA
 <213> Human

20 <400> 19

ctccctaaat gatttttaaaa taaattggat aaacatatga tataaagtgg gtactttaga 60
 aaccgccttt gcatattttt tatgtacaaa tctttgtata caattccgat gttccttata 120
 25 tattccctat atagcaaacc aaaaccagga cctcccaact gcatgcctca agtccctgtg 180
 gagcactctg gcaactggat ggccctactt gctttctgac aaaatagctg gaaaggagga 240
 gggaccaatt aaatacctcg gccgcgacca cgctgg

<210> 20
 <211> 2361
 30 <212> DNA
 <213> Human

<400> 20

35 attgtaccag ccttgatgaa cgtggggcct gcttcgcttt tgagggccat aagctcattg 60
 cccactgggt tagaggctac cttatcattg tctcccgtga ccggaagggt tctcccaagt 120
 cagagtttac cagcagggat tcacagagct ccgacaagca gattctaaac atctatgacc 180
 tgtgcaacaa gttcatagcc tatagaccg tctttgagga tgtagtggat gtgcttgctg 240
 40 agtggggctc cctgtacgtg ctgacgcggg atgggcgggt ccacgcactg caggagaagg 300
 acacacagac caaactggag atgctgttta agaagaacct atttgagatg gcgattaacc 360
 ttgccaagag ccagcatctg gacagtgtg ggctggccca gattttcatg cagtatggag 420
 accatctcta cagcaagggt aaccacgatg gggctgtcca gcaatatatc cgaaccattg 480
 gaaagtggga gccatcctac gtgatccgca agtttctgga tgcccagcgc attcacaacc 540
 tgactgccta cctgcagacc ctgcaccgac aatccctggc caatgccgac cataccaccc 600
 45 tgctcctcaa ctgctatacc aagctcaagg acagctcgaa gctggaggag ttcatacaga 660
 aaaagagtga gagtgaagtc cactttgatg tggagacagc catcaagggt ctcgggcagg 720
 ctggctacta ctcccatgcc ctgtatctgg cggagaacca tgcacatcat gagtggtagc 780
 tgaagatcca gctagaagac attaagaatt atcaggaagc ccttcgatac atcggcaagc 840
 50 tgccctttga gcaggcagag agcaacatga agcgtacgg caagatcctc atgcaccaca 900
 taccagagca gacaactcag ttgctgaagg gactttgtac tgattatcgg cccagcctcg 960
 aaggccgcag cgataggagg gccccagggt gcagggccaa ctctgaggag ttcattccca 1020
 tctttgccaa taaccgcgca gagctgaaag ccttcctaga gcacatgagt gaagtgcagc 1080
 cagactcacc ccaggggatc tacgacacac tccttgagct gcgactgcag aactgggccc 1140
 acgagaagga tccacagggt aaagagaagc ttcacgcaga ggccatttcc ctgctgaaga 1200
 55 gtggtcgctt ctgcgacgtc tttgacaagg ccctggctct gtgccagatg cagcacttcc 1260
 aggatggtgt cctttacctt tatgagcagg ggaagctgtt ccagcagatc atgcactacc 1320
 acatgcagca cgagcagtac cggcagggtc tcagcgtgtg tgagcgccat ggggagcagg 1380
 acccctcctt gtgggagcag gccctcagct acttcgctcg caaggaggag gactgcaagg 1440
 agtatgtggc agctgtcctc aagcatatcg agaacaagaa cctcatgcca cctcttctag 1500
 60 tgggtgcagac cctggcccac aactccacag ccacactctc cgtcatcagg gactacctgg 1560
 tccaaaaact acagaaacag agccagcaga ttgcacagga tgagctgcgg gtgcggcggt 1620
 accgagagga gaccaccggt atccgcccagg agatccaaga gctcaaggcc agtcctaaga 1680
 ttttccaaaa gaccaagtgc agcatctgta acagtgcctt ggagttgccc tcagtccact 1740
 65 tcctgtgtgg ccactccttc caccaacact gctttgagag ttactcgga agtgatgctg 1800
 actgccccac ctgcctccct gaaaaccgga aggtcatgga tatgatccgg gccaggaac 1860
 agaaacgaga tctccatgat caattccagc atcagctcaa gtgctccaat gacagctttt 1920

ctgtgattgc tgactacttt ggcagaggtg ttttcaacaa attgactctg ctgaccgacc 1980
 ctcccacagc cagactgacc tccagcctgg aggctgggct gcaacgcgac ctactcatgc 2040
 actccaggag gggcacttaa gcagcctgga ggaagatgtg ggcaacagtg gaggaccaag 2100
 5 agaacagaca caatgggacc tgggcgggcg ttacacagaa ggctggctga catgcccagg 2160
 gctccactct catctaattgt cacagccctc acaagactaa agcggaactt tttcttttcc 2220
 ctggccttcc ttaattttta gtcaagcttg gcaatccctt cctctttaac taggcaggtg 2280
 ttagaatcat ttccagatta atggggggga aggggaacct caggcaaacc tcctgaagtt 2340
 ttggaaaaaa aagctgggtt c

10 <210> 21
 <211> 179
 <212> DNA
 <213> Human

15 <400> 21

aggtgttaga tgctcttgaa aaagaaactg catctaagct gtcagaaatg gattctttta 60
 acaatcaact aaaggaactg agagaaacct acaacacaca gcagttagcc cttgaacagc 120
 20 tttataagat caacgtgaca agttgaagga aattgaaagg aaaaaattag aactaatgc

<210> 22
 <211> 905
 <212> DNA
 <213> Human

25 <400> 22

30 tttttttttt ttctttaacc gtgtggtcct tatttcagtg ccagtgttac agatacaaca 60
 caaatgttcc agttagaagg aattcaaacg gaatgccaa gccaagcca ggctcaagaa 120
 ataaaaaggg aggtttggag taatagataa gatgactcca atactcactc ttccctaaggg 180
 caaagggtact ttgatacag agtctgatct ttgaaactgg tgaactcctc ttccacccat 240
 taccatagtt caaacaggca agttatgggc ttaggagcac tttaaaattt gtggtgggaa 300
 tagggtcatt aataactatg aatatactt ttagaagggt accattttgc actttaaaagg 360
 35 gaatcaattt tgaatatcat ggagactatt catgactaca gctaaagaat ggcgagaaag 420
 gggagctgga agagccttgg aagtttctat tacaaataga gcaccatata cttcatgcca 480
 aatctcaaca aaagctcttt ttaactccat ctgtccagtg tttacaaata aactcgcaag 540
 gtctgaccag ttcttggtta caaacatata tgtgtgtgtc tgtgtgtata cagcaatgca 600
 cagaaaaggc taccaggagc ctaatgcctc tttcaaakat tgggggaacc agtagaaaaa 660
 ggcagggtct cctaattgtc attattacat ttccattccg aatgccagat gttaaaagtg 720
 40 cctgaagatg gtaaccagc tagtgaggaa taaatacccc acctgcca gtccacagag 780
 aaacaacagt agaaagaagg ggcaactctt tgctgcagag acaaagttag tgttttttcg 840
 ccatggattg cagtcctctc ctccagacca gctgcttatt tcctcagggg cccagggaat 900
 gttga

45 <210> 23
 <211> 2134
 <212> DNA
 <213> Human

50 <400> 23

55 ggtctcttct ttcttttttt tttttccaaa agtgttcttt tatttctagt aacatatatt 60
 gtataaatac tctattttat atgcacttcc acaaaagcga tataatttaa agttttttt 120
 cattagaaat aaatgtataa aaataaataa gttattatag gcatttatta ctaactatag 180
 tccttcttgg aaggaacacc caaaccaata cttataaagt acatgtaatt tatagtaaca 240
 tattttacta tatacatatg gaaaaaatca tattctcaca gaagagctga acagacattc 300
 accaggatac gactgttgga ccagctgctg gagatggacc tgctaccctt cagcagcctc 360
 cccaccacaa gacaagtgat ctcaatgtcc ccaaactgtt gggaccctgt tctacacacc 420
 tcatttttgt tccggcgttt catcctcctt gtgtgattgt actgattttc atgagacaca 480
 60 agttacttct ttacatccat attcccaaag cagggttaca tggtaggaaa gaaaggaagt 540
 tggagggtact aagctcattg tgtctcctct agcttttacc agcatctaatt gcttcactgc 600
 tttttttcca ttgtagactt taatgcactt gaataaatac atggagttgt ttttctctca 660
 aaatgaatta cacaaataaa gactgagatg gtccaaaaaa ggaaagagga agccatttgc 720
 gttattttcac gttgctgagc ctttctctca tgttgaacaa tctgaagttt taattctcgg 780
 65 tagaaataat gtataaacat tctctgaaac catagcagcc ataaacagtg ctggtcaaag 840
 atcctatttg tactcctttc tccccccatt gttagttagg taaagtaaaa caggtcttag 900

5 taaaatctca cttttctcct actttttcatt tcccaacccc catgatacta agtattttgat 960
 aagtaccagg aaacaggggt tgtaatagtt ctaacttttt ttgacaattg ctttgttttt 1020
 tctaaacttg taatagatgt aacaaaagaa ataataataa taatgcccgg ggctttatta 1080
 tgctatatca ctgctcagag gttaataatc ctcactaact atcctatcaa atttgcaact 1140
 10 ggcagtttac tctgatgatt caactccttt tctatctacc ccataatcc caccttactg 1200
 atacacctca ctggttactg gcaagatacg ctggatccct ccagccttct tgctttccct 1260
 gcaccagccc ttctcactt tgccttgccc tcaaagctaa caaccactta accacttaac 1320
 tgcattctgc cattgtgcaa aagtctatga aatgttttagg tttcttttaa ggatcacagc 1380
 tctcatgaga taacaccctt ccatcatggg acagacactt caagcttctt tttttgtaac 1440
 15 ccttcccaca ggtcttagaa catgatgacc actccccag ctgccactgg gggcagggat 1500
 ggtctgcaca aggtctgggt ctggctgggt tcacttcctt tgcacactcg gaagcaggct 1560
 gtccattaat gtctcggcat tctaccagtc ttctctgcca acccaattca catgacttag 1620
 aacattcgcc ccactcttca atgacccatg ctgaaaaagt ggggatagca ttgaaagatt 1680
 ccttcttctt ctttacgaag taggtgtatt taatttttagg tcgaagggca ttgcccacag 1740
 20 taagaacctg gatggtcaag ggctctttga gagggctaaa gctgcgaatt ctttccaatg 1800
 ccgcagagga gccgctgtac ctcaagacaa cacctttgta cataatgtct tgctctaagg 1860
 tggacaaagt gtagtcacca ttaagaatat atgtgccatc agcagctttg atggcaagaa 1920
 agctgccatt gtctctggat cccctctggg tccgctgttt cacttcgatg ttggtggctc 1980
 cagttggaat tgtgatgata tcatgatatc caggttttgc actagtaact gatcctgata 2040
 25 tttttttaca agtagatcca tttccccgc aaacaccaca tttatcaaac ttttttttgg 2100
 agtctatgat gcgatcacia ccagctttta caca

 <210> 24
 <211> 1626
 <212> DNA
 <213> Human

 <400> 24

 30 ggacaatttc tagaatctat agtagtatca ggatatattt tgctttaaaa tatatttttg 60
 ttattttgaa tacagacatt ggctccaaat ttcatcttt gcacaatagt atgacttttc 120
 actagaactt ctcaacattt gggaaactttg caaatatgag catcatatgt gttaaggctg 180
 tatcatttaa tgctatgaga tacattgttt tctccctatg ccaaacaggt gaacaaacgt 240
 35 agttgttttt tactgatact aaatgttggc tacctgtgat tttatagtat gcacatgtca 300
 gaaaaaggca agacaaatgg cctctgtgac tgaatacttc ggcaaactta ttgggtcttc 360
 attttctgac agacaggatt tgactcaata tttgtagagc ttgcgtagaa tggattacat 420
 ggtagtgatg cactggtaga aatggttttt agttattgac tcagaattca tctcaggatg 480
 aatcttttat gtctttttat tgtaagcata tctgaattta ctttataaag atggtttttag 540
 40 aaagctttgt ctaaaaattt ggcctaggaa tggtaacttc attttcagtt gccaaagggg 600
 agaaaaataa tatgtgtgtt gttatgttta tgtaaacata ttattaggta ctatctatga 660
 atgtatttaa atatttttca tattctgtga caagcattta taatttgcaa caagtggagt 720
 ccatttagcc cagtgggaaa gtcttgggaa tcagggttacc cttgaaggat atgctggcag 780
 ccactctctt gatctgtgct taaactgtaa tttatagacc agctaaatcc ctaacttgga 840
 45 tctggaatgc attagttagt ccttgtacca ttcccagaat ttcaggggca tctgtgggtt 900
 ggtctagtga ttgaaaacac aagaacagag agatccagct gaaaaagagt gatcctcaat 960
 atcctaacta actggtcctc aactcaagca gagtttcttc actctggcac tgtgatcatg 1020
 aaacttagta gaggggattg tgtgtatttt atacaaattt aatacaatgt cttacattga 1080
 taaaattctt aaagagcaaa actgcatttt atttctgcat ccacattcca atcatattag 1140
 50 aactaagata tttatctatg aagatataaa tgggtgcagag agactttcat ctgtggattg 1200
 cgttgtttct tagggttcct agcactgatg cctgcacaag catgtgatat gtgaaataaa 1260
 atggattctt ctatagctaa atgagttccc tctggggaga gttctgggtac tgcaatcaca 1320
 atgccagatg gtgtttatgg gctatttgtg taagtaagtg gtaagatgct atgaagtaag 1380
 tgtgtttgtt ttcatcttat ggaaactctt gatgcatgtg cttttgtatg gaataaattt 1440
 55 tgggtgcaata tgatgtcatt caactttgca ttgaattgaa ttttggttgt atttatatgt 1500
 attatacctg tcacgcttct agttgcttca accattttat aaccattttt gtacatattt 1560
 tacttgaaaa tatttttaaat ggaaatttaa ataaacattt gatagtttac ataataaaaa 1620
 aaaaaa

 <210> 25
 <211> 1420
 <212> DNA
 <213> Human

 <400> 25

 65 gttcagcatt gtttctgctt ctgaaatctg tatagtacac tggtttgtaa tcattatgtc 60

5 ttcattgaaa tccttgctac ttctcttcct cctcaatgaa agacacgaga gacaagagcg 120
 acacaagctt aagaaaaacg agcaaggaag agtatcttca ttattctcat tttctctgag 180
 ttggaaacaa aaacatgaag gactccaact agaagacaga tatttacatt taaatagatt 240
 agtgggaaaa ctttaagagt ttccacatat tagttttcat tttttgagtc aagagactgc 300
 tccttgctact gggagacact agtagtatat gtttgtaatg ttactttaaa attatctttt 360
 tattttataa ggcccataaa tactggttaa actctgttaa aagtgggcct tctatcttgg 420
 atggtttcac tgccatcagc catgctgata tattagaaat ggcaccccta tctacttact 480
 ttaatgctta aaattataca taaaatgctt tatttagaaa acctacatga tacagtgggtg 540
 10 tcagccttgc catgtatcag tttcacttga aatttgagac caattaaatt tcaactgttt 600
 agggtggaga aagagggtact ggaaaacatg cagatgagga tatcttttat gtgcaacagt 660
 atcctttgca tgggaggaga gttactcttg aaaggcaggc agcttaagtg gacaatgttt 720
 tgtatatagt tgagaatttt acgacacttt taaaaattgt gtaattgtta aatgtccagt 780
 tttgctctgt tttgcctgaa gtttttagtat ttgttttcta ggtggacctc tgaaaaccaa 840
 15 accagtacct ggggagggtta gatgtgtgtt tcaggcttgg agtgtatgag tggttttgct 900
 tgtattttcc tccagagatt ttgaacttta ataattgcgt gtgtgttttt ttttttttaa 960
 gtggctttgt ttttttttct caagtaaaat tgtgaacata tttcctttat aggggcaggg 1020
 catgagtttag ggagactgaa gagtattgta gactgtacat gtgccttctt aatgtgtttc 1080
 tcgacacatt ttttttcagt aacttgaaaa ttcaaaaggg acatttggtt aggttactgt 1140
 20 acatcaatct atgcataaat ggcagcttgt tttcttgagc cactgtctaa attttgtttt 1200
 tatagaaatt ttttatactg attggttcat agatggtcag ttttgtacac agactgaaca 1260
 atacagcact ttgccaaaaa tgagtgtagc attgtttaaa cattgtgtgt taacacctgt 1320
 tctttgtaat tgggttgtgg tgcattttgc actacctgga gttacagttt tcaatctgtc 1380
 agtaaataaa gtgtccttta acttcaaaaa aaaaaaaaaa

25 <210> 26
 <211> 689
 <212> DNA
 <213> Human

30 <400> 26

35 aaacaaacaa aaaaaaagtt agtactgtat atgtaaatac tagcttttca atgtgctata 60
 caaacaatta tagcacatcc ttctttttac tctgtctcac ctcttttagg tgagtacttc 120
 cttaaaataag tgctaaacat acatatacgg aacttgaaag ctttggttag ccttgcccta 180
 ggtaatcagc ctagttttaca ctgtttccag ggagtagttg aattactata aaccatttagc 240
 cacttgcttc tgcaccattt atcacaccag gacaggggtct ctcaacctgg gcgctactgt 300
 catttggggc caggtgatcc ttcttgcaa gggctgtcct gtacctgccg gggcgccgcg 360
 tcgaagcgtg gtcgcggccg aggtactgaa aggaccaagg agctctggct gccctcagga 420
 attccaaatg accgaaggaa caaagcttca gggctctggg tgggtgtctcc cactattcag 480
 40 gaggtgggtc gaggtaacgc agcttcattt cgtccagtc tttccagtat ttaaagttgt 540
 tgtcaagatg ctgcattaaa tcaggcaggt ctacaaaggc atcccaagca tcaaacaatgt 600
 ctgtgatgaa gtaatcaatg aaacaccgga acctccgacc acctcctgaa tagtgggaga 660
 cacaccaga gcctgaagtt tgtccttcg

45 <210> 27
 <211> 471
 <212> DNA
 <213> Human

50 <400> 27

55 tcccagcggc atgaagtttg agattggcca ggccctgtac ctgggcttca tctccttcgt 60
 ccctctcgct cattggtggc accctgcttt gcctgtcctg ccaggacgag gcacctaca 120
 agccctaacc caggccccgc ccagggccac cagcaccact gcaaacaccg cacctgccta 180
 ccagccacca gctgcctaca aagacaatcg ggccccctca gtgacctcg ccaccacagc 240
 gggtacaggc tgaacgacta cgtgtgagtc cccacagcct gcttctcccc tgggctgctg 300
 tgggctgggt cccggcgagg ctgtcaatgg aggcaggggt tccagcacia agtttacttc 360
 tgggcaattt ttgtatccaa ggaaataatg tgaatgcgag gaaatgtctt tagagcacag 420
 ggacagaggg ggaaataaga ggaggagaaa gctctctata ccaaagactg a

60 <210> 28
 <211> 929
 <212> DNA
 <213> Human

65 <400> 28

5 ggtgaactca gtgcattggg ccaatgggtc gacacaggct ctgccagcca caaccatcct 60
 gctgcttctg acggtttggc tgctgggtgg ctttccctc actgtcattg gaggcattct 120
 tgggaagaac aacgccagcc cttttgatgc accctgtcgc accaagaaca tcgcccggga 180
 gattccaccc cagccctggt acaagtctac tgtcatccac atgactgttg gaggcttcct 240
 gcctttcagt gccatctctg tggagctgta ctacatcttt gccacagtat ggggtcggga 300
 gcagtacact ttgtacggca tcctcttctt tgtcttcgcc atcctgctga gtgtgggggc 360
 ttgcatctcc attgcaactca cctacttcca gttgtctggg gaggattacc gctgggtggtg 420
 gcgatctgtg ctgagtgttg gctccaccgg cctcttcac ttcctctact cagtcttcta 480
 10 ttatgcccg cgctccaaca tgtctggggc agtacagaca gtagagtctt tcggctactc 540
 cttactcact ggttatgtct tcttcctcat gctgggcacc atctcctttt tttcttcctt 600
 aaagtctac cggtatatct atgttaacct caagatggac tgagtctgt atggcagaac 660
 tattgctgtt ctctcccttt ctctcatgcc tgttgaactc tcctaccage ttctctcttg 720
 attgactgaa ttgtgtgatg gcattgttgc ctccctttt tccctttggg cattccttcc 780
 15 ccagagaggg cctggaaatt ataaatctct atcacataag gattatata ttgaactttt 840
 taagttgcct ttagtttttg tcctgatttt tctttttaca attacaaaaa taaaatttat 900
 taagaaaaag aaaaaaaaaa aaaaaaaaaa

<210> 29
 <211> 1775
 <212> DNA
 <213> Human

25 <400> 29

30 gaacgtgatg ggaacttttg gaggatgtct gagaaaatgt ccgaagggat tttggccaac 60
 accagaaaac gccaatgtcc taggaattcc ctcccaaat gcttcccaa aaattactca 120
 ttgacaattc aaattgcact tggctggcgg cagcccgggc ggcttccagt ccgtgtgggg 180
 cgcccgctg gccttctcct cgtaggactc cccaaactcg ttcactctgc gtttatccac 240
 aggataaagc caccgctggt acaggtagac cagaaacacc acgtcgtccc ggaagcaggc 300
 cagccggtga gacgtgggca tgggtgatgat gaaggcaaag acgtcatcaa tgaaggtgtt 360
 gaaagccttg taggtgaagg ccttccaggg cagatgtgcc actgacttca acttgtagtt 420
 cacaagagagc tggggcagca tgaagaggaa accaaaggca tagaccccg tgaagagct 480
 gttgattaac caggagtacc agctcttata tttgatattc aggagtgaat agacagcacc 540
 35 cccgacacag agaggggtaca gcaggtaga caagtacttc atggcctgag tatcgtactc 600
 ctccggtttt ctctcagatt cgctgtaagt gccaaactga aattcgggca tcaggcctct 660
 ccaaaaaata gtcattctca atgccttctt cactttccac agctcaatgg cggctccaac 720
 acccgccggg accagcacca gcaggctcgt ctgctcgtcc agcaggaaca gaaagatgac 780
 cagcgtgctg aagcagcgcc agagcactgc cttgggtggac atgccgatca tgccttctt 840
 40 cttcttccag aaactgatgt catttttaaa ggccaggaaa tcaaagagaa gatggaacgc 900
 tgcgacaaag aaggtcagcg ccagggaagta taagttggta tctacaaaaa ttcctttcac 960
 ctcatcagca tctttctctg aaaaccgaa ctgctgcagg gagtacacgg cgtcctgcat 1020
 gtggatccag aagcgcagcc gcccagtgga gaccttgcg taggacacgg tgaggggcag 1080
 ctccggtggtg gagcgggtta tgaccatcag gtccttcac cggttgctga gctggctgat 1140
 45 gaacaggatg ggcaggtaat gcacggtttt cccagctgg atcatcttca tgtaccgatg 1200
 cacatcgga ggcaggagg acccgtcaa gacaaagtg tccgcatca cgttcagcgc 1260
 cagcccggt cgccagtggg aactggctc atccaggga ctcgtcggct tcttctccgc 1320
 ctcgatctgc tgtgtatcag actccccgt gagcagggtg atttcttctg gcttggggac 1380
 catgtaggtg gtcagaggac tgaccagggt cacctgcttc ccgtcgtgcc acggcaggac 1440
 50 cccagcgtga tggaggaaga tgtaggcata cagcgtccca ttgtttctcg ttttctttg 1500
 tacagaaaca ttaactgtcc tttcaaattt ggactccaca tcaaagtctt ccacattcaa 1560
 gaccaggtcg atgttgttct cagcaccag gtgggacctc gtcgtggtgt acacgctcag 1620
 ctgcagcttg ggccgcccgc ccaggtaggg ctggatgcag ttggcgtcgc cggagcacgg 1680
 gcggtgtag acgatgccgt acatgacca gcagggtgac accacgtaga ccacgaacac 1740
 55 gccaccacc aagctggtga aggagctgcg gccc

<210> 30
 <211> 1546
 <212> DNA
 <213> Human

60 <400> 30

65 aaaataagta ggaatgggca gtgggtattc acattcacta caccttttcc atttgctaatt 60
 aaggccctgc caggctggga gggaattgtc cctgcctgct tctggagaaa gaagatattg 120

	acaccatcta	cgggcacccat	ggaactgctt	caagtgaacca	ttcttttttct	tctgcccagt	180
	atttgcagca	gtaacagcac	aggtgtttta	gaggcagcta	ataattcact	tggtgttact	240
	acaacaaaac	catctataac	aacaccaaac	acagaatcat	tacagaaaaa	tggtgtcaca	300
5	ccaacaactg	gaacaactcc	taaaggaaca	atcaccaatg	aattacttaa	aatgtctctg	360
	atgtcaacag	ctactttttt	aacaagtaaa	gatgaaggat	tgaaagccac	aaccactgat	420
	gtcaggaaga	atgactccat	catttcaaac	gtaacagtaa	caagtgttac	acttccaaat	480
	gctgtttcaa	cattacaaag	ttccaaaccc	aagactgaaa	ctcagagttc	aattaaaaca	540
	acagaaatac	caggtagtgt	tctacaacca	gatgcatcac	cttctaaaac	tggtacatta	600
	acctcaatac	cagttacaat	tccagaaaac	acctcacagt	ctcaagtaat	aggcactgag	660
10	ggtggaaaaa	atgcaagcac	ttcagcaacc	agccggtctt	attccagtat	tattttgccg	720
	gtggttattg	ctttgattgt	aataacactt	tcagtatttg	ttctggtggg	tttgtaccga	780
	atgtgctgga	aggcagatcc	gggcacacca	gaaaatggaa	atgatcaacc	tcagtctgat	840
	aaagagagcg	tgaagcttct	taccgttaag	acaatttctc	atgagtctgg	tgagcactct	900
	gcacaaggaa	aaaccaagaa	ctgacagctt	gaggaattct	ctccacacct	aggcaataat	960
15	tacgcttaat	cttcagcttc	tatgcaccaa	gcgtggaaaa	ggagaaagtc	ctgcagaatc	1020
	aatccccgact	tccatacctg	ctgctggact	gtaccagacg	tctgtcccag	taaagtgatg	1080
	tccagctgac	atgcaataat	ttgatggaat	caaaaagaac	cccggggctc	tcctgttctc	1140
	tcacatttaa	aaattccatt	actccattta	caggagcgtt	cctaggaaaa	ggaatttttag	1200
	gaggagaatt	tgtgagcagt	gaatctgaca	gcccaggagg	tggtgctcgt	gataggcatg	1260
20	actttcctta	atgttttaaag	ttttccgggc	caagaatttt	tatccatgaa	gactttccta	1320
	cttttctcgg	tggttcttata	ttacctactg	ttagtattta	ttgtttacca	ctatgttaat	1380
	gcagggaaaa	gttgacagtg	tattattaaa	tattaggtag	aatcatacc	atgctacttt	1440
	gtacatatata	gtattttatt	cctgctttcg	tgttactttt	aataaataac	tactgtactc	1500
	aataactctaa	aaatactata	acatgactgt	gaaaatggca	aaaaaa		
25	<210> 31						
	<211> 750						
	<212> DNA						
	<213> Human						
30	<400> 31						
	cacttgggca	cccccathtt	ctaaaaaaat	ggaaatctgg	agggcaaaaa	aggtgtgctg	60
	aaggggaagt	cctctgatgg	cccaaaaacc	ttcttccaaa	ctagtgtagg	aatggaatgg	120
35	atagcaaagt	gatccttttt	ggcctccttt	ggagcatgcc	ttccctatct	tatccttggc	180
	cccactaaag	cagaacgtta	cggatatttc	tggttttgcc	attggatgcc	tatctggcca	240
	aacagccttt	ccctaattgg	aaaatgcagt	cctgtttaaa	acctttgatt	tacgactact	300
	tgtacatgct	tgctcattac	aattttgaca	ttttttacat	agtgaagacc	ccaaacatat	360
	cagtgaacaa	tgacaagatc	ataaagaaca	gtatcatatt	attatttagt	cgcttttaca	420
40	gtggcaagcc	aattttgaaa	tatctcattt	aaaactcaga	cccaattcac	tgagttatac	480
	ttttaatagc	ttcctcagca	cactatttcc	catgcattaa	atatgataaa	ataatctatc	540
	actgcccata	ggtcttgtaa	aaaggaagtc	tgaatacaga	gcccaacaac	ctaaaattgt	600
	ttttctagct	acaaagtata	gcatacatca	cacagacacg	atttggactc	cctgacaggt	660
	ggattggaaa	acggtgttta	aagagaagag	aacattttta	cataaatgtc	attaagaatc	720
45	ccaaaggcct	tatttgtcac	caccgtcccg				
	<210> 32						
	<211> 1620						
	<212> DNA						
50	<213> Human						
	<400> 32						
	gcaattcccc	cctcccacta	aacgactccc	agtaattatg	tttacaaccc	attggatgca	60
55	gtgcagccat	tcataagaac	cttgggtgcc	cagaaaaatc	tgctcttttt	ggtaccacaa	120
	ctgaggtctt	ttggaagata	atgtagaaaa	ccactaccta	ttgaaggcct	gttttggcta	180
	atctgtgcaa	actctgatga	tacctgcctt	atgtggatcc	ttttccacac	tgctttcatt	240
	tttaagtata	aagacttaga	aaactagaat	aatgctttta	caaataatta	aaagtatgtg	300
	atgttctggg	tttttttctt	cttttttagaa	ccccgcctcc	atttaaaaaa	ttaaaaaaa	360
60	aaaaaaaaact	tttaacattt	aaaaaataaa	aattaacaaa	atttcactta	ttccaggaca	420
	cgctggcatt	tggaactcaat	gaaaagggca	cctaaagaaa	ataaggctga	ctgaatgttt	480
	tccataattt	tcacacaata	acagtccctt	tctatccagc	ttgccttcca	tttatctcta	540
	gggttagctt	ttcaggcaac	atccttggtc	attgcccaga	aagtacctga	gctatcagtg	600
	attggaatgg	cacaggaaac	cgaatcacat	gggtgcccct	cccttggttt	tcaagtatct	660
65	tgagattgtg	cacaaaaatt	aggtcatgcc	ttcagtgtct	tggtctttta	acctaccctt	720
	tgacaatcag	gtgctaataa	ttgtatacta	ttaaaaccag	cacataagta	ttgtaaatgt	780

gtgttcctcc taggttgga gaaatgtctt tccttctatc tgggtcctgt taaagcgggt 840
 gtcagttgtg tcttttcacc tcgatttgtg aattaataga attgggggga gaggaaatga 900
 tgatgtcaat taagtttcag gtttggcatg atcatcattc tcgatgatat tctcactttg 960
 5 tcgcaaatct gcccttatcg taagaacaag ttccagaatt ttccctccac tatacgactc 1020
 cagtattatg tttaacaatcc attggatgag tgcagcatta taagaccttg gtgcccagaa 1080
 aaatctgtcc tttttggtac caaacctgag gtcttttgga agataatgta gaaaaccact 1140
 acctattgaa ggcctgtttt ggctaactctg tgcaaactct gatgatacct gcttatgtgg 1200
 attcttttcc acactgcttt catttttaag tataaagact tagaaaacta gaataatgct 1260
 10 tttaaaata attaaaagta tgtgatgttc tgggtttttt ccttcttttt agaaccctgt 1320
 atttaaaaca gccttctttt taagtcttgt ttgaaattta agtctcagat cttctggata 1380
 ccaaatcaaa aacccaacgc gtaaaacagg gcagtatttg tgttcctaata tttaaaaagc 1440
 tttatgtata ctctataaat atagatgcat aaacaacact tccccttgag tagcacatca 1500
 acatacagca ttgtacatta caatgaaaat gtgtaactta agggatttat atatataaat 1560
 15 acatatatac ctttgtaacc ttataactgt aaataaaaaa gttgcttttag tcaaaaaaaa 1620
 <210> 33
 <211> 2968
 <212> DNA
 <213> Human
 20 <400> 33
 gaaaaagtag aaggaaacac agttcatata gaagtaaaag aaaaccctga agaggaggag 60
 25 gaggaggaag aagaggaaga agaagatgaa gaaagtgaag aggaggagga agaggaggga 120
 gaaagtgaag gcagtgaagg tgatgaggaa gatgaaaagg tgtcagatga gaaggattca 180
 gggaagacat tagataaaaa gccaaagtaa gaaatgagct cagattctga atatgactct 240
 gatgatgatc ggactaaaga agaaagggct tatgacaaag caaaacggag gattgagaaa 300
 cggcgacttg aacatagtaa aaatgtaaac accgaaaagc taagagcccc tattatctgc 360
 gtacttgggc atgtggacac agggagagaca aaaattctag ataagctccg tcacacacat 420
 30 gtacaagatg gtgaagcagg tggatcacaca caacaaattg gggccacca tgttctctct 480
 gaagctatta atgaacagac taagatgatt aaaaattttg atagagagaa tgtacggatt 540
 ccaggaatgc taattattga tactcctggg catgaatctt tcagtaatct gagaaataga 600
 ggaagctctc tttgtgacat tgccatttta gttgttgata ttatgcatgg tttggagccc 660
 35 cagacaattg agtctatcaa ccttctcaaa tctaaaaaat gtcccttcat tgttgactc 720
 aataagattg ataggttata tgattggaag aagagtcctg actctgatgt ggctgctact 780
 ttaaagaagc agaaaaagaa tacaaaagat gaatttgagg agcgagcaaa ggctattatt 840
 gtagaatttg cacagcaggg tttgaatgct gctttgtttt atgagaataa agatccccgc 900
 acttttgtgt ctttggtacc tacctctgca catactgggtg atggcatggg aagtctgatc 960
 40 taccttcttg tagagttaac tcagaccatg ttgagcaaga gacttgcaac ctgtgaagag 1020
 ctgagagcac aggtgatgga ggttaaagct ctcccgggga tgggcaccac tatagatgtc 1080
 atcttgatca atgggcggtt gaaggaagga gatacaatca ttgttcttg agtagaaggg 1140
 cccattgtaa ctcagattcg aggcctcctg ttacctctc ctatgaagga attacgagtg 1200
 aagaaccagt atgaaaagca taaagaagta gaagcagctc aggggggtaaa gattcttgga 1260
 45 aaagacctgg agaaaacatt ggctgggtta cccctccttg tggcttataa agaagatgaa 1320
 atccctgttc ttaaagatga attgatccat gagttaaagc agacactaaa tgctatcaaa 1380
 ttagaagaaa aaggagtcta tgtccaggca tctacactgg gttcttttga agctctactg 1440
 gaatttctga aaacatcaga agtgccctat gcaggaatta acattggccc agtgcataaa 1500
 aaagatgtta tgaaggcttc agtgatgttg gaacatgacc ctgagtatgc agtaattttg 1560
 50 gccttcgatg tgagaattga acgagatgca caagaaatgg ctgatatgtt aggagttaga 1620
 atttttagtg cagaaattat ttatcattta tttgatgcct ttacaaaata tagacaagac 1680
 tacaagaaac agaaacaaga agaatttaag cacatagcag tatttccctg caagataaaa 1740
 atcctccctc agtacatttt taattctcga gatccgatag tgatgggggt gacgggtgga 1800
 gcaggtcagg tgaaacaggg gacacccatg tgtgtcccaa gcaaaaattt tgttgacatc 1860
 55 ggaatagtaa caagtattga aataaaccat aaacaagtgg atgttgcaaa aaaaggacaa 1920
 gaagtgtgtg taaaaataga acctatccct ggtgagtcac ccaaaatgtt tggaagacat 1980
 tttgaagcta cagatattct tgttagtaag atcagccggc agtccattga tgcactcaaa 2040
 gactggttca gagatgaaat gcagaagagt gactggcagc ttattgtgga gctgaagaaa 2100
 gtatttgaaa tcatctaatt ttttcacatg gagcaggaac tggagtaaat gcaatactgt 2160
 60 gttgtaatat cccaacaaaa atcagacaaa aaatggaaca gacgtatttg gacactgatg 2220
 gacttaagta tggaaggaag aaaaataggt gtataaaatg ttttccatga gaaaccaaga 2280
 aacttacact ggtttgacag tggtcagtta catgtcccca cagttccaat gtgcctgttc 2340
 actcacctct cccttcccca acccttctct acttggctgc tgttttaaaag tttgcccttc 2400
 cccaaatttg gatttttatt acagatctaa agctcttctg attttatact gattaaatca 2460
 65 gtactgcagt atttgattaa aaaaaaaaaa gcagattttg tgattcttgg gacttttttg 2520
 acgtaagaaa tacttcttta tttatgcata ttcttcccac agtgattttt ccagcattct 2580
 tctgccatat gcctttaggg cttttataaa atagaaaatt aggcattctg atatttcttt 2640

5 agctgctttg tgtgaaacca tgggtgtaaaa gcacagctgg ctgcttttta ctgcttgtgt 2700
agtcacgagt ccattgtaat catcacaatt ctaaaccaaa ctaccaataa agaaaacaga 2760
catccaccag taagcaagct ctgttaggct tccatgggta gtggtagctt ctctcccaca 2820
agttgtcctc ctaggacaag gaattatctt aacaaactaa actatccatc acactacctt 2880
ggtatgccag cacctgggta acagtaggag attttataca ttaatctgat ctgtttaatc 2940
tgatcggttt agtagagatt ttatacat

10 <210> 34
<211> 6011
<212> DNA
<213> Human

<400> 34

15

20 acggggcgcc ggacgacccg cacatcttat cctccacgcc ccaactcgac tcggagcggg 60
accgccccgg actccccctc ggcccgccca ctcgaggagt gaggagagag gccgcccggc 120
cggcttgagc cgagcgcagc acccccgcg ccccgcgcca gaagtttggt tgaaccgggc 180
tgccgggaga aacttttttc ttttttccc ctctcccggg agagtctctg gaggaggagg 240
ggaactcccc cggcccaagg ctcgtgggct cggggtcgcg cggccgcaga aggggcgggg 300
tcgcccgcg aggggaggcg cccccggga cccgagaggg gggtagaggac cgcgggctgc 360
tggtagcggc gcggcagcgt gtgcccgcg caggggaggc gccgccccgc tcccggccccg 420
25 gctgcgagga ggaggcggcg gcggcgcagg aggatgtact tggtagcggg ggacaggggg 480
ttggccggct gcgggcacct cctggtctcg ctgctggggc tgctgctgct gccggcgcgc 540
tcgggcaccc gggcgctggt ctgcctgcc tgtgacgagt ccaagtgcga ggagcccagg 600
aaccgccccg ggagcatcgt gcaggcgctc tgcggctgct gctacacgtg cgccagccag 660
gggaacgaga gctgcggcgg caccttcggg atttacggaa cctgcgaccg ggggctgcgt 720
30 tgtgtcatcc gcccccgct caatggcgac tccctcaccg agtacgaagc gggcgcttgc 780
gaagatgaga actggactga tgaccaactg cttgggttta aaccatgcaa tgaaaacctt 840
attgctggct gcaatataat caatgggaaa tgtgaatgta acaccattcg aacctgcagc 900
aatccctttg agtttccaag tcaggatatg tgcctttcag ctttaaagag aattgaagaa 960
gagaagccag attgctccaa ggcccgtgt gaagtccagt tctctccacg ttgtcctgaa 1020
35 gattctgttc tgatcgaggg ttatgtcct cctggggagt gctgtccctt acccagccgc 1080
tgctgtgca accccgcagg ctgtctgcgc aaagtctgcc agccgggaaa cctgaacata 1140
ctagtgtcaa aagcctcagg gaagccggga gagtgtgtg acctctatga gtgcaaacca 1200
gttttcggcg tggactgcag gactgtggaa tgccctactg ttcagcagac cgcgtgtccc 1260
ccggacagct atgaaactca agtcagacta actgcagatg gttgctgtac ttgccaaca 1320
40 agatgcgagt gtctctctgg cttatgtggt ttccccgtgt gtgaggtggg atccactccc 1380
cgcatagtct ctcgtggcga tgggacacct ggaaagtgt gtgatgtctt tgaatgtgtt 1440
aatgatacaa agccagcctg cgtatttaac aatgtggaat attatgatgg agacatgttt 1500
cgaatggaca actgtcgggt ctgtcgatgc caagggggcg ttgccatctg cttcaccgcc 1560
cagtgtgggt agataaactg cgagaggtac tacgtgcccg aaggagagtgt ctgcccagtg 1620
45 tgtgaagatc cagtgtatcc ttttaataat cccgctggct gctatgcaa tggcctgatc 1680
cttgcaccag gagaccggtg gcgggaagac gactgcacat tctgccagtg cgtcaacggt 1740
gaacgccact gcgttgcgac cgtctgcgga cagacctgca caaacctgt gaaagtgcct 1800
ggggagtgtt gccctgtgtg cgaagaacca accatcatca cagttgatcc acctgcatgt 1860
ggggagtatt caaactgcac tctgacacgg aaggactgca ttaatgggtt caaacgcgat 1920
50 cacaatgggt gtccgacctg tcagtgcata aacaccagg aactatgttc agaacgtaaa 1980
caaggctgca ccttgaactg tcccttcggt ttccttactg atgccccaaa ctgtgagatc 2040
tgtgagtgcc gcccaaggcc caagaagtgc agaccataa tctgtgacaa gtattgtcca 2100
cttggaattgc tgaagaataa gcacggctgt gacatctgtc gctgtaagaa atgtccagag 2160
55 ctctcatgca gtaagatctg ccccttgggt ttccagcagg acagtcacgg ctgtcttatc 2220
tgcaagtgca gagaggcctc tgcttcagct gggccaccca tccgtgcggg cacttgtctc 2280
accgtggatg gtcacatca taaaaatgag gagagctggc acgatgggtg ccgggaatgc 2340
tactgtctca atggacggga aatgtgtgcc ctgatcacct gcccggtgcc tgcctgtggc 2400
aaccaccaca ttcaccctgg acagtgtgc ccatcatgtg cagatgactt tgtggtgcag 2460
aagccagagc tcagtactcc ctccatttgc cagccccctg gaggagaata ctttgtggaa 2520
60 ggagaaacgt ggaacattga ctctgtact cagtgcacct gccacagcgg acgggtgctg 2580
tgtgagacag aggtgtgccc accgctgtct tgccagaacc cctcacgcac ccaggattcc 2640
tgctgcccac agtgtacaga tcaacctttt cggccttcc tgtcccga taacagcgta 2700
cctaattact gcaaaaatga tgaaggggat atattcctgg cagctgagtc ctggaagcct 2760
gacgtttgta ccagctgcat ctgcattgat agcgtaatga gctgtttctc tgagtcctgc 2820
65 ccttctgtat cctgtgaaag acctgtcttg agaaaaggcc agtgtgtgcc ctactgcata 2880
aaagacacaa ttccaaagaa ggtggtgtgc cacttcagtg ggaaggccta tgccgacgag 2940

5 gagcgggtggg accttgacag ctgcacccac tgctactgcc tgcagggcca gaccctctgc 3000
tcgaccgtca gctgcccccc tctgccctgt gttgagccca tcaacgtgga aggaagttgc 3060
tgcccaatgt gtccagaaat gtatgtccca gaaccaacca atatacccat tgagaagaca 3120
aaccatcgag gagaggttga cctggaggtt cccctgtggc ccacgcctag tgaaaatgat 3180
atcgteccatc tccctagaga tatgggtcac ctccaggtag attacagaga taacaggctg 3240
cacccaagtg aagattcttc actggactcc attgcctcag ttgtggttcc cataattata 3300
tgctctctta ttataatagc attcctattc atcaatcaga agaaacagtg gataccactg 3360
ctttgctggt atcgaacacc aactaagcct tcttccttaa ataatcagct agtatctgtg 3420
gactgcaaga aaggaaccag agtccagggtg gacagttccc agagaatgct aagaattgca 3480
10 gaaccagatg caagattcag tggcttctac agcatgcaaa aacagaacca tctacaggca 3540
gacaatttct accaaacagt gtgaagaaag gcaactagga tgaggtttca aaagacggaa 3600
gacgactaaa tctgctctaa aaagtaaact agaatttgtg cacttgctta gtggattgta 3660
ttggattgtg acttgatgta cagegctaag accttactgg gatgggctct gtctacagca 3720
atgtgcagaa caagcattcc cacttttccct caagataact gaccaagtgt tttcttagaa 3780
15 ccaaagtttt taaagttgct aagatatatt tgctgtgaag atagctgtag agatatttgg 3840
ggtgggggaca gtgagtttgg atggggaaag ggggtgggag gtggtgttgg gaagaaaaat 3900
tggtcagctt ggctcgggga gaaacctggt aacataaaaag cagttcagtg gccagagggt 3960
tatttttttc ctattgctct gaagactgca ctggttgctg caaagctcag gcctgaatga 4020
gcaggaaaca aaaaaggcct tgcgacccag ctgccataac caccctagaa ctaccagacg 4080
20 agcacatcag aaccctttga cagccatccc aggtctaaag ccacaagttt cttttctata 4140
cagtcacaac tgcagtaggc agtgaggaag ccagagaaat gcgatagcgg catttctcta 4200
aagcgggtta ttaaggatat atacagttac actttttgct gcttttattt tcttccaagc 4260
caatcaatca gccagttcct agcagagtca gcacatgaac aagatctaag tcatttcttg 4320
atgtgagcac tggagctttt tttttttaca acgtgacagg aagaggaggg agagggtgac 4380
25 gaacaccagg catttccagg ggctatatatt cactgtttgt tgttgctttg ttctgttata 4440
ttgttggttg ttcatagttt ttgttgaagc tctagcttaa gaagaaactt tttttaaaaa 4500
gactgttttg ggattctttt tcttattat atactgattc taaaaaatag aaactacttc 4560
attttaattg tatattatc aagcacctt gttgaagctc aaaaaaatg atgcctcttt 4620
aaactttagc aattatagga gtatttatgt aactatctta tgcttcaaaa aacaaaagta 4680
30 tttgtgtgca tgtgtatata atatatatat atacatatat atttatacac atacaattta 4740
tgttttctctg ttgaatgtat ttttatgaga ttttaaccag acaaaggca gataaacagg 4800
cattccatag cagtgccttt gatcacttac aaattttttg aataacacaa aatctcattc 4860
tacctgcagt ttaattggaa agatgtgtgt gtgagagtat gtatgtgtgt gtgtgtgtgt 4920
gtgtgtgctg gcgcacgcac gccttgagca gtcagcattg cacctgctat ggagaagggt 4980
35 attcctttat taaaatcttc ctcatcttga tttgctttca gttggttttc aatttgctca 5040
ctggccagag acattgatgg cagttcttat ctgcatcact aatcagctcc tggatttttt 5100
tttttttttt tcaaacaatg gtttgaaaca actactggaa tattgtccac aataagctgg 5160
aagtttggtg tagtatgcct caaatataac tgactgtata ctatagtggg aacttttcaa 5220
acagccctta gcacttttat actaattaac ccatttgtgc attgagtttt cttttaaaaa 5280
40 tgcttggtgt gaaagacaca gataccaggt atgcttaacg tgaaaagaaa atgtgttctg 5340
ttttgtaaag gaactttcaa gtattgttgt aaatacttgg acagagggtg ctgaacttta 5400
aaaaaaatta atttattatt ataattgacct aatttattaa tctgaagatt aaccattttt 5460
ttgtcttaga atatcaaaaa gaaaaagaaa aagggtgttct agctgtttgc atcaaaggaa 5520
aaaaagattt attatcaagg ggcaatattt ttatcttttc caaaataaat ttgttaatga 5580
45 tacattacaa aaatagattg acatcagcct gattagtata aattttgttg gtaattaatc 5640
cattcctggc ataaaaagtc tttatcaaaa aaaattgtag atgcttgctt tttgtttttt 5700
caatcatggc catattatga aaatactaac aggatatagg acaagggtga aattttttta 5760
ttattatttt aaagatatga tttatcctga gtgctgtatc tattactctt ttactttggt 5820
tcctgttgtg ctcttgtaaa agaaaaatat aatttcctga agaataaaat agatatatgg 5880
50 cacttgaggt gcatcatagt tctacagttt gtttttgttt tcttcaaaaa agctgtaaga 5940
gaattatctg caacttgatt ctgggcagga aataaacatt ttgagttgaa atcaaaaaaa 6000
aaaaaaaaa a

55 <210> 34a
<211> 1036
<212> DNA
<213> Human

60 <400> 34a

65 mylvagdrgl agcghllvsl lgllllpars gtralvclpc deskceepn rpgsivqgvc 60
gccytcasgg nescggtfgi ygtcdrglrc virpplngds lteyeagvce denwtdqll 120
gfkpcnenli agcniingkc ecntirtcsn pfefpsqdmc lsalkrieee kpdcskarce 180
vqfsprcped svliegyapp geccpplsrc vcnpagclrk vcqpgnlnil vskasgkpgc 240

ccdlyeckpv fgvdcrvec ptvqqtacpp dsetqvrlt adgcctlptr ceclsglclgf 300
pvcevgstpr ivsrgdgtpg kccdvfecvn dtkpacvfnv veyydgdmdfr mdncrfrcrcq 360
ggvaicftaq cgeinceryy vpegeccpvc edpvypfnnp agcyanglil ahgdrwredd 420
ctfcqcvnge rhcvatvcgq tctnrvkvpg eccpvcept iitvdppacg elsnctltkr 480
5 dcingfkrdh ngcrtcqcin tqelcserkq gctlncpfgf ltdaqnceic ecrprpkkr 540
piicdkycpl gllknkhgcl icrckkcpel scskicplgf qgdshgcllc kcreasasag 600
ppilsgtclt vdghhkhnee shwdgcrecy clngremcal itcpvpacgn ptihpggccp 660
scaddfvvqk pelstpsich apggeyfvge etwnidsctq ctchsgrvlc etevcppllc 720
qnsrtdqsc cpqctdqpfr pslsrnnsvp nyckndegdi flaaeswkpd vctscicids 780
10 viscfesep svscerpvlr kgqccpycik dtipkkvch fsgkayadee rwdldscthc 840
yclqggtlcs tvscplpcv epinvegsc pmcpemyvpe ptnipiekt hrgevdlevp 900
lwptpsendi vhlprdmghl qvdyrdnrh psedssldsi asvvvpiliic lsiiiaflfi 960
nqkkqwipll cwyrtpkps slnnqlvsvd ckkgtrvqv ssqrmrlrae pdarfsgfys 1020
15 mqkqnhlqad nfyqtv

<210> 35

<211> 716

<212> DNA

20 <213> Human

<400> 35

25 gcagtacctg gagggtcctg caggggggaaa gcgaaccggg ccctgaagtc cgggggcagtc 60
acccgggggt cctggggcgc tctgccgggc tggggctgag cagcgatcct gctttgtccc 120
agaagtccag agggatcagc ccagaaacac accctcctcc ccgggacgcc gcagctttct 180
ggaggctgag gaaggcatga agagtgggct ccacctgctg gccgactgag aaaagaattt 240
30 ccagaactcg gtcctatttt acagattgag aaactatggg tcaagaagag aggacggggc 300
ttgagggaat ctctgattc tccttatatg acctcaaact gaccatacta aacagtgtag 360
aaggctcttt taaggctcta aatgtcaggg tctcccatcc cctgatgcct gacttgtaca 420
gtcagtgtgg agtagacggg ttcctccacc caggggtgac tcagggggat gatctgggtc 480
ccattctggg cttaagaccc caaacaaggg ttttttcagc tccaggatct ggagcctcta 540
tctggttagt gtcgtaacct ctgtgtgcct cccgttacct catctgtcca gtgagctcag 600
35 ccccatcca cctaacaggg tggccacagg gattactgag ggtaagacc ttagaactgg 660
gtctagcacc cgataagagc tcaataaatg ttgttccttt ccacatcaaa aaaaaa

<210> 36

<211> 395

40 <212> DNA

<213> Human

<400> 36

45 ccaatacttc attcttcatt ggtggagaag attgtagact tctaagcatt ttccaaataa 60
aaaagctatg atttgatttc caacttttaa acattgcatg tcctttgcca ttactacat 120
tctccaaaaa aaccttgaaa tgaagaaggc cacccttaaa atacttcaga ggctgaaaat 180
atgattatta cattggaatc ctttagccta tgtgatattt ctttaacttt gcactttcac 240
gccagtaaaa accaaagtca gggtaaccaa tgtcatttta caaatgtta aaaccctaata 300
50 tgcagttcct tttttaaat attttaaaga ttacttaaca acattagaca gtgcaaaaaa 360
agaagcaagg aaagcattct taattctacc atcct

<210> 37

<211> 134

55 <212> DNA

<213> Human

<400> 37

60 ccctcgagcg gccgcccggg caggtacttt taccaccgaa ttgttcactt gactttaaga 60
aaccataaa gctgcctggc tttagcaaac aggcctatca acaccatggg gacttccat 120
aaggacacc gtgt

<210> 38

<211> 644

65 <212> DNA

<213> Human

<400> 38

5 aagcctgttg tcatggggga ggtggtggcg cttggtggcc actggcggcc gaggtagagg 60
cagtggcgct tgagttggtc gggggcagcg gcagatttga ggcttaagca acttcttccg 120
gggaagagtg ccagtgcagc cactgttaca attcaagatc ttgatctata tccatagatt 180
ggaatatttg tgggccagca atcctcagac gcctcactta ggacaaatga ggaaactgag 240
gcttggtgaa gttacgaaac ttgtccaaaa tcacacaact tgtaaagggc acagccaaga 300
10 ttcagagcca ggctgtaaaa attaaaatga acaaattacg gcaaagtttt aggagaaaga 360
aggatgttta tgttccagag gccagtcgtc cacatcagtg gcagacagat gaagaaggcg 420
ttcgccaccg aaaatgtagc ttcccgggta agtaccttgg ccatgtagaa gttgatgaat 480
caagaggaat gcacatctgt gaagatgctg taaaaagatt gaaagctgaa aggaagttct 540
tcaaaggctt ctttggaaaa actggaaaga aagcagttta agcagtttct gtgggtctaa 600
15 gcagatggac tcagaggttg tggatgaaaa actaaggacc tcat

<210> 39

<211> 657

<212> DNA

20 <213> Human

<400> 39

25 ctttttgttt gggttttcca atgtagatgt ctcagtgaat tgtgcagata tactttgttc 60
cttatatggt caccagtgtt aattatggac aaatacatta aaacaagggt tcctggccca 120
gcctcccata taatctcttt gatactcttg gaatctaagt ctgaggagcg atttctgaat 180
tagccagtgt tgtaccaact ttctgttagg aattgtatta gaataacctt tctttttcag 240
acctgctcag tgagacatct tggggaatga agtaggaaaa tagacatttg gtggaaaaac 300
agcaaaatga gaacattaaa aagactcatt caagtatgag tataaagggc atggaaattc 360
30 tggtcctttg agcaaaatga gaagaaaaaa ttctgctcag cagtattcac tgtgttaaga 420
ttttttgttt tttacacgaa tggaaaaaat atgtgtaagt ggtatagatt ttaatcagct 480
aacagtcact ccagagattt tgatcagcac caattcctat agtagtaagt atttaaaagt 540
taagaaatac tactacattt aacattataa agtagagtgc tggacataac tgaaaattag 600
atgtttgctt caatagaaat ttgttccac ttgtattttc aacaaaatta tcggaac

<210> 40

<211> 1328

<212> DNA

<213> Human

40

<400> 40

45 acaattttta aataactagc aattaatcac agcatatcag gaaaaagtag acagtgagtt 60
ctggttagtt tttgtaggct cattatgggt agggctcgta agatgtatat aagaacctac 120
ctatcatgct gtatgtatca ctcattccat tttcatgttc catgcatact cgggcatcat 180
gctaatatgt atccttttta gcactctcaa ggaaacaaaa gggcctttta tttttataaa 240
ggtaaaaaaa attccccaat tttttgcac tgaatgtacc aaagggtgaag ggacattaca 300
atatgactaa cagcaactcc atcacttgag aagtataata gaaaatagct tctaaatcaa 360
acttccttca cagtgcggtg tctaccacta caaggactgt gcatctaagt aataattttt 420
50 taagattcac tatatgtgat agtatgatat gcatttattt aaaatgcatt agactctctt 480
ccatccatca aatactttac aggatggcat ttaatacaga tatttcgtat ttccccact 540
gctttttatt tgtacagcat cattaaacac taagctcagt taaggagcca tcagcaacac 600
tgaagagatc agtagtaaga attccatttt ccctcatcag tgaagacacc acaaattgaa 660
actcagaact atattttctaa gcctgcattt tcaactgatgc ataattttct tagtaattat 720
55 aagagacagt ttttctatgg catctccaaa actgcatgac atcactagtc ttacttctgc 780
ttaattttat gagaagggtat tcttcatttt aattgctttt gggattactc cacatctttg 840
tttattttct gactaatcag attttcaata gagtgaagtt aaattggggg tcataaaagc 900
attggattga catatgggtt gccagcctat gggtttacag gcattgcccc aacatttctt 960
tgagatctat atttataagc agccatggaa ttctatttat gggatgttgg caatcttaca 1020
60 ttttatagag gtcatatgca tagttttcat aggtgttttg taagaactga ttgctctcct 1080
gtgagttaag ctatgtttac tactgggacc ctcaagagga ataccactta tgttacactc 1140
ctgcactaaa ggcacgtact gcagtgtgaa gaaatgttct gaaaaagggt tatagaaatc 1200
tggaataaag aaaggaagag ctctctgtat tctataattg gaagagaaaa aaagaaaaac 1260
ttttaactgg aatgttagt ttgtacttat tgatcatgaa tacaagtata tatttaattt 1320
65 tgaaaaaa

<210> 41
<211> 987
<212> DNA
<213> Human

5

<400> 41

10 aacagagact ggcacaggac ctcttcattg caggaagatg gtagtgtagg caggtaacat 60
tgagctcttt tcaaaaaaagg agagctcttc ttcaagataa ggaagtggta gttatggtgg 120
taacccccgg ctatcagtcg ggatgggttg caccctcctt gctgtaggat ggaagcagcc 180
atggagtgagg agggaggcgc aataagacac ccctccacag agcttgatcat catgggaagc 240
tggttctacc tcttcctggc tcctttgttt aaaggcctgg ctgggagcct tccttttggg 300
tgtctttctc ttctccaacc aacagaaaag actgctcttc aaaggtggag ggtcttcatg 360
15 aaacacagct gccaggagcc caggcacagg gctggggggc tggaaaaagg agggcacaca 420
ggaggaggga ggagctggta gggagatgct ggctttacct aaggtctcga aacaaggagg 480
gcagaatagg cagaggcctc tccgtcccag gcccatTTTT gacagatggc gggacggaaa 540
tgcaatagac cagcctgcaa gaaagacatg tgttttgatg acaggcagtg tggccgggtg 600
gaacaagcac aggccttgga atccaatgga ctgaatcaga accctaggcc tgccatctgt 660
cagccgggtg acctgggtca attttagcct ctaaaagcct cagtctcctt atctgcaaaa 720
20 tgaggcttgt gatacctgtt ttgaagggtt gctgagaaaa ttaaagataa gggatatcaa 780
aatagtctac ggccatacca ccctgaacgt gcctaattctc gtaagctaag cagggtcagg 840
cctgggttagt acctggatgg ggagagtatg gaaaacatac ctgcccgagc ttggagttgg 900
actctgtctt aacagtagcg tggcacacag aaggcactca gtaaatactt gttgaataaa 960
tgaagtagcg atttggtgtg aaaaaa

25

<210> 42
<211> 956
<212> DNA
<213> Human

30

<400> 42

35 cggacgggtg ggcggacgcg tgggtgcagg agcagggcgg ctgccgactg cccaaccaa 60
ggaaggagcc cctgagtcct cctgcgcctc catccatctg tccggccaga gccggcatcc 120
ttgcctgtct aaagccttaa ctaagactcc cgccccgggc tggccctgtg cagaccttac 180
tcaggggatg tttacctggt gctcgggaag ggagggggaa gggccgggga gggggcacgg 240
caggcgtgtg gcagccacac gcaggcggcc agggcgccca gggacccaaa gcaggatgac 300
cacgcacctc cacgccactg cctccccga atgcatttgg aaccaaagtc taaactgagc 360
tcgcagcccc cgcgccctcc ctccgcctcc catcccgctt agcgtctctg acagatggac 420
40 gcaggccctg tccagcccc agtgcgctcg ttccgggtccc cacagactgc cccagccaac 480
gagattgctg gaaaccaagt caggccaggt gggcgacaaa aagggccagg tgcggcctgg 540
ggggaacgga tgctccgagg actggactgt ttttttcaca catcggttgc gcagcgggtg 600
gaaggaaaagg cagatgtaaa tgatgtgttg gtttacaggg tatatttttg ataccttcaa 660
tgaattaatc cagatgtttt acgcaaggaa ggacttacct agtattactg ctgctgtgct 720
45 tttgatctct gcttaccgtt caagaggcgt gtgcaggccg acagtcggtg accccatcac 780
tcgcaggacc aagggggcgg ggactgctgg ctcacgcccc gctgtgtcct ccctccctc 840
ccttccttgg gcagaatgaa ttcgatgcgt attctgtggc cgccatctgc gcagggtgg 900
ggtattctgt catttacaca cgctgttcta attaaaaagc gaattatact ccaaaa

50

<210> 43
<211> 536
<212> DNA
<213> Human

55

<400> 43

60 aaataaacac ttccataaca ttttgttttc gaagtctatt aatgcaatcc cacttttttc 60
cccctagttt cttaatgtta aagagagggg aaaaaaggct caggatagtt ttcacctcac 120
agtgttagct gtcttttatt ttactcttgg aaatagagac tccattaggg ttttgacatt 180
ttgggaaccc agttttacca ttgtgtcagt aaaacaataa gatagtttga gagcatatga 240
tctaaataaa gacatttgaa gggttagttt gaattctaaa agtaggtaat agccaaatag 300
cattctcatc ccttaacaga caaaaactta tttgtcaaaa gaattagaaa aggtgaaaat 360
atTTTTTcca gatgaaactt gtgccacttc caattgacta atgaaataca aggagacaga 420
ctggaaaaag tgggttatgc cacctttaaa accctttctg gtaaataatta tggtagctaa 480
65 aggggtggtt ccccggcacc tggacctgga caggtagggg tccgtgggta accagt

<210> 44
<211> 1630
<212> DNA
<213> Human
5
<400> 44
ggggagggac gagtatggaa ccctgaaggt agcaagtcca ggcactggcc tgaccatccg 60
gctccctggg caccaagtcc caggcaggag cagctgtttt ccatcccttc ccagacaagc 120
10 tctattttta tcacaatgac ctttagagag gtctcccagg ccagctcaag gtgtcccact 180
atccccctctg gaggggaagag gcaggaaaat tctccccggg tccctgtcat gctactttct 240
ccatcccagt tcagactgtc caggacatct tatctgcagc cataagagaa ttataaggca 300
gtgatttccc ttaggcccag gacttgggcc tccagctcat ctgttccttc tgggcccatt 360
catggcagggt tctgggctca aagctgaact ggggagagaa gagatacaga gctaccatgt 420
15 gactttacct gattgccctc agtttggggt tgcttattgg gaaagagaga gacaaagagt 480
tacttgttac gggaaatatg aaaagcatgg ccaggatgca tagaggagat tctagcaggg 540
gacaggattg gctcagatga ccctgaggg ctcttccagt cttgaaatgc attccatgat 600
attaggaagt cgggggtggg tgggtggtggg gggctagtgt ggtttgaatt taggggcccga 660
tgagcttggg tacgtgagca ggggtgttaag ttagggctct cctgtatttc tgggtcccctt 720
20 ggaaatgtcc ccttcttcag tgtcagacct cagtccaggt gtccatatac tgcccagaaa 780
agtagacatt atcctgcccc atcccttccc cagtgcactc tgacctagct agtgcctggg 840
gccagtgac ctgggggagc ctggctgcag gccctcactg gtccctaaa ccttgggtggc 900
tgtgattcag gtccccaggg gggactcagg gaggaatatg gctgagttct gtagtttcca 960
gagttggctg gtagagcctt ctagagggtc agaataatag cttcaggatc agctgggggt 1020
25 atggaattgg ctgaggatca aacgtatgta ggtgaaagga taccaggatg ttgctaaagg 1080
tgagggacag tttgggtttg ggacttacca ggggtgatgt agatctggaa cccccaagtg 1140
aggctggagg gagttaaggt cagtatggaa gatagggttg ggacagggtg ctttggaatg 1200
aaagagtgc cttagagggc tccttgggcc tcaggaatgc tcctgctgct gtgaagatga 1260
gaagggtgct ttactcagtt aatgatgagt gactatattt accaaagccc ctacctgctg 1320
30 ctgggtccct tgtagcacag gagactgggg ctaaggggccc ctcccaggga agggacacca 1380
tcaggcctct ggctgaggca gtagcataga ggatccattt ctacctgcat tcccagagg 1440
actagcagga ggcagccttg agaaaccggc agttcccagg ccagcgctct gctgttctct 1500
cattgtcact gccctctccc caacctctcc tctaaccac tagagattgc ctgtgtcctg 1560
cctcttgctt cttgtagaat gcagctctgg ccctcaataa atgcttctct cattcatctg 1620
35 caaaaaaaaa
<210> 45
<211> 169
<212> DNA
40 <213> Human
<400> 45
tcttttgctt ttagcttttt atttttgtat taacaggagt cttattacac ataggtctga 60
45 taaaactggg ttatgatctt cagtctgatt ccagtgtgc ataactagat aacgtatgaa 120
ggaaaaacga cgacgaacaa aaaagtaagt gcttggaaga cttagttga
<210> 46
<211> 769
50 <212> DNA
<213> Human
<400> 46
tgcaggctcat atttactatc ggcaataaaa ggaagcaaag cagtattaag cagcgggtgga 60
atgtgtcgct ttcacttttt ataaagtgtc acataaaatg tcatatttcc aaatttataa 120
acataactcc agttcttacc atgagaacag catgggtgat acgaaggatc ttcttgaaaa 180
aaacaaaaac aaaaacaaaa aacaatgatc tcttctgggt atcacatcaa atgagataca 240
aagggtgtact aggcaatctt agagatctgg caacttattt tatatataag gcatctgtga 300
60 ccaagagacg ttatgaatta aatgtacaaa tgtattatgt ataatgtat taaatgcaag 360
cttcatataa tgacaccaat gtctctaagt tgctcagaga tcttgactgg ctgtggccct 420
ggccagctcc tttcctgata gtctgattct gccttcatat ataggcagct cctgatcatc 480
catgccagtg aatgagaaaa caagcatgga atatataaac tttaacatta aaaaatgttt 540
tattttgtaa taaaatcaaa tttcccattg aaaccttcaa aaactttgca gaatgaggtt 600
65 ttgatatatg tgtacaagta gtaccttctt agtgcaagaa aacatcatta tttctgtctg 660
cctgcctttt tgttttttaa aatgaagact atcattgaaa caagtttgtc ttcagtatca 720

ggacatgttg acggagagga aaggtaggaa agggtaggg atagaagcc

<210> 47
 <211> 2529
 <212> DNA
 <213> Human

<400> 47

10 tttagttcat agtaatgtaa aaccatttgt ttaattctaa atcaaatac tttcacaaca 60
 gtgaaaatta gtgactgggt aagggtgtgcc actgtacata tcatcatttt ctgactgggg 120
 tcaggacctg gtcctagtcc acaagggtgg caggaggagg gtggaggcta agaacacaga 180
 aaacacacaa aagaaaggaa agctgccttg gcagaaggat gaggtggtga gcttgccgag 240
 ggatggtggg aagggggctc cctgttgggg ccgagccagg agtcccaagt cagctctcct 300
 15 gccttactta gtccttgcca gaggttgagt ggggacctac gaggttcaaa atcaaattggc 360
 atttggccag cctggcttta ctaacagggt cccagagtgc ctctgttggc tgagctctcc 420
 tgggctcact ccatttccatt gaagagtcca aatgattcat tttcctaccc acaacttttc 480
 attattcttc tggaacccca tttctgttga gtccatctga cttaagtcct ctctccctcc 540
 actagttggg gccactgcac tgaggggggt cccaccaatt ctctctagag aagagacact 600
 20 ccagaggccc ctgcaacttt gcggatttcc agaaggatga aaaaagagca ctcttgagtg 660
 ggtgcccgag aatgttttaa atctatcagg cacactataa agctggtggt ttcttcctac 720
 caagtggatt cggcatatga accacctact caatacttta tattttgtct gtttaaacac 780
 tgaactctgg tgttgacagg taaaaggag aagagatggg gactgtgaag aggggagggc 840
 ttccctcatc ttctcaaga tctttgttcc cataaactat gcagtcataa ttgagaaaaa 900
 25 gcaatagatg gggcttccta ccatttgttg gttattgctg ggggttagcca ggagcagtgt 960
 ggatggcaaa gtaggagaga ggcccagagg aaagcccatc tccctccagc tttggggtct 1020
 ccagaaagag gctggatttc tgggatgaag cctagaaggc agagcaagaa ctgttccacc 1080
 aggtgaacag tctacctgc tttgttaccat agtccctcaa taagattcag aggaagaagc 1140
 ttatgaaact gaaaatcaaa tcaaggatatt gggaagaata atttccctc gattccacag 1200
 30 gaggaagac cacacaatat cattgtgctg gggctcccca aggccctgcc acctggcttt 1260
 acaaatcatc aggggttgcc tgcttggcag tcacatgctt ccctggtttt agcacacata 1320
 caaggagttt tcagggaact ctatcaagcc ataccaaaat cagggtcaca tgtgggtttc 1380
 ccctttcctt gcctcttcat aaaagacaac ttggcttctg aggatgggtg tcttttgcac 1440
 gcagttgggc tgacctgaca aagcccccag tttcctgttg caggttctgg gagaggatgc 1500
 35 attcaagctt ctgcagccta ggggacaggg ctgcttgttc agttattact gcctcggagc 1560
 tccaaatccc accaaagtcc tgactccagg tctttcctaa tgcacagtag tcagtctcag 1620
 cttcggcagt attctcggct gtatgttctc tggcagagag aggcagatga acatagtttt 1680
 agggagaaag ctgatgggaa acctgtgagt taagccacat gtctcaccag gaataattta 1740
 tgccaggaaa ccaggaagtc attcaagttg ttctctgagg ccaaagacac tgagcacagc 1800
 40 ccagagccaa taaaagatct ttgagtctct ggtgaattca cgaagtgacc ccagctttag 1860
 ctactgcaat tatgattttt atgggacagc aatttcttgc atctctacag aggaagaaga 1920
 gggggagtgg gaggggaagg aaagagaaca gagcggcact gggatttgaa aggggaacct 1980
 ctctatctga ggagccccc ctggcttcag aagcaactta ccaaggggta tttaaagaca 2040
 tgaaaatttc cagaaatacc atttggtgca tccctttgtt tctgtaatat taaactcagg 2100
 45 tgaaattata ctctgacagt ttctctcttt ctgcctcttc cctctgcaga gtcaggacct 2160
 gcagaactgg ctgaaacaag atttcatggt gtcacccatg agagatgact caatgccaag 2220
 gcctgaagtt atagagtgtt tacagcgggt gcgatattca ggggtcatcg ccaactggtc 2280
 tcgagttcca aagctctgat gaagaaacaa gactccttga tgtgttactg atcccactga 2340
 50 ttccaggagt caagattagc caggaagcca aacaccagga gttgggggtg cacgtcacca 2400
 gtccagagcc ctgccacgga tgtacgcagg agccagcat taggcaatca ggagccagaa 2460
 catgatcacc agggccacaa ataggaagag gcgtgacagg aactgctcgt ccacatacct 2520
 ggggtgtcc

<210> 48
 <211> 1553
 <212> DNA
 <213> Human

<400> 48

60 tttttttttt tttttgattt ctgggacaat taagctttat ttttcatata tatatatatt 60
 ttcatatata tatatacata catatataaa ggaaacaatt tgcaaattta cacacctgac 120
 aaaaccatat atacacacat atgtatgcat acacacagac agacacacac acccgaagct 180
 ctagccaggc cegttttcca tccetaagta ccattctctc atttgggccc ttctagggtt 240
 65 ggggccctga gcttggtttt tagaagtttg gtgctaatat aaccatagct ttaatcccca 300
 tgaaggacag tgtagacctc atctttgtct gctccccgct gcctttcagt tttacgtgat 360

5 ccatcaagag ggctatggga gccaaagtga cacgggggat tgaggctaata tcacctgaac 420
 tcgaaaacag cgcccagctt cctcaccgca ggcacgcgtc ttttcttttt ttttcctcga 480
 gacggagtct cgctgtgttg cccaggctgg agtgcagtgg caaggctctg gctcactgca 540
 agctccacct cctggattca taccattctc ctgcttcagc cttccgagta gctgggacta 600
 taggtgccaa ccactacgcc tagctaattt tttttgtat ttttagtaga gacagggttt 660
 caccgtgtta gccaggatgg tctcgtcctg actttgtgat ccgcccgcct cggcctccca 720
 aagtgtctggg attacaggcg tgagccacca cacctggccc cggcacgtat cttttaagga 780
 atgacaccag ttcctggctt ctgaccaaag aaaaaatgtc acaggagact ttgaagaggc 840
 10 agacaggagg gtggtggcag caacactgca gctgcttctg gatgtgtctg ggggtgtctc 900
 cggagcgggt gtgaacagcg cacttcaaca tgagcaggcg cctggctccg gtgtgtctc 960
 acttcagtgg tgcacctgga tgggtggaagc cagccttttg ggcaggaaac cagctcagag 1020
 aggctacca gctcagctgc tggcaggagc caggatatta cagccataat gtgtgttaaag 1080
 aaaaaacacg ttctgcaaga aactctccta cccgctcggg agactggggc tccttgcttg 1140
 ggatgagctt cactcaacgt ggagatgggt gtggactggg ccctgaaaag cgggccttgc 1200
 15 agggccaagt gaggtcctca ggtcctaac ccagtggccc tctgaaaggg ggtgtgcagg 1260
 cgaggggagc aggaggcttc tctctagtcc ctttgagggc tttggctgag agaagagtga 1320
 gcagggagct gggaatggtc caggcaggga agggagctga agtgattcgg ggctaatacc 1380
 tcagatcgat gtatttctct ccctgggtct cggagaccct cttgtcaccg ctgctgccct 1440
 20 gcaggaggcc catctcttct gggagcttat ctgacttaac ttcaactaca agttcgctct 1500
 tacgagaccg ggggtagcgt gatctcctgc ttccttgagc gcctgcacgg cag

<210> 49

<211> 921

<212> DNA

25 <213> Human

<400> 49

30 ctgtggctcc agctactcag gaggtgagg cgggaggatt gcttgagccc aggagtggga 60
 tggtgcagtg agccaagatc gcaccattgc cctccactct gggccacgga gcaataccct 120
 gtctcagaaa acaacaaca aaaagcagaa acgctgaagg ggtcggttta cgggaaaacc 180
 gcctgtcaga acacttggct actcctaccc cagatcagtg gacctgggaa tgagggttgg 240
 tcccgggagg cttttctcca agctgttgcc accagaccgg ccatgggaac cctggccaca 300
 35 gaagcctccc ggggagttag ccagagcctg gaccgctgtg ctgatgtgtc tggggtggag 360
 ggaggggtgg gagtgtgcaa ggggtgtgtg gtgcccgggg ggtgttcatg ggcaagcatg 420
 tgcgtgcctg tgtgtgtgag tgcctctccc ctgcagccgt cggtggtatc tccctccagc 480
 cccttcgcca ccttctgagc attgtctgtc cagtgagac tgcccagaga cagcagagct 540
 ccacgtgggt ttaaggggag acctttccct ggacctgggg gtctcgcctg atctcatgac 600
 caggtgctaa atgacccgac atgcatcacc tgcctttcga tgaccaacct ccctgtcccc 660
 40 gtcccgtgta cctgcccccg tggcgtctca cggatgatgc tgctcctgac attggtgttc 720
 actgtagcaa actacattct ggatgggaat tttcatgtac atgtgtggca tgtggaaaat 780
 ttcaataaaa atggacttga tttagaaagc caaaaagctg tgtggctcct ccagcacgga 840
 tactttgacc tcttgccctac aacccttccc ttgggtccga ggctggtagc tttgttccat 900
 45 tcagatgggt gggggcgggt g

<210> 50

<211> 338

<212> DNA

<213> Human

50

<400> 50

55 atgatctatc tagatgccct accgtaaaaat caaaacacaa aaccctactg actcattccc 60
 tcccttccag atattacccc atttctctac ttcccattgt agccaaactt tccaaaaatt 120
 catgtttctgt cttcatttcc tcatgttcaa cccacctgt cttagctacc acccctcagt 180
 aacgacctag cctgggtaga aacaaatgtc agcatgatac catactcaat gatccttcgt 240
 cactgttgtc attgtcatca ttccatggcc ttactttccc tctcagcgcc atttgctaca 300
 gtaagaaact ttctttcttg aattcttggg tctcttgg

60 <210> 51

<211> 1191

<212> DNA

<213> Human

65 <400> 51

	ctagcaagca	ggtaaacgag	ctttgtacaa	acacacacag	accaacacat	ccggggatgg	60
	ctgtgtgttg	ctagagcaga	ggctgattaa	acactcagtg	tggttgctct	ctgtgccact	120
	cctggaaaat	aatgaattgg	gtaaggaaca	gttaataaga	aaatgtgcct	tgctaactgt	180
	gcacattaca	acaaagagct	ggcagctcct	gaaggaaaag	ggcttgtgcc	gctgccgttc	240
5	aaacttgtca	gtcaactcat	gccagcagcc	tcagcgtctg	cctccccagc	acaccctcat	300
	tacatgtgtc	tgtctggcct	gatctgtgca	tctgtctcga	gacgtccttg	acaagtcggg	360
	aatttctcta	tttctccact	ggtgcaaaga	gcggatttct	ccctgttctt	cttctgtcac	420
	ccccgtcct	ctccccagc	aggtccttg	atttatggta	gctttggact	tgcttccccg	480
	tctgactgtc	cttgacttct	agaatggaag	aagctgagct	ggtgaaggga	agactccagg	540
10	ccatcacaga	taaaagaaaa	atacaggaag	aaatctcaca	gaagcgtctg	aaaatagagg	600
	aagacaaact	aaagcaccag	catttgaaga	aaaaggcctt	gaggagagaa	tggttcttag	660
	atggaatcag	cagcggaaaa	gaacaggaag	agatgaagaa	gcaaaatcaa	caagaccagc	720
	accagatcca	ggttctagaa	caaagtatcc	tcaggcttga	gaaagagatc	caagatcttg	780
	aaaaagctga	actgcaaata	tcaacgaagg	aagaggccat	tttaaagaaa	ctaaagtcaa	840
15	ttgagcggac	aacagaagac	attataagat	ctgtgaaagt	ggaaagagaa	gaaagagcag	900
	aagagtcaat	tgaggacatc	tatgctaata	tccctgacct	tccaaagtcc	tacatacctt	960
	ctagggttaag	gaaggagata	aatgaagaaa	aagaagatga	tgaacaaaat	aggaaagctt	1020
	tatatgccat	ggaaattaaa	gttgaaaaag	acttgaagac	tgagagaaagt	acagttctgt	1080
	cttccaatac	ctctggccat	cagatgactt	taaaaggtac	aggagtaaaa	gtttaagatg	1140
20	atgggcaaaa	gtccagtgtg	ttcagtaaag	tgctaatac	aagttggagg	t	
	<210>	52					
	<211>	1200					
	<212>	DNA					
25	<213>	Human					
	<400>	52					
	aacagggact	ctcactctat	caaccccagg	ctggagtccg	gtgcgcccac	cctggctccc	60
30	tgcaacctec	gcctcccagg	ctcaagcaac	tctcctgcct	cagtcgctct	agtagctggg	120
	actacaggca	cacaccacca	tgcccagcca	atttttgcat	tttttgtaga	gacagggttt	180
	cgccttctgt	ccaggccggc	atcatatact	ttaaatcatg	cccagatgac	tttaatacct	240
	aatacaatat	atcaggtttg	tttaaaaata	attgcttttt	tattattttt	gcattttttg	300
	accaacctta	atgctatgta	aatagttggt	atactgttgc	ttaacaacag	tatgacaatt	360
35	ttggcttttt	ctttgtatta	ttttgtattt	ttttttttta	ttgtgtggtc	tttttttttt	420
	ttctcagtgt	tttcaattcc	tccttggttg	aatccatgga	tgcaaaaccc	acagatatga	480
	agggctggct	atatatgcat	tgatgattgt	cctattatat	tagttataaa	gtgtcattta	540
	atatgtagt	aaagttatgg	tacagtggaa	agagttagtg	aaaacataaa	catttgagacc	600
	tttcaagaaa	ggtagcttgg	tgaagttttt	caccttcaaa	ctatgtccca	gtcagggctc	660
40	tgctactaat	tagctataat	ctttgcacaa	attacatcac	ctttgagtct	cagttgcctc	720
	acctgtaaaa	tgaaagaact	ggatactctc	taaggctcact	tccagccctg	tcattctata	780
	actctgttat	gctgaggaag	aaattcacat	tgtgttaact	gtatgagtca	aactgaaaat	840
	gattattaaa	gtgggaaaaa	gccaattgct	tctcttagaa	agctcaacta	aatttgagaa	900
	gaataatctt	ttcaattttt	taagaattta	aatattttta	agggtttgac	ctattttatt	960
45	agagatgggg	tctcactctg	tcacccagac	tgagtagacg	tggcacaatc	atagctcact	1020
	gctgcctcaa	attcatgggc	tcaagtgate	ctcctgcctc	tgccctccaga	gtagctgcga	1080
	ctatgggcat	gtgccaccac	gcctggctaa	catttgtatt	gacctattta	tttattgtga	1140
	tttatatctt	tttttttttt	tctttttttt	ttttttacaa	aatcagaaat	acttattttg	1200
50	<210>	53					
	<211>	989					
	<212>	DNA					
	<213>	Human					
55	<400>	53					
	aagccaccac	tcaaaacttc	ctatacattt	tcacagcaga	gacaagtga	cattttatttt	60
	tatgcctttc	ttcctatgtg	tattttcaagt	ctttttcaaa	acaaggcccc	aggactctcc	120
	gattcaatta	gtccttgggc	tggtcgactg	tgccaggagtc	caggagacct	ctacaaatgc	180
60	agagtgactc	tttaccaaca	taaaccttag	atacatgcaa	aaagcaggac	ccttcctcca	240
	ggaatgtgcc	atttcagatg	cacagcaccc	atgcagaaaa	gctggaattt	tccttgggaa	300
	cgactgtgat	agaggtgctt	acatgaacat	tgctactgtc	tttctttttt	tttgagacag	360
	gtttcgcttg	tgcccaggct	gagtgcattg	cgtgatctca	ctcactgcaa	ttccacctcc	420
	aggttcaagc	attctcctgc	tcagcctcct	agtagctggg	ttacaggcac	tgccaccatg	480
65	ccggctaatt	ttgtattttt	gtagagatgg	atttctccat	ttggtcaggc	ggtctcgaac	540
	cccaacctca	gtgatctgcc	acctcagcct	cctaagtgtt	ggattacagg	atgagccacc	600

cgaccggcca ctactgtctt tctttgaccc ttccagtttc gaagataaag aggaaataat 660
ttctctgaag tacttgataa aatttccaaa caaaacacat gtccacttca ctgataaaaa 720
atltaccgca gtttggcacc taagagtatg acaacagcaa taaaaagtaa tttcaaagag 780
5 ttaagatttc ttcagcaaaa tagatgattc acatcttcaa gtcctttttg aaatcagtta 840
ttaatattat tctttcctca tttccatctg aatgactgca gcaatagttt tttttttttt 900
tttttttttt ttgcgagatg gaatctcgct ctgtcgccca gcgggagtgc actggcgcaa 960
gcccggtcca ccgcaatctc tgccaccgg

<210> 54
10 <211> 250
<212> DNA
<213> Human

<400> 54
15 catttcccca ttggtcctga tgttgaagat ttagttaaag aggctgtaag tcaggttcga 60
gcagaggcta ctacaagaag tagggaatca agtccctcac atgggctatt aaaactaggt 120
agtgggtggag tagtgaaaaa gaaatctgag caacttcata acgtaactgc ctttcaggga 180
20 aaagggcatt ctttaggaac tgcattctgg aaccacacacc ttgatccaag agctagggaa 240
acttcagttg

<210> 55
<211> 2270
<212> DNA
25 <213> Human

<400> 55

gcgccccga gcagcgcccg cgccctccgc gccttctccg ccgggacctc gagcgaaaga 60
30 ggcccgcgcg ccgcccagcc ctgcctccc tgcccaccgg gcacaccgcg ccgccacccc 120
gaccccgcgt cgacggcct gtccgctgca caccagcttg ttggcgtctt cgtcgccgcg 180
ctcgccccgg gtaactcctg cgcgccacaa tgagctcccg catcgccagg gcgctcgctt 240
tagtcgtcac cttctccac ttgaccaggc tggcgctctc cacctgcccc gctgcctgcc 300
actgccccct ggaggcgccc aagtgcgcgc cgggagtcgg gctggtccgg gacggctgcg 360
35 gctgctgtaa ggtctgcgcc aagcagctca acgaggactg cagcaaaacg cagccctgcg 420
accacaccaa ggggctggaa tgcaacttcg gcgccaagtc caccgctctg aaggggatct 480
gcagagctca gtcagagggc agaccctgtg aatataacte cagaatctac caaaacgggg 540
aaagtittca gcccaactgt aaacatcagt gcacatgtat tgatggcgcc gtgggctgca 600
ttcctctgtg tccccagaa ctatctctcc ccaacttggg ctgtcccaac cctcggttg 660
40 tcaaagttac cgggcagtg tgcgaggagt gggctctgta cgaggatagt atcaaggacc 720
ccatggagga ccaggacggc ctcttggca aggagctggg attcgatgcc tccgaggtgg 780
agttgacgag aaacaatgaa ttgattgcag ttggaaaagg cagctcactg aagcggtcc 840
ctgttttttg aatggagcct cgcattctat acaaccctt acaaggccag aaatgtattg 900
ttcaaaacac ttcattggtc cagtgtcaca agacctgtgg aactggtatc tccacacgag 960
45 ttaccaatga caaccctgag tgccgccttg tgaaagaaac ccgatttgt gaggtgcggc 1020
cttgtggaca gccagtgtac agcagcctga aaaagggcaa gaaatgcagc aagaccaaga 1080
aatccccga accagtcagg tttacttacg ctggatgttt gagtgtgaag aaataccggc 1140
ccaagtactg cggttcctgc gtggacggcc gatgctgcac gcccagctg accaggactg 1200
tgaagatgcg gttccgctgc gaagatgggg agacattttc caagaacgct atgatgatcc 1260
50 agtcctgcaa atgcaactac aactgcccgc atgccaatga agcagcgttt cccttctaca 1320
ggctgttcaa tgacattcac aaatttaggg actaaatgct acctgggttt ccagggcaca 1380
cctagacaaa caaggagaa gagtgtcaga atcagaatca tggagaaaat gggcggggt 1440
gggtgtgggt atgggactca ttgtagaaag gaagccttgc tcattcttga ggagcattaa 1500
ggattttcga aactgccaag ggtgctgggt cggatggaca ctaatgcagc cagattgga 1560
55 gaatactttg cttcatagta ttggagcaca tgttactgct tcatttttga gcttgtggag 1620
ttgatgactt tctgttttct gtttctaatt tatttgctaa gcatattttc tctaggcttt 1680
tttctttttg ggtttctaca gtcgtaaaag agataataag attagttgga cagtttaag 1740
cttttattcg tcttttgaca aaagtaaatg ggagggcatt ccattccctc ctgaaggggg 1800
acaactccat agtgtctgtg agaggcagct atctgcactc taaactgcaa acagaaatca 1860
60 ggtgttttaa gactgaatgt tttatttatc aaaatgtagc ttttggggag ggaggggaaa 1920
tgtaatactg gaataattt taaatgattt taattttata ttcagtgaag agattttatt 1980
tatggaatta accatttaat aaagaaatat ttacctata tctgagtgtg tgccattcgg 2040
tatttttaga ggtgctccaa agtcattagg aacaacctag ctacagtact caattattca 2100
aacaggactt attgggatac agcagtgaat taagctatta aaataagata atgattgctt 2160
65 ttataccttc agtagagaaa agtcttttgc tataaagtaa tgtttaaaaa acatgtattg 2220
aacacgacat tgtatgaagc acaataaaga ttctgaagct aaaaaaaaaa

<210> 56
 <211> 1636
 <212> DNA
 5 <213> Human

<400> 56

```

10 cttgaatgaa gctgacacca agaaccgagg gaagagcttg ggcccaaagc aggaaagggg 60
    agcgctcgag ttggaaagga accgctgctg ctggccgaac tcaagcccgg gcgccccac 120
    cagtttgatt ggaagtccag ctgtgaaacc tggagcgctg ccttctcccc agatggctcc 180
    tggtttgctt ggtctcaagg acactgcac gtcaaaactga tcccctggcc gttggaggag 240
    cagttcatcc cttaaagggtt tgaagccaaa agccgaagta gcaaaaatga gacgaaaggg 300
    cggggcagcc caaaagagaa gacgctggac tgtggtcaga ttgtctgggg gctggccttc 360
15 agcccgtggc cttccccacc cagcaggaag ctctgggcac gccaccacc ccaagtgcc 420
    gatgtctctt gectggttct tgctacggga ctcaacgatg ggcatgcaa gatctgggag 480
    gtgcagacag ggctcctgct tttgaatctt tccggccacc aagatgtcgt gagagatctg 540
    agcttcacac ccagtggcag tttgattttg gtctccgctg cacgggataa gactcttcgc 600
    atctgggacc tgaataaaca cggtaaacag attcaagtgt tatcggggcca cctgcagtgg 660
20 gtttactgct gttccatctc cccagactgc agcatgctgt gctctgcagc tggagagaag 720
    tccgtctttc tatggagcat gaggtcctac acgttaattc ggaagctaga gggccatcaa 780
    agcagtgttg tctcttgtga cttctcccc gactctgccc tgcttgtcac ggcttcttac 840
    gataccaatg tgattatgtg ggaccctac accggcgaaa ggctgaggtc actccaccac 900
    acccaggttg accccgccat ggatgacagt gacgtccaca ttagctcact gagatctgtg 960
25 tgcttctctc cagaaggctt gtaccttgcc acggtggcag atgacagact cctcaggatc 1020
    tgggccctgg aactgaaaac tcccattgca tttgctccta tgaccaatgg gctttgctgc 1080
    acatttttcc cacatggttg agtcattgcc acagggacaa gagatggcca cgtccagttc 1140
    tggacagctc ctagggtcct gtccctcactg aagcacttat gccggaaagc ccttcgaagt 1200
    ttcctaacia cttaccaagt cctagcactg ccaatcccca agaaaatgaa agagtccctc 1260
30 acatacagga ctttttaagc aacaccacat cttgtgcttc tttgtagcag ggtaaatacgt 1320
    cctgtcaaag ggagttgctg gaataatggg ccaaacatct ggtcttgcat tgaaatagca 1380
    tttctttggg attgtgaata gaatgtagca aaaccagatt ccagtgtaca taaaagaatt 1440
    tttttgtctt taaatagata caaatgtcta tcaactttaa tcaagttgta acttatattg 1500
    aagacaattt gatacataat aaaaaattat gacaatgtcc tgggaaaaaa aaaatgtaga 1560
35 aagatggtga agggtgggat ggatgaggag cgtggtgacg ggggcctgca gcgggttggg 1620
    gaccctgtgc tgcgtt
  
```

<210> 57
 <211> 460
 40 <212> DNA
 <213> Human

<400> 57

```

45 ccatgtgtgt atgagagaga gagagattgg gagggagagg gagctcacta gcgcatatgt 60
    gcctccaggg ggctgcagat gtgtctgagg gtgagcctgg tgaaagagaa gacaaaagaa 120
    tggaaatgagc taaagcagcc gcctgggggtg ggaggccgag ccattttgta tgcagcaggg 180
    ggcaggagcc cagcaaggga gcctccattc ccaggactct ggagggagct gagaccatcc 240
    atgcccgcag agccctccct cacactccat cctgtccagc cctaattgtg caggtgggga 300
50 aactgaggct gggaagtcac atagcaagtg actggcagag ctgggactgg aaccaacca 360
    gcctcctaga ccacggttct tcccatcaat ggaatgctag agactccagc caggtgggta 420
    ccgagctcga attcgtaatc atggtcatag ctgtttcctg
  
```

<210> 58
 <211> 1049
 <212> DNA
 <213> Human

<400> 58

```

60 atctgatcaa gaatacctgc cctgggtcact ctgcggatgt ttctgtccac ttgttcacat 60
    tgaggaccaa gatatccttt tttacagagg cacttgctcg gtctaacaca gacacctcca 120
    tgacgacatg ctggctcaca ttttgaggtt ctgcagaagt cccctccca gcctggacta 180
    cagcagcact ttcccgtggg ggtgcagtag ccgtttcgac agagcctgga gcactctgaa 240
65 gtcagtgtct gtgcaggttg taccgtggct ctgcattcct caggcattaa aggtcttttg 300
    ggatctacaa ttttgtagag ttttccattg tgagtctggg tcatactttt actgcttgat 360
  
```

5 aaaatgtaaa cttcacctag ttcattcttct ccaaatecca agatgtgacc ggaaaagtag 420
 cctctacagg acccactagt gccgacacag agtgggtttt cttgccactg ctttgtcaca 480
 ggactttgct ggagagttag gaaattccca ttacgatctc caaacacgta gcttccatac 540
 aatctttctg actggcagcc ccggtataca aatccacca ccaaaggacc attactgaat 600
 ggcttgaatt ctaaaagtga tggctcactt tcataatctt tcccctttat tatctgtaga 660
 attctggctg atgatctgtt ttttccattg gagtctgaac acagtatcgt taaattgatg 720
 tttatatcag tgggatgtct atccacagca catctgcctg gatcgtggag cccatgagca 780
 aacacttcgg ggggctggtt ggtgctgttg aagtgtgggt tgctccttgg tatggaataa 840
10 ggcacgttgc acatgtctgt gtccacatcc agccgtagca ctgagcctgt gaaatcactt 900
 aaccatcca tttcttccat atcatccagt gtaatcatcc catcaccaag aatgatgtac 960
 aaaaaccgt cagggccaaa gagcagttgc cctcccagat gctttctgtg gagttctgca 1020
 acttcaagaa agactctggc tgttctcaa

15 <210> 59
 <211> 747
 <212> DNA
 <213> Human

20 <400> 59

25 tttttcaa at cacatatggc ttctttgacc ccatcaaata actttattca cacaaacgtc 60
 ccttaattta caaagcctca gtcattcata cacattaggg gatccacagt gttcaaggaa 120
 cttaaata at atgtatcata ccaacccaag taaaccaagt acaaaaaata ttcataataa 180
 gttggttcaca cgtaggctct agattaccag cttctgtgca aaaaaaggaa atgaagaaaa 240
 atagatttat taactagtat tggaaactaa ctttgtgcct ggcttaaaac ctccctcacg 300
 ctcgtctgtc ccacacaaat gttaagaag tcaactgcaat gtactccccg gctctgatga 360
 aaagaagccc ctggcacaaa agattccagt gccctgaag aggctccctt cctcctgtgg 420
 gctctcctag aaaaccagcg ggacggcctc cctgctgata ccgtctataa ccttaggggg 480
30 ccctcgggca ggcaacggca gtggactcat ctcggtgatg gctgtagatg ctaacactgg 540
 ccaattcaat gccacaccta ctggttacce tttgagggca tttctccaga cagaagcccc 600
 ttgaagccta ggtagggcag gatcagagat acaccogtgt ttgtctcgaa gggctccaca 660
 gccagtagc acatgcttgc agaagtagta tctctggact tctgcctcca gtcgaccggc 720
 cgcgaaattta gtagtaatag cggccgc

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.